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ABSTRACT 
 
Neurodegenerative diseases are becoming increasingly prevalent due to the 
ageing population, and are among the major contributors to disability and 
disease worldwide. The identification of the gene defects responsible for many 
of these conditions has played a major role in our understanding of the 
pathogenic processes involved, and provided opportunity to develop targeted 
treatment strategies.  
Cholinergic neurotransmission supports a wide range of physiological and 
behavioural processes and its dysfunction of cholinergic signalling has been 
associated with a number of disorders, including myasthenias, cardiovascular 
disease(1), attention-deficit hyperactivity disorder (ADHD) (2), Alzheimer’s 
disease (ADi), schizophrenia, addiction(3), and depression(4). SLC5A7 
encodes the Na+/Cl- dependent, high-affinity choline transporter (CHT) which 
represents the rate limiting step in acetylcholine (Ach) synthesis and is critical 
for normal cholinergic signalling. The work in this thesis details two new 
inherited disorders, caused by distinct pathogenic disease mechanisms, 
associated with novel SLC5A7 mutations. 
Chapter three documents the discovery of two autosomal-dominantly acting 
SLC5A7/CHT mutations associated with adult onset motor neurone disorders. 
Initially we identified a frameshift mutation that results in premature truncation of 
the transporter protein in a large Welsh kindred affected with distal hereditary 
motor neuropathy type VII (dHMN-VII), in which neurodegeneration and muscle 
paresis is largely restricted to the distal limb muscles and vocal cords. The 
mutation responsible results in the dominant-negative interference of the mutant 
molecule with function of the wild type choline transporter, resulting in 
significantly reduced (although not completely abolished) transporter activity. 
This finding is further evidenced by the discovery of a second dHMN family 
associated with a distinct frameshift SLC5A7 mutation indicative of a similar 
dominant-negative disease mechanism. Together these findings corroborate a 
dominant-negative disease mechanism arising from C-terminal truncating 
SLC5A7 mutations associated with dHMN, and provide further insight into the 
role of aberrant choline transporter function in neurological disease. 
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Chapter four describes N-terminal missense mutations located in the 
transmembrane spanning region of SLC5A7/CHT, associated with a severe 
infantile neuromuscular disorder characterised by predominantly central 
hypotonia and developmental delay. The phenotypic effects of these mutations 
are likely to result from the near abolition of CHT-mediated choline transport in 
homozygous individuals, and are in keeping with those observed in CHT knock-
out mouse models(5). 
The development of a mouse model of the human motor neurone disease 
arising from SLC5A7 frameshift mutations should allow for further investigation 
of the mechanism by which truncated CHT leads to the dHMN phenotype. 
Chapter 5 details treatment hypotheses for dHMN, as well as the generation of 
a patient-specific knock-in mouse model carrying an Slc5a7 mutation 
orthologous to that identified in dHMN-VII families in chapter 3, and results from 
preliminary neurological phenotyping of the mouse model. This model will be 
crucially important for the exploration of treatment options in dHMN-VII motor 
neurone disease as a prelude to clinical trials in humans. 
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1 INTRODUCTION 
 
1.1 Neurogenetics 
One of the fundamental goals in human genetics is to link gene function to 
disease phenotype, yet the functions of the majority of the genes and their 
encoded molecules in the human body are still poorly understood. 
Neurogenetics is a field of research which, with interplay between the fields of 
molecular biology and clinical neurology, aims to provide better understanding 
of the genetic basis of the normal (and abnormal) development in regard to the 
function (and malfunction) of the nervous system. Identification of disease 
causing gene mutations in monogenic neurological disorders has provided 
invaluable insights into specific molecular pathways important to normal 
neuronal function, and which may lead to neurodegenerative disease when 
defective. In recent years, genome wide association studies (GWAS) have 
identified polymorphisms associated with increased risk for a number of 
neurological diseases, including autism, schizophrenia, Alzheimer’s disease 
(ADi), Parkinson’s disease (PD), and the frontotemporal  lobar 
degeneration/amyotrophic lateral sclerosis (FTLD/ALS) spectrum(6, 7). These 
studies have also highlighted variations in genes with low penetrance, which 
contribute to polygenic, multifactorial neurological conditions. Investigation into 
copy number variants (CNVs), epigenetic, and epistatic effects have also more 
recently become recognised as important contributors to the heritability of 
neurological disease. Elucidation of the biochemical and physiological 
mechanisms which result in the genotype-phenotype correlation connecting 
disease gene mutations to the manifestation of their resultant neurological 
disorders leads to a more precise disease classification, an understanding of 
the underlying molecular pathways involved, recognition of neurodegenerative 
common pathways, and ultimately the identification of possible targeted 
treatments.  
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1.2 Neurodegenerative disease 
The term ‘neurodegenerative disease’ is broad and encompasses a large group 
of highly clinically and genetically heterogeneous diseases which result in the 
loss of structure and function of neurones, and can be either sporadic or 
inherited.  The most common neurodegenerative diseases are ADi and PD, 
however there are a huge diversity of other disorders involving nervous system 
dysfunction including other forms of dementia, epilepsy, multiple sclerosis, 
amyotrophic lateral sclerosis, Huntington’s disease (HD), and Prion disease. 
Both the central and peripheral nervous systems may be involved, and the 
diseases can be widespread or restricted to certain neurones or body regions, 
and may also be associated with other non-neurological features.  
Neurodegenerative diseases are among the major contributors to disability and 
disease, and are becoming increasingly prevalent with the aging of the general 
population(8). Together these diseases are amongst the most costly and 
devastating of diseases to both the patients and their families. According to the 
Neurological Alliance, in 2014 there were estimated to be 12.5 million cases of 
various neurological diseases in England alone, resulting in an annual cost of 
£4.5 billion to the National Health Service (NHS), representing 4.2% of overall 
NHS expenditure(9). Of these 12.5 million cases, ~350,000 (~2.8%) individuals 
require help for most of their daily activities. Between the years of 2003/4 and 
2013/13, NHS expenditure on neurological conditions increased by >200% and, 
in addition to this, it is estimated that £2.4 billion is spent on social care services 
for people suffering from neurological conditions each year. Parkinson’s disease 
(PD) alone, the second most common neurodegenerative disorder, has an 
estimated direct and indirect cost of care and treatment of approximately £2 
billion in the UK.  
The advent of modern genomic technologies has recently enabled pioneering 
research into the pathogenic disease mechanisms and putative treatment 
strategies of a range of neurodegenerative diseases(8). Mutations causative of 
neurodegenerative conditions have been identified in a number of disease 
genes, providing a better understanding of the underlying molecular pathways 
involved as well as identifying possible future treatments. Genetic analysis has 
also shed invaluable light on a number of the pathways underlying 
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neurodegenerative disease, and identified common biological processes that 
appear to be shared between different disease phenotypes. These studies have 
shown that neurodegenerative disease may relate to a wide range of 
pathogenic mechanisms, including oxidative modification, mitochondrial 
dysfunction, impaired protein degradation, and defective axonal transport 
mechanisms. Factors contributing to neurodegeneration include genetic factors, 
including the normal aging of the nervous system, and environmental factors 
(10-12). 
 
1.3 Embryogenesis and development of the nervous system 
In order to understand degenerative diseases of the nervous system, it is first 
important to understand normal neurological development. The information that 
follows gives an up-to-date outline of the current understanding of neurological 
development and is collated from well-established medical text books(13-17) 
and review articles(18-22).  
 
1.3.1 Gastrulation and embryonic germ layer formation 
There are a number of essential processes and cell differentiation steps during 
the very early stages of embryogenesis which lay down the initial foundations 
for the development of the nervous system.  About 4 days following fertilisation, 
once the embryo reaches 8-16 cells (morula), the cells differentiate into two 
groups: the trophoblast (outer cell layer) and the embryoblast (inner cell mass), 
collectively known as a blastocyst. The trophoblast develops to form a large part 
of the placenta. The embryoblast will give rise to the embryo itself as well is its 
associated extraembryonic membranes. By the end of the first week of 
development the embryoblast splits into the hypoblast and epiblast layers to 
form the embryonic disk. At the start of the third week of development, by a 
process of cell migration called gastrulation the epiblast layer subdivides to form 
the three germ cell layers: ectoderm (outer), mesoderm (middle), and endoderm 
(inner).  
Gastrulation commences with the appearance of the primitive streak, which by a 
process known as invagination, deepens as epiblast cells move through it to 
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form the ectoderm layer beneath (figure 1). At the caudal end, the addition of 
cells causes it to elongate, whilst its cranial end proliferates to form the primitive 
node. The primitive node contains a circular depression called the primitive pit, 
from which a trough like depression called the primitive groove runs caudally 
down the midline of the primitive streak. After the primitive streak is well 
established, most cells leave via the primitive pit and groove into the interior of 
the embryonic disc where some invade the hypoblast and replace its cells with 
a layer of definitive endoderm, whilst others move between endoderm and 
ectoderm where they form the intraembryonic mesoderm. At this stage, the 
three primary germ layers have formed, each of which will eventually give rise 
to all of the bodies tissues and organs. It is also during gastrulation that body 
axes of the developing embryo are established. 
 
Figure 1. Invagination. A) Dorsal side of the embryonic disk showing the 
movement of epiblast cells (solid black lines) through the primitive streak and 
primitive node, and the subsequent movement of cells between hypoblast and 
epiblast (greyed lines). B) Cross section through the primitive streak showing 
invagination. Modified (Sadler, 2012(15)) 
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1.3.2 Neural induction 
During gastrulation, cells derived from the primitive node migrate cranially 
resulting in the appearance of the notochord plate which folds to form a solid 
cylinder called the notochord. This cellular rod which underlies the future neural 
tube, further defines the axis of the embryo, gives it some rigidity, and indicates 
the future site of the vertebral bodies. The notochord functions as the primary 
inductor in the early embryo and induces overlying ectoderm to thicken forming 
the neural plate. This is the first allocation of a group of ectodermal cells as the 
earliest rudiment of the nervous system.  
Neurulation is the name given to the process whereby the neural plate forms 
the neural tube, the embryo’s precursor to the brain and spinal cord. Towards 
the end of the third week of development the ectoderm thickens and forms the 
neural plate. The lateral margins of the neural plate then elevate to form neural 
folds (figure 2A), which meet and fuse to form the neural tube (figure 2B). Some 
cells from the lateral edges of the neural plate subsequently separate to form 
neural crest cells (figure 2A). These migrate to various locations in the embryo 
where they differentiate into a number of structures and cell types, including 
spinal ganglion cells, glial cells, and peripheral Schwann cells (figure 2C). Late 
in the fourth week of development, the neural tube closes and sinks beneath the 
ectoderm, and neurulation is complete. The central nervous system (CNS) is 
represented by a closed tubular structure of which the narrow caudal end will 
give rise to the spinal cord, and the thicker cranial end will form the brain (figure 
2D).  
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Figure 2. Stages of neurulation.  Shown as diagrams of transverse sections of 
the embryo and the whole embryo A) At 19 days the lateral margins of the neural 
plate start to elevate and the neural crest cells form. B) At 20 days the neural 
groove deepens and neural folds further elevate, meet, and fuse to form the 
neural tube. Neural crest cells detatch and migration in the direction of the blue 
arrows initiates. C) At 21 days the neural tube has started to close and, after 
migration, neural crest cells contribute to a heterogeneous array of structures. 
D) At around 25 days, the cranial opening (neuropore) closes, the caudal 
neuropore closes 2-3 days later (27 or 28 days), and neurulation is complete. 
Modified (Mitchell & Sharma, 2009 (13)) 
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1.3.3 Brain and spinal cord development  
The cranial end of the neural tube forms three dilations that correspond to the 
primary brain vesicles: the prosencephalon (forebrain), the mesencephalon 
(midbrain), and the rhombencephalon (hindbrain). During the fifth week growth 
of the head exceeds that of other body regions and the three primary vesicles 
develop into five secondary vesicles. The prosencephalon forms the 
telencephalon and diencephalon, and the rhombencephalon becomes the 
metencephalon and the myelencephalon. The telencephalon is formed of a mid-
portion between two bilateral portions, which represent the primitive cerebral 
hemispheres.  
The extension of the neural tube caudal to the rhombomeric vesicles gives rise 
to the spinal cord. The lateral walls of the neural tube thicken and form a 
pseudostratified, columnar epithelium known as the ventricular layer, consisting 
of neuroepithelial cells. Neuroblasts migrate peripherally through the wall to 
form a layer directly around the ventricular layer called the mantle layer, the 
precursor of grey matter. The outer most layer of the spinal cord is the marginal 
layer, containing the axons of the neuroblasts entering and leaving the mantle 
layer, which appears white after myelination (white matter). 
During the sixth embryonic week, the walls of the neural tube exhibit ventral and 
dorsal thickening, forming the alar plates (dorsal) and basal plates (ventral), 
separated by the sulcus limitans groove. Alar plates will form the dorsal horn 
and will generally become part of the sensory system, while the basal plates 
become the ventral horn and will contribute predominantly to motor functions 
(figure 3A). The dorsal and ventral aspects of the now diamond shaped lumen 
of the neural tube become the roof and floor plates respectively, and do not 
contain neuroblasts, but act as connecting pathways for nerve fibres crossing 
from one side to the other. The cell bodies of the efferent sensory neurones are 
in the posterior dorsal root ganglia, on the dorsal side of the spinal cord, and will 
give rise to axons that enter the dorsal root and synapse with neuronal cell 
bodies in the dorsal horn (figure 3B). Neurones in the ventral horn give rise to 
axons that enter directly into the ventral root. A group of neurones also 
accumulates between the dorsal and ventral horns to form a small intermediate 
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horn present only at thoracic and upper lumbar levels of the spinal cord, 
containing the sympathetic neurones of the autonomic nervous system (ANS). 
From the third month the vertebral column and dura start to lengthen more 
quickly than the neural tube, the terminal end of which starts gradually shifting 
to a higher level. This disproportionate growth causes the spinal nerves, which 
till now have passed through the intervertebral foramina adjacent to their level 
of origin, to run obliquely from their place of origin within the spinal cord to their 
corresponding level of the vertebral column. Therefore in adults, the lower 
extremity of the spinal cord is located at the L2-L3 level of the vertebral column 
but its nerve fibres descend to lowers levels to leave from their respective 
intervertebral foramina at the sacral level of the spine.  
 
Figure 3. Cross section of the spinal cord during development. A) In the sixth 
week the alar and basal plates form. B) in the ninth week, grey horns form from 
the basal and alar plates. Modified (Tarant County College, 2014(23)) 
 
1.3.4 Genetic and molecular regulation of spinal cord development  
Normal functioning of the nervous system allowing motor coordination and 
sensory perception is reliant on the formation of extraordinarily spatiotemporally 
precise and complex cell connections between distinct cell types.  Generation of 
neuronal diversity, and proliferation and migration of the various neuronal cells, 
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is a multistep process requiring finely balanced control from both intrinsic and 
extrinsic influences.  
At the neural plate stage, the entire plate in the spinal cord region of the embryo 
expresses homeodomain containing transcription factors: paired box genes 3 
and 7 (PAX3 and PAX7) and muscle segment homeobox genes 1 and 2 (MSX1 
and MSX2). Sonic hedgehog (SHH) and bone morphogenetic proteins 4 and 7 
(BMP4 and BMP7) control the expression pattern of these transcription factors, 
and provide positional cues. SHH secreted from the notochord is essential for 
roof plate and floor plate induction, as well as motor neurone specification. 
Ventral (floor plate) patterning commences prior to dorsal (roof plate) patterning 
and results in the production of specific motor neurone subtypes in localised 
domains of the ventral cord. SHH represses transcription of class I 
homeodomain transcription factors (PAX6, PAX7, brain developing homeobox 2 
[DBX2], Iroquois-class homeodomain protein [IRX3]), ventralising the neural 
tube. Once formed, the floor plate also secretes SHH forming a concentration 
gradient across the spinal cord which generates 5 subclasses of ventral 
neurones. Downstream class II homeodomain proteins such as NKX6.1, 
NKX6.2 and IRX3 have roles in motor neurone specification, positioning of 
motor neurone initiation, and maintenance of progenitors potential to become 
motor neurones. BMP4 and BMP7 are secreted by the non-neuronal ectoderm 
overlying the neural tube establishing a second signalling centre in the roof 
plate. BMP4 and 7 trigger their own production in a positive feedback loop, and 
stimulate the production of wingless-related mouse mammary tumour virus 
integration site (WNT) proteins. WNT signalling is vital for the control of 
proliferation, migration, and axon guidance of neighbouring dorsal 
interneurones. The presence of BMP4 in the roof plate initiates a cascade of the 
following transforming growth factor beta (TGF-β) proteins within the roof plate 
and its surroundings: BMP5, BMP7, activin and dorsalin-1. As in ventral 
patterning, temporal and spatial organisation of this cascade creates 
concentration gradient of the mentioned morphogens from the floor plate - 
ventrally. BMP7 also plays a role in axon guidance. BMP inhibitors noggin, 
follistatin, and chordin also play an important role in dorsal patterning. On the 
dorsal side of the neural tube, the expression of BMP4 and BMP7 also 
regulates and maintains PAX3 and PAX7, major regulators of the early 
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development of neural crest cells in the top of the neural fold. However, their 
role and those of MSX1 and MSX2 in differentiation of sensory neurones and 
interneurones is yet to be elucidated. It has been suggested that MSX1 and 2 
may act as transcriptional activators of atonal homologue 1 (ATOH1)(24). Their 
expression throughout the neural plate during earlier stages is essential for the 
formation of ventral cell types, despite their being excluded from ventral regions 
in later stages by SHH. With exception to the midline, PAX6 is expressed 
throughout the elevating neural fold and is maintained following the neural tube 
closure. 
An important aspect of spinal cord development is the grouping of neurones 
with common functions into longitudinal columns. Signals from the presomitic 
mesoderm, particularly fibroblast growth factor (FGF) and retinoic acid (RA) 
appear vital for inducing appropriate columns at appropriate spinal levels. A 
number of columns and sub-columns form, identifiable by their unique patterns 
of homeodomain transcription factor expression. This patterning and 
longitudinal column formation is regulated by a number of factors including the 
LIM/homeodomain family of transcription factors (ISL1, ISL2, LIM1,LIM 3) and 
HOX restriction factors, which act in cooperation with RA, FGF, WNT and TGF-
β superfamily members.  
 
1.3.5 Histological differentiation 
1.3.5.1 Neurone development 
All neurones, glia, and ependymal cells of the CNS arise exclusively from 
neuroepithelial cells of the ventricular layer. Once neuroblasts form from these 
cells, they lose their ability to divide. Neuroblasts initially have a central process 
extending to the lumen. As they migrate into the mantle layer they become 
temporarily round and apolar before further differentiation results in the 
appearance of two new processes on opposite sides of the cell, forming a 
bipolar neuroblast. One of these processes undergoes rapid elongation to form 
the primitive axon, and the other develops a number of cytoplasmic 
arborisations which represent primitive dendrites. This multipolar neuroblast is 
the direct precursor of the neurone. Neuronal axons in the basal plate migrate 
through the marginal layer to form the ventral motor root of the spinal nerve, 
where they conduct motor impulses from the spinal cord to the muscle fibres 
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(figure 4).  Axons of sensory neurones in the alar plate (dorsal horn) also 
penetrate to the marginal layer of the spinal cord; however from here they 
ascend to either higher or lower levels to form interneurones. 
 
 
Figure 4. Cross section of the spinal cord showing a typical motor neurone 
originating in the ventral horn. A single axon extends from the cell body to the 
effector (muscle) cell. Modified (http://classes.midlandstech.edu/carterp/Courses/ 
bio110/chap08/chap08.htm)  
 
1.3.5.2 Glial cells, neural crest cells, and spinal nerves 
After cessation of neuroblast production, the ventricular layer starts to form a 
new cell type from the neuroepithelial cells, glioblasts. These migrate to the 
mantle and marginal layers where they differentiate into protoplasmic and 
fibrillar astrocytes. In the marginal layer glioblasts form oligodendroglial cells. 
Later in development glioblasts form a third cell type, microglial cells, in the 
CNS. All glioblast derived cells act as supporting cells, and following cessation 
of their production by neuroepithelial cells, they differentiate into ependymal 
cells and line the central canal. Neural crest cells form along each edge of the 
neural folds during neural plate elevation and extend throughout the length of 
the neural tube and give rise to the sensory dorsal root ganglia of the spinal 
nerves. Neuroblasts that do not become neurones or glial cells develop into 
sensory nerve cells. Neuroblasts of the sensory ganglia form two processes. 
One is centrally growing and penetrates the dorsal portion of the neural tube to 
form the dorsal sensory root of the spinal nerve and either end in the dorsal 
35 
 
horn, or ascend through the marginal layer to one of the higher brain centres. 
The other peripherally growing processes join fibres of the ventral motor root 
and terminate in the sensory receptor organs. Sympathetic neuroblasts, 
Schwann cells, pigment cells, odontoblasts, meninges, and mesenchyme of the 
pharyngeal arches also derive from neural crest cells. Motor neurones arise 
from cells in the ventral horns collecting into bundles called ventral roots. Dorsal 
roots form from bundles of sensory nerve fibres originating in the dorsal root 
ganglia. Bundles of central processes from the dorsal root ganglia grow into the 
spinal cord opposite the dorsal horns and distal processes join the ventral roots 
to form a spinal nerve. Spinal nerves then almost instantly start to divide into 
ventral and dorsal primary rami. The ventral primary rami form the brachial and 
lumbosacral plexuses. 
 
1.3.5.3 Myelination 
The myelin sheath is a multilamellar spiral of modified plasma membrane 
wrapped around neuronal axons larger than 1µm in diameter that acts as an 
electrical insulator allowing for fast and efficient impulse conduction. Myelin 
sheaths surrounding nerve fibres within the spinal cord are formed by 
oligodendrocytes, and those surrounding the axons of peripheral nerve fibres 
are formed by Schwann cells. Schwann cells originate from the neural crest, 
where from they migrate peripherally and each wraps around a single axon of a 
peripheral nerve to form a neurilemma sheath. Oligodendrocytes are able to 
myelinate upto 50 axons. Myelination of nerve fibres within the spinal cord 
begins during the fourth month of foetal life into the first postnatal year. Fibre 
tracts generally become myelinated at around the same time they become 
functional. 
 
1.3.6 Brain development 
Towards the end of the fourth week of development the cranial end of the 
neural tube forms three dilations corresponding to the primary brain vesicles: 
the prosencephalon (forebrain), the mesencephalon (midbrain), and the 
rhombencephalon (hindbrain). Simultaneously with their appearance, the brain 
bends to produce two flexures; the midbrain (cephalic) flexure located in the 
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mesencephalon, and the cervical flexure at the junction between the 
rhombencephalon and the spinal cord. In the rhombencephalon and 
mesencephalon there are distinct basal and alar plates on either side of the 
midline representing motor and sensory areas, respectively. This is known as 
the brainstem, and as a direct continuation of the spinal cord, it has a similar 
organisation. Conversely, in the prosencephalon, or higher centres, 
accentuation of the alar plates and regression of the basal plates is seen. In the 
fifth week the forebrain further divides into the telencephalon and diencephalon, 
and the hindbrain divides into the metencephalon and myelencephalon. The 
midbrain does not divide and thus the brain now comprises five secondary 
vesicles. The telencephalon will give rise to the cerebral cortex, the corpus 
striatum, and the olfactory bulb (cerebral hemispheres), and the diencephalon 
will develop into the thalamus, hypothalamus and the neural portion of the 
retina. In the hindbrain, the myelencephalon is the predecessor of the medulla 
oblongata, and the metencephalon that of the pons and cerebellum. A third 
flexure, the pontine flexure, develops later in the brain’s development between 
the metencephalon and myelencephalon. The central cavity that forms within 
the brain as it folds becomes the ventricular system.  
 
1.3.6.1 Genetic and molecular regulation of brain development 
The brain is patterned along the craniocaudal and dorsoventral axes. 
Craniocaudal patterning of the CNS commences during gastrulation and neural 
induction. Following establishment of the neural plate, homeobox genes 
expressed in the notochord, prechordal plate, and neural plate signal formation 
of the brain’s three primary vesicles. The Antennapedia class of homeobox 
(HOX) genes, are a family of transcription factors located in clusters on the 
genome that are expressed in overlapping patterns. Genes at the 3’ end of the 
cluster have more anterior boundaries and are expressed earlier than those at 
the 5’ end, establishing a temporal expression pattern of these genes along the 
craniocaudal axis of the hindbrain, activating cascades of genes regulating 
processes such as axis and segmentation. HOX genes thus pattern the 
craniocaudal axis in the rhombencephalon and specify segment identity. Other 
homeodomain containing transcription factors such as LIM/homeobox protein 1 
(LHX1) and orthodenticle homolog 2 (OTX2) pattern the craniocaudal axis of 
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the prosencephalon and mesencephalon. Following formation of the neural fold, 
further homeobox genes are expressed: orthodenticle homolog 1 (OTX1), and 
empty spiracles homolog 1 and 2 (EMX1 and EMX2). Like HOX gene 
expression in the hindbrain, these genes are expressed in specific and 
overlappig patterns specifiying the identity of the prosencephalon and 
mesencephalon. The anterior neural ridge and the encephalic isthmus are two 
other organising centers which form after establishment of the primary vesicles 
and secrete fibroblast growth factor 8 (FGF8). In both locations, FGF8 serves 
as an inducing factor of subsequent gene expression that regulates 
differentiation. Transcription factor forkhead box protein 1 (FOXG1) is 
expressed in the anterior neural ridge in response to FGF8 release and which 
regulates development of the telencephalon. In the isthmus, FGF8 induces the 
expression of engrailed homeobox 1 and 2 (EN1 and EN2) which regulate 
differentiation of the cerebelum and the roof of the mesencephalon. FGF8 also 
induces WNT family member 1 (WNT1) expression, which interacts with EN1 
and EN2 to regulate development of a circumferential area anterior to the region 
of growth factor expression that includes the cerebellum. As in the spinal cord, 
SHH is secreted by the prechordal plate and nototcord ventralising the 
prosencephalon and mesencephalon, and inducing expression of homeobox 
protein NK-2 homologue A (NKX2.1), which regulates development of the 
hypothalamus. BMP4 and BMP7, expressed in the noneuronal ectoderm, 
induce and maintain expression of dorsalising genes such as MSX1.  
As the brain is patterned both along the craniocaudal and dorsoventral axes, 
the expression patterns of the genes regulating these processes overlap and 
interact at the borders of these regions. Additionally, some areas of the brain 
are able to respond to specific signals that others are not, which assists in 
specifying regional differentiation. The molecular mechanisms controlling the 
neuronal diversity of the CNS are not well known or understood, and are only 
now starting to be unravelled. For example, the transcription factor SRY (sex 
determining region Y)-box 5 (SOX5) was recently shown to control 
differentiation of corticofugal neurone subtypes by preventing the premature 
formation of normally later-born corticifugal neurones(25), and the roles of a 
number of transcription factors and transmembrane receptors have been 
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described in the regulation of differentiation of the diverse dopaminergic 
system(26). 
 
1.4 The adult motor system 
The following information gives a description of the current understanding of 
neurological development and is collated from well-established medical and 
anatomy text books(17, 27-31). 
The human motor system controls a complex neuromuscular network, and must 
do so in response to sensory information including visual and auditory, and can 
be divided into several interconnecting parts (figure 5). The motor system 
includes cortical and subcortical areas of grey matter; the corticobulbar, 
corticospinal, corticopontine, rubrospinal, reticulospinal,  vestibulospinal, and 
tectospinal descending tracts; grey matter of the spinal cord; efferent nerves; 
and the cerebellum and basal ganglia. However, control of movement is 
generally regarded as being dependent on the interplay of two major 
descending neuronal motor systems: the extrapyramidal motor system which 
controls involuntary movement and is comprised entirely of fibres originating in 
the brainstem and higher centres; and the pyramidal motor system 
(corticospinal tract) , which controls voluntary movement of skeletal muscle and 
can be further subdivided into two pathways; the upper motor neurone (UMN) 
pathway, and the lower motor neurone (LMN) pathway (figure 6).  
 
1.4.1 The upper motor system 
UMNs are neurones of the brain that innervate, either directly or via 
interneurones, the lower motor neurones of the brainstem and spinal cord. The 
most significant UMNs are those that originate in the cerebral cortex and project 
to either the spinal cord via the pyramidal, or corticospinal tract, or to the 
brainstem via the corticobulbar tract (figure 5). They do not directly innervate 
muscles, yet are essential for the control of LMNs and the coordination of 
movement. Lesions or degeneration of UMNs can lead to severe movement 
defects often referred to as pyramidal tract signs: hyperreflexia, including 
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muscle spasticity, brisk reflexes, Babinsky sign,  and loss of ability to perform 
fine movements.    
 
1.4.1.1 The corticospinal/pyramidal tract 
The corticospinal tract is the most important pathway for voluntary control over 
fine movements and is involved in regulation of posture. Corticospinal tract 
fibres primarily arise from pyramidal cells in the motor cortex. They begin their 
descent as corona radiata before descending to pass through the pyramidal 
decussation in the lower medulla oblongata. Here approximately 90% of the 
fibres cross to the opposite side and descend into the spinal cord where they 
form the lateral corticospinal tract. The other 10% of fibres continue to descend 
on the same side from which they originated as the anterior corticospinal tract. 
80% of these fibres will also cross to the contralateral side and terminate in 
synaptic contact with LMNs and with interneurones of the anterior horn on both 
sides of the spinal cord. Ultimately, 98% of corticospinal tract fibres provide 
contralateral innervation and only 2% remain ipsilateral over their entire course. 
Disruption of the corticospinal tract at or below its cortical origin leads to 
impairment of movement on the opposite side of the body. Corticospinal tract 
fibres signal to alpha motor neurones (see 1.4.2.1) either directly or via 
interneurones. The presence of direct connections between the higher brain 
centres and LMNs allows for rapid transmission from the CNS to the periphery. 
The lateral corticospinal tract serves to regulate voluntary control over fine 
movements of the extremities such as the hands, and the anterior corticospinal 
tract is involved in regulation of postural mechanisms. Some corticospinal 
neurones that innervate the dorsal horn do not signal to muscles to produce 
movement, but act as modulators of primary sensory afferent information 
directed toward the cerebral cortex. The pyramidal tract signs mentioned earlier 
are thus often seen in combination with sensory symptoms. 
 
1.4.1.2 The corticobulbar tract 
The corticobulbar tract is also considered a pyramidal tract with its fibres arising 
from the lateral aspect of the primary motor cortex, and closely following the 
descending pathway of the corticospinal tract. However, unlike those of the 
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corticospinal tract, these fibres contribute to the control of the spinal cord 
indirectly by acting on neurones of the brainstem that project to the spinal cord. 
Other corticobulbar fibres serve as upper motor neurones to all cranial nerves, 
with which they make either direct or indirect synaptic contact. Most 
corticobulbar fibres that supply cranial nerves do so bilaterally. Lesions of the 
corticobulbar fibres that supply cranial nerves causes weakness of the affected 
muscles, known as facial palsy. Lesions to those that supply muscles involved 
in breathing, speech, mastication, swallowing and movement of the tongue 
cause weakness known as pseudobulbar palsy. 
 
1.4.2 The lower motor system 
LMNs are cranial nerves, located in the cranial nerve nuclei of the brainstem, or 
spinal nerves, located in the anterior horn of the spinal cord. The axons of these 
cells leave the spinal cord through the ventral root and extend to the muscles of 
the head and neck, and skeletal muscle respectively, and serve as the final 
motor neurones that innervate skeletal muscles at the neuromuscular junction. 
They receive sensory information via interneurones as part of the reflex arc, as 
well as motor signals from the pyramidal and extrapyramidal systems. LMNs 
are important for both spinal and cranial nerve reflex pathways, and for 
voluntary movement. Lesions or degeneration in, or distal of, the anterior horn 
cell result in weakness of the affected muscles with decreased tone and 
atrophy, absent or diminished reflexes, and muscle fasciculations.  
 
1.4.2.1 Alpha and gamma motor neurones 
There are two types of LMN important for muscle movement and reflexes: alpha 
(α) and gamma (γ) motor neurones. α-motor neurones are large LMNs with 
axon diameters of 12-20µm that transmit rapid action potentials (conduction 
velocity = 70-120m/s) and innervate extrafusal muscle fibres via the 
neuromuscular junction (NMJ) to initiate contraction. Extrafusal muscle fibres 
are the main skeletal muscle fibres responsible for muscle contraction. 
Inhibitory interneurones called Renshaw cells located in the ventral horn receive 
excitatory input via branches of α-motor neurones and project back to α-alpha 
motor neurones to form part of local feedback circuits that prevent over activity 
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of the α-motor neurones. γ-motor neurones have small axons compared with α-
motor neurones (3-6µm in diameter) and make up 25-30% of the fibres in the 
ventral root. Firing of γ-motor neurones does not lead to directly detectable 
muscle contraction, but has a role in keeping muscle spindles taut by increasing 
tension on them, increasing sensitivity to overall stretch. γ-motor neurones 
innervate intrafusal muscle fibres of skeletal muscle. Each muscle spindle 
contains 2-10 small intrafusal muscle fibres which stretch and shorten in 
correspondence with contraction and relaxation of the whole muscle, and serve 
as proprioceptors to modulate the muscle contraction. This is important for 
allowing α-motor neurones to continue discharging without losing the 
contraction, and for maintaining posture. 
 
 
Figure 5. Diagram of the organisation of the motor system. Lower motor 
neurones make up the final common pathway to the muscles, and are under the 
control of upper motor neurones, as well as supraspinal control for spinal cord 
reflex mechanisms. The brainstem and the cerebral cortex are the only brain 
regions with direct control of the spinal cord. The basal ganglia receive 
innervation from the cerebral cortex, and control movement by feeding back 
signals to motor regions of the frontal cortex that are involved in movement 
initiation. The cerebellum receives signals from most parts of the CNS involved 
in motor functions, creating feedback loops with each and synchronising the 
output signals, serving as the main intergrater of motor function.  
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Figure 6. Schematic diagram showing upper and lower motor neurones of the 
pyramidal pathway originating in the cerebral cortex, and fibres of the 
extrapyramidal pathway orginating in the brainstem. Both pathways transmit to 
lower motor neurones, which in turn elicite muscle movement. Modified 
(http://highscope.ch.ntu.edu.tw/wordpress/?p=11860) 
 
1.4.2.2 The neuromuscular junction  
The neuromuscular junction (NMJ) is a specialised synapse that provides for 
reliable transmission between the presynaptic nerve terminal of the α-motor 
neurone and postsynaptic muscle cells (figure 53, appendix).  Transmission of 
an electrical impulse across the NMJ is achieved by the release of the 
neurotransmitter acetylcholine (ACh). Its precursors, choline which is 
synthesised in the neuronal soma and then transported to the axon terminals 
via the high affinity choline transporter, and acetyl coenzyme A (CoA) which is 
synthesised in mitochondria, are acetylated by choline acetyltransferase (ChAT) 
to produce ACh. ACh transported into presynaptic vesicles by the vesicular 
acetylcholine transporter (VAChT), and stored until depolarisation of the cell’s 
membrane stimulates its release into the synaptic cleft. This release is 
modulated by receptors at the presynaptic nerve ending, synaptosome-
associated proteins (SNAPs), and vesicle-associated membrane proteins 
(VAMPs). ACh can bind to both inotropic receptors and metabotropic receptors 
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on the postsynaptic muscle cell membrane to stimulate a depolarisation 
response in the muscle cell. In order to prevent multiple synaptic 
depolarisations, ACh is cleaved back into its two component molecules by the 
enzyme acetylcholine esterase (AChE), which are then taken up into the 
presynaptic nerve terminal for reprocessing. Choline is transported into the 
presynaptic nerve terminal by the hemicholinium-3 (HC-3) sensitive, Na+/Cl- 
dependent, high affinity choline transporter (CHT). 
There are two forms of NMJ; “en plaque”, or twitch fibers, where the NMJ 
consists of a typical motor end plate and the terminal axon contains many 
synaptic vesicles, and “en grappe”, where the NMJ consists of multiple contacts 
of nerves much thinner than the en plaque. En grappe synapses innervate tonic 
fibers that are present on only a small number of mammalian muscle fibers 
(extraocular, stapedius, tensor tympani, laryngeal and tongue muscle fibers), 
and have been shown to release ACh by almost an order of magnitude longer 
than twitch terminals. Evidence suggests a role for CHT primarily in sustained, 
high frequency ACh signalling(32), and that reserve stores of ACh are available 
to sustain low frequency ACh signalling(33). Choline can also be acquired 
through other mechanisms for low frequency signalling, such as the 
transporters that maintain choline phospholipid synthesis in all cells. 
 
1.5 Mechanisms of neurodegeneration 
Neurodegeneration is the progressive loss of structure and function of specific 
populations of neurones. In the last 20 years many of the genetic defects 
underlying familial neurodegenerative diseases have been identified, which 
have defined common molecular pathogenic mechanisms. Biological processes 
frequently associated with neurodegenerative disease are summarised in figure 
7 and include aberrant protein structures, mitochondrial dysfunction, oxidative 
DNA damage and repair mechanisms, altered axonal transport and function, 
lipid homeostasis, and neuroinflammation(10, 11, 34-37). The definition of the 
genetic causes of neurodegenerative disease or disease susceptibility has 
furthered our understanding of the mechanisms underlying neurodegenerative 
disease. It is likely that better understanding of the dysfunctional cellular 
processes shared between common neurodegenerative disorders will lead to 
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the development of disease modifying pharmacotherapeutic interventions that 
may be beneficial to a variety of clinical phenotypes(10, 11, 34, 38-45). 
 
Figure 7.  Conceptual model of candidate pathways leading to 
neurodegeneration grouped according to their major site or mode of action 
(intracellular mechanisms, local tissue environment influences, systemic 
influences, and mechanisms related to neurodevelopment and aging). Those in 
bold are discussed in their involvement in neurodegenerative disease in this 
section. Modified (Ramanan, 2013(11))  
 
1.5.1 Selective neuronal vulnerability 
Neurodegenerative diseases often selectively target subpopulations of 
neurones and involve characteristic ranges of pathological and molecular 
features(38). It is important in understanding genotype-phenotype correlation to 
elucidate why only certain cell types may become dysfunctional, degenerate, 
and die, as not only will the vulnerable cell type direct the clinical presentation, 
but may also highlight potential targets for treatment(46). In ADi, cholinergic 
neurones are the most vulnerable to degeneration, yet in PD it is the 
dopaminergic neurones that fall victim, while in ALS upper and lower motor 
neurones degenerate. Although various hypotheses have been proposed, 
precisely why certain groups of neurones are more susceptible than others in 
various neurodegenerative disorders is not well understood. Various 
hypotheses have been suggested to explain the susceptibility of neurones of 
the substantia nigra to oxidative stress by reactive oxygen species (ROS)-
induced injury in PD, including their high levels of copper and iron compared to 
other cells types which can catalyse ROS formation(10), or their low stores of 
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antioxidant molecules, but these do not explain the selective neuronal 
vulnerability of other affected brain regions. In demyelinating forms of the 
peripheral nerve disorder Charcot-Marie-Tooth disease (CMT-I) where cellular 
vulnerability results from peripheral myelin protein-22 (PMP22) and myelin 
protein zero (MPZ) mutations, both associated with the neuronal insulator 
myelin, the factors determining cellular vulnerability are more obvious and better 
understood. 
 
1.5.2 Intracellular mechanisms 
A range of intracellular mechanisms involved in the normal functioning of 
neuronal cells as well as other cell types have been identified as having a role 
in neurodegeneration. The pathways implicated are highly interrelated, and in 
many cases have overlapping or interacting components, and are reviewed in 
this section. 
Apoptosis: Apoptosis and autophagy are basic physiological processes 
encompassing pathways that contribute to the maintenance of cellular 
homeostasis. Apoptosis is generally defined as ‘programmed cell death’, and is 
the predominant form of cell death in chronic neurodegenerative disease. 
Normal cellular apoptotic processes remove old and damaged cells to maintain 
tissue homeostasis without harming adjacent cells(47). Dysregulation of 
apoptosis is associated with many diseases, and is not limited to those that are 
neurodegenerative. However, a characteristic of many hereditary or acquired 
neurodegenerative diseases including stroke, brain trauma, spinal cord injury, 
amyotrophic lateral sclerosis (ALS), HD, ADi, and PD, is aberrant neuronal cell 
death(48). Examples of neurodegenerative disease resulting from dysregulation 
of apoptosis include CMT types -4A, -IIK, and recessive intermediate type A 
(tables 31 and 32, appendix), caused by mutations in ganglioside-induced 
differentiation-associated protein 1 (GDAP1), a regulator of mitochondrial 
dynamics and inducer of apoptosis by promotion of mitochondrial fission(40, 49, 
50); and CMT-4X (table 31, appendix), resulting from mutations AIFM1, an 
apoptosis inducing factor which acts via caspase activation(41). 
Autophagy: Autophagy is the controlled digestion of long-lived, unnecessary, 
or dysfunctional cytosolic proteins and organelles. Failure to degrade and 
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remove misfolded or potentially toxic proteins can lead to organelle damage, 
and the formation of aberrant protein aggregates and inclusion bodies. There 
are two pathways known to be responsible for the elimination of damaged 
cellular components: the ubiquitin-proteasome system, and the autophagy-
lysosome pathway (ALP), both integral to cell function and survival, especially in 
the case of neurones and other long-lived, non-regenerative cell types(51). 
Mitochondria and their physical dynamics play a vital role during numerous 
stages of autophagy (51). Failure to recruit autophagy-associated anchoring 
proteins to the mitochondrial membrane by mutant mitofusin (MFN2), a 
mediator of mitochondrial anchoring to the endoplasmic reticulum, results in 
CMT-IIA2 (table 32, appendix) (51, 52), and failure of protein sorting and 
redistribution of lysosomes essential for the ALP by mutant DYNC1H1, a crucial 
subunit of the cytoplasmic dynein complex, results in lower limb predominating 
spinal muscular atrophy 1 (SMALED1) and CMT-IIO (table 35 and 32, 
appendix) (43, 53). 
Mitochondrial dysfunction: Neuronal cells have an exceptionally high energy 
demand, the primary supply of which comes from mitochondrial oxidative 
phosphorylation(54). Disruption of any one of a number of mitochondrial 
processes, including ATP production, generation or removal of ROS, and 
calcium buffering can lead to mitochondrial dysfunction. Such mutations 
contribute to a number of neurodegenerative diseases, including α-synuclein 
and parkin mutations in PD, superoxide dismutase [Cu-Zn] mutations in ALS, 
huntingtin in HD, and GDAP1 in CMT-4A (table 31, appendix). 
Oxidative stress: The normal aerobic metabolism of oxygen by cells produces 
cytotoxic ROS, or free radicals, as a by-product. Therefore in all cells, but in 
particular in highly metabolically active cells such as neurones, there is constant 
ROS production and subsequent need for their elimination. Oxidative stress 
occurs when there is an imbalance between ROS generation, its metabolism, 
and damage repair(55). Repairing the DNA damage caused by ROS requires 
substantial metabolic energy, presenting a yet greater demand on the 
mitochondria of already highly metabolically demanding cells such as neurones. 
Mutations in genes encoding proteins involved in both ROS production 
(components of the NADPH oxidase enzyme complex) and elimination DJ-1 
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and (SOD1) can lead to increased oxidative stress and subsequent neuronal 
cell death(10).  
Aberrant protein structures: The ubiquitin-proteasome system (UPS) is 
responsible for the targeted degradation of misfolded, aggregated, or otherwise 
abnormal proteins. Where the ALP degrades long-lived proteins, the UPS 
degrades aberrant short-lived proteins in the cytoplasm and nucleus(51). The 
UPS is activated by the ubiquitin labelling of a protein for degradation, causing it 
to be directed to proteasomes in cellular compartments containing protease 
enzymes and/or the ability to recognise ubiquitin-labelled proteins. While 
diverse neurodegenerative disorders involve unique proteins and selectively 
disparate brain regions, they often share two common features: formation of 
insoluble deposits of protein aggregates and neurone degeneration(56). Many 
of the defective proteins that result in mitochondrial dysfunction in 
neurodegenerative disease also cause the formation of protein aggregates.  
Axonal transport: As protein synthesis is restricted to the cell body of 
neurones, and because the axons can extend for great distances from the cell 
body, neuronal cells are presented with unique challenges in transporting 
proteins between the cell body and their synaptic domains. While anterograde 
transport is important in supplying proteins, lipids and mitochondria to the distal 
synapse, retrograde transport is responsible for both the clearance of misfolded 
and aggregated proteins from the axon, and for the transport of distal trophic 
signals to the soma(57). A number proteins involved in axonal transport have 
been identified as being defective in neurodegenerative disease, with roles 
ranging from regulation of neurofilament and microtubule formation and stability 
(mutant NEFL in CMT-IIE: table 32, appendix), to retrograde  and anterograde 
vesicle transport (mutant p150Glued subunit of the dynactin complex and 
DYNC1H1 in dHMN-VIIB, and SMALED1 and CMT-IIO respectively: tables 32 
and 35, appendix)(43, 53, 58-60).  
 
1.5.3 Local tissue environment  
Cell adhesion is the binding of a cell to another cell or to an extracellular 
surface, and is important for the maintenance of synaptic contacts, blood-brain 
barrier integrity, and for efficient neurotransmission and intracellular 
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signalling(11). Altered expression of cell adhesion genes is a consistent finding 
in ADi (APOE ε4), PD (L1CAM) and CMT (MPZ).  
Mutations in genes that interfere with endosomal signalling are among the many 
pathways implicated in neurodegenerative disease such as DYNC1H1 in 
SMALED1 (table 35, appendix) which plays a role in the redistribution of 
organelles such as endosomes and lysosomes, and FIG4 mutations in CMT-4J 
(table 31, appendix) involved in the biogenesis of endosome carrier vesicles. 
Neurotransmitters are endogenous substances that transmit signals across a 
chemical synapse. Pathways involved in neurotransmission, such as calcium 
signalling, and neurotransmitter synthesis, recycling, transport and degradation, 
have been implicated in many neurodegenerative diseases, and can affect all 
types of neurotransmitter signalling (dopaminergic, serotoninergic, 
noradrenergic,  GABAergic and cholinergic)(11, 45) 
 
1.5.4 Systemic environment  
Neuronal membranes contain a substantial amount of cholesterol and other 
lipids, and the myelin sheath of peripheral nerves is formed of proteins and 
phospholipids. Thus, disruption in lipid pathways has often been proposed to 
affect synaptic signalling, neuronal plasticity, and neurodegeneration(11). 
PARK2 and LRRK2 are PD associated genes known to regulate cellular uptake 
of lipid rich structures(11). Immune reactions inside the central nervous system 
are carefully regulated, and undergo several check-points in order to optimise 
protection of the fragile tissue(61). Disturbances in inflammation and immune 
pathways have been reported in ADi, PD, and multiple sclerosis(11, 61).  
 
1.6 Motor neurone degenerative disorders 
The term motor neurone disease (MND), although often used interchangeably 
with the most common form of MND, which is ALS, in fact encompasses a 
range of neurodegenerative disorders which selectively affect motor neurones 
of the spinal cord, brainstem, and motor cortex. The process of 
neurodegeneration in these conditions is often remarkably selective, leaving 
special senses and cerebellar, sensory and autonomic functions intact. There is 
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variation in patterns of involvement between different motor neurone disorders, 
however common early signs motor neurone dysfunction or degeneration allow 
for diagnosis and include: muscle weakness, and eventually wasting that may 
be restricted to a single muscle group; often the lower or upper limbs, a single 
limb, or muscles involved in swallowing, speech and breathing. Clinically, 
subtypes of motor neurone disease are distinguished according to the major 
site of motor neurone degeneration and of the affected muscles. The common 
major subtypes of motor neurone disease include ALS, spinal muscular atrophy, 
progressive bulbar palsy, progressive muscular atrophy, CMT, and primary 
lateral sclerosis (62). MNDs are also classified according to whether they are 
inherited or sporadic, and whether degeneration occurs in the upper or lower 
motor neurones, or both (tables 1 and 2)(63). Diagnosis is made from a detailed 
patient and family history, blood tests, physical examination and neurological 
examination, including electromyography (EMG) and magnetic resonance 
imaging (MRI). 
 
Table 1. Simplified overview of broad clinical features arising from UMN or 
LMN lesions  
Clinical test UMN LMN 
Reflexes Hyperreflexia Hyporeflexia 
Muscle tone Increased (spastic) Decreased (flaccid) 
Fasciculation None Present 
Wasting None Present 
Babinski sign Present Absent 
Abbreviations: LMN=Lower motor neurone; UMN=Upper motor neurone 
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Table 2. Common motor neurone degenerative disorders and their 
features, in which either UMNs, LMNs, or both are affected 
Affected 
neurones 
Associated 
condition 
Features 
LMNs SMA Usually infant to juvenile onset. Distal muscle weakness 
and wasting- often more sever in the trunk and upper leg 
and arm muscles than in muscles of hands and feet. 
Areflexia. Respiratory difficulties.  
CMT Usually childhood or early adulthood onset. Distal muscle 
weakness and wasting- usually presenting and 
predominating in the muscles of the feet and hands. 
UMNs PLS Progressive weakness of voluntary muscle movements of 
the arms, legs and face causing spasticity and stiffness, 
and speech slowing or slurring  
LMNs & 
UMNs 
PBP Weakness of pharyngeal, jaw, facial, and tongue muscles 
causing loss of speech and difficulty swallowing. Limb 
weakness with upper and lower motor neurone signs. 
Emotional outbursts. 
ALS Onset usually between 40 and 60 years. Bilateral 
weakness and wasting of the bulbar muscles and muscles 
of the arms and legs. Spasticity and rigidity of affected 
muscles, and loss of ability to sit upright. 
Abbreviations: LMN=Lower motor neurone; UMN=Upper motor neurone; SMA=Spinal muscular atrophy; 
CMT=Charcot-Marie-Tooth disease; PLS=Primary lateral sclerosis; PBP=Progressive bulbar palsy; 
ALS=Amyotrophic lateral sclerosis 
 
1.7 Overview of hereditary peripheral nerve disorders 
Hereditary peripheral neuropathies have been the focus of investigation by both 
the research and medical communities since the 1800’s when Charcot, Marie, 
and Tooth first descried families with what we now know as a dominantly 
inherited form of CMT. CMT, also known as hereditary motor and sensory 
neuropathy (HMSN) or peroneal muscular atrophy (PMA), is a clinically and 
genetically heterogeneous group of disorders characterised by distal muscle 
weakness and atrophy, and sensory loss(64). With an estimated prevalence of 
17 to 40 per 10,000(65), CMT is one of the most common neurogenetic 
disorders, and the most commonly inherited disorder of the peripheral nervous 
system and thus clinically, an important problem.  
Interplay between fields of genetics, molecular biology and clinical neurology in 
recent years has allowed for pioneering research into the genetic and molecular 
basis of neurodegenerative disease, allowing for more complex and accurate 
disease classification. Common pathways underlie a number of hereditary 
disorders of the peripheral nervous system; often single phenotypes have been 
found to have multiple genetic aetiologies, and conversely, there are many 
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reports of mutations of a single gene producing different and sometimes very 
distinct phenotypes(46). These disorders are highly heterogeneous, and for 
CMT alone, over 1,000 distinct mutations have been reported in over 70 
disease-associated genes(66), encompassing a diverse range of pathogenic 
mechanisms.  
In order to make an accurate diagnosis of a particular neuropathy, it is important 
to first establish that the disorder under investigation is in fact inherited, and not 
sporadic or acquired. In addition to observation of any of the mentioned clinical 
features, neuromuscular analysis such as nerve conduction studies, laboratory 
testing, and histopathologic evaluation may be used to assist in the 
identification of the inherited component beyond family history(67).  
The inherited peripheral neuropathies can be broadly divided into two groups: 
those that are associated with a syndrome (syndromic) and those that are not 
(non-syndromic)(68). Syndromic neuropathies are those which occur as part of 
a group of symptoms that consistently occur together, and characterise a 
disease or medical condition. Neuropathy may or may not be the presenting 
and dominating feature of the syndrome. Giant axonal neuropathy-1 (GAN-1) is 
an example of an axonal syndromic inherited peripheral neuropathy. GAN-1 and 
is characterised by mental retardation, spasticity, early onset peripheral 
neuropathy with giant axons and slowed motor and sensory nerve conduction 
velocities (NCVs), and distinct ‘frizzly’ hair, and is caused my mutations in 
GAN1 and BAG3(68, 69). Further classification can be made according to the 
mode of inheritance, penetrance, age of onset, the presence of absence of 
sensory involvement, whether the neuropathy is demyelinating, axonal, or 
mitochondria related, and the presence of clinical features. 
 
1.7.1 Charcot-Marie-Tooth disease and distal hereditary motor 
neuropathy 
As mentioned earlier, CMT accounts for the majority of cases of inherited 
peripheral neuropathy, and is both clinically and genetically heterogeneous. Age 
of onset is typically during the first or second decade and disease progression 
slow; however both vary between disease subtypes. The cardinal features of 
CMT arise from progressive length-dependent axonal loss resulting in impaired 
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motor and sensory nerve function and subsequent distal muscle weakness and 
atrophy. In addition to peripheral muscle weakness and wasting, key features of 
the disease include diminished or absent deep tendon reflexes and bony 
deformities of the feet such as pes cavus. However, these characteristics 
present with variable expression both between subtypes and between individual 
subjects affected with the same subtype. Individuals affected by CMT usually 
present with symptoms related to weakness, most commonly originating in the 
feet and progressing to the upper limbs. Weakness often presents as an 
abnormal gait as well as frequent tripping and falling, and difficulty running. 
Atrophy of the hand muscles may develop a claw-like positioning of the hand. 
There are several forms of CMT which are often difficult to diagnose due to the 
high clinical and genetic heterogeneity of the disease. This has led to a complex 
classification system(70) that is in a state of constant change as the original 
clinical classification benefits from newer genetic information.  
CMT can be transmitted via all types of Mendelian inheritance and in 2005, was 
broadly subdivided into three distinct forms; a demyelinating form (CMT-I or 
HMSN-I), an axonal form (CMT-II or HMSN-II), and the distal hereditary motor 
neuropathies (dHMNs) or spinal CMT(71). For distinction between the 
demyelinating and axonal forms of CMT, motor nerve conduction velocities 
(mNCVs) of <38m/s are considered indicative of CMT-I, and those above 
38m/s, of CMT-II. Autosomal dominant and recessive intermediate forms of 
CMT (DI-CMT and RI-CMT) also exist in which median mNCVs range from 25-
45m/s. CMT and other related hereditary neuropathies have also been 
classified according to which features predominate. Hereditary neuropathies are 
classified as hereditary motor and sensory neuropathy (HMSN) where muscle 
weakness predominates with mild sensory deficits, distal hereditary motor 
neuropathy (dHMN) if the deficit is purely or predominantly motor, and 
hereditary sensory neuropathy (HSN) is sensory deficits dominate. 
To date, genetic variants associated with CMT have been reported in more than 
70 different genes, encompassing a broad range of protein functions, including: 
structural proteins (PMP22 and lamin A/C)(68, 72), adhesion molecules 
(MPZ/P0)(73), mitochondrial transport proteins (KIF1B and DYNC1H1)(53, 74), 
vesicular transport proteins (DNM2)(75), intracellular membrane trafficking 
regulation proteins (RAB7)(76), neurofilament proteins (NEFL)(58), transcription 
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factors (EGR2)(77), and proteins involved in protein degradation (LITAF)(78) 
(tables 31-35, appendix). Members of groups of functionally related proteins 
have been implicated in various forms of CMT. For example, members of the 
heat-shock family of related housekeeping proteins that are up-regulated in 
response to various cellular stressors, have been reported as being defective in 
CMT. HSPB8 mutations have been reported in axonal CMT-IIL(79) and purely 
motor dHMN-IIA(80), HSPB1 variants have been observed in CMT-IIF and 
dHMN-IIB(81), HSPB3 mutations have been found to cause dHMN-IIC(82), and 
mutations in DNAJB2, encoding heat-shock protein 40 (HSP40) have been 
implicated in both CMT-IIT and distal spinal muscular atrophy type 5 
(dSMA5)(83, 84) (tables 32 and 35, appendix). Six aminoacyl-transfer RNA 
(tRNA) synthetase (ARS) proteins (GARS, YARS, AARS, KARS, HARS and 
MARS) have been associated with CMT-IID, DI-CMTC, CMT-IIN, and RI-CMTB, 
dHMN-II respectively (tables 32, 33 and 35, appendix)(85-89). ARSs are 
ubiquitously expressed, essential enzymes responsible for attaching amino 
acids to cognate tRNA molecules, the first step of protein translation(90). 
 
1.7.1.1 Demyelinating Charcot-Marie-Tooth disease (Type I) 
Charcot-Marie-Tooth disease Type I (CMT-I) is a demyelinating form of 
hereditary motor and sensory neuropathy and is the most frequent subtype of 
CMT. CMT-I is caused by mutations in genes encoding proteins involved in the 
myelination of neurones such as PMP22 (peripheral myelin protein 22) and 
myelin protein zero (MPZ or P0) (figure 8). As described in section 1.3.5.3, 
myelin is a sheath formed of proteins and phospholipids by Schwann cells that 
is wrapped at regular intervals around certain neuronal axons and, when 
normal, aids neurons to transmit impulses more rapidly than non-myelinated 
nerve fibres. Due to the demyelination of axons in CMT-I, it is distinguishable 
from other forms of CMT by markedly reduced nerve conduction velocities 
(NCVs) of less than 38m/s. Neurological features also include enlargement of 
the peripheral nerves, and a segmental pattern of extensive de- and re-
myelination with onion bulb formation, which may lead to diminished feeling in 
the feet and essential tremor of the hands(91, 92). The muscle weakness seen 
in this form of CMT typically results in gait abnormalities and clumsiness with 
increased instability in the ankle(92). CMT-I is divided into further subtypes 
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classified according to genetic characteristics, unusual clinical features, and age 
of onset and severity of the disease (table 31, appendix). However, all cases 
display a combination of the classic CMT features with a great degree of 
overlap of features with other CMT subtypes, with or without additional unusual 
clinical features. Penetrance and severity varies between subtypes, and even 
within the same subtype. Recessively inherited demyelinating forms of CMT 
have been reclassified as CMT-4(68)(table 31, appendix) 
PMP22 and MPZ mutations are the most common causes of CMT-I and have 
each been implicated in a number of subtypes (table 31, appendix), as well as 
Déjérine-Sottas neuropathy, congenital hypomyelinating neuropathy, and in the 
case of MPZ, intermediate and axonal forms of CMT(68).Where duplication of 
PMP22 results in a CMT-IA phenotype (the most common form of CMT), 
PMP22 deletions lead to hereditary neuropathy with liability to pressure palsies 
(HNPP), and different point mutations in this gene may cause either 
phenotype(93). 
 
 
Figure 8. The architecture of the myelinated axon in the peripheral nervous 
system and the myelin proteins defected in CMT-I. A) Shows Schwann cells 
positioned along the axon, one of which has been “unrolled” to expose the 
regions forming compact myelin and non-compact myelin (paranodes and 
incisures). B) Shows that CMT-I associated proteins P0 (MPZ), PMP22, are 
situtated within the compact myelin. Modified (Scherer, 2015 (68)) 
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1.7.1.2 Axonal Charcot-Marie-Tooth disease (Type II) 
Where CMT-I is due to myelination abnormalities, CMT-II is caused by defects 
in proteins with a role within the axon or cell body of the nerves. These include 
proteins involved in vesicular, mitochondrial and ion transport, in organelle 
structure, and in a cells response to oxidative stress. The classic CMT features 
described earlier are seen in CMT-II patients. In addition, restless leg syndrome 
is seen in almost 40% of CMT-II cases(94). However, the majority of CMT 
cases are distinguished as being either the demyelinating form or axonal form 
by use of a motor median NCV cut off value of 38m/s, whereby CMT-II is 
associated with NCVs above this value. Diagnosis of CMT-II may be hindered 
by axonal loss making it impossible to measure motor NCVs in some patients. 
Histological examination of CMT-II patients has shown axonal neuropathy with 
loss of large myelinated axons and indication of axonal regeneration with many 
small, thinly myelinated axons(95). In some cases, this secondary 
demyelination causes NCVs to be reduced leading to further diagnostic 
complication.  Similarly to CMT-I, CMT-II can be subdivided into further 
subtypes according to genetic characteristics and the presence of unusual 
clinical features, such as involvement of both upper and lower limb muscles, 
presentation and predominance of muscle weakness and atrophy in the hands, 
pyramidal tract signs, pupillary abnormalities and varying degrees of hearing 
loss, and the presence of ulcers and infections which lead to the amputation of 
toes (table 32, appendix). As in CMT-I, age of onset and severity of the disease 
varies both between subtypes and within the same subtype. 
 
1.7.1.3 Intermediate Charcot-Marie-Tooth disease 
Increasing numbers of CMT patients manifest features of both CMT types I and 
II, further complicating classification and diagnosis. The term intermediate CMT 
was proposed to described CMT patients in which median motor NCVs are 
between 25 and 45m/s(96). Intermediate motor NCVs are often found in males 
with X-linked CMT, however, both autosomal dominant (DI-CMT) and 
autosomal recessive (RI-CMT) forms of intermediate CMT have been described 
(table 33, appendix and figure 9). Interestingly, different mutations in some of 
the genes implicated in either demyelinating or axonal CMT result in CMT with 
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intermediate NCVs. It has been suggested that MPZ is the second most 
frequent gene resulting in intermediate CMT(65). 
 
Figure 9. Diagram of a myelinated nerve fibre showing the locations of the 
proteins mutated in autosomal dominant (black) and autosomal recessive (red) 
forms of intermediate CMT. Modified (Liu, 2014 (65)) 
1.7.1.4 X-linked Charcot-Marie-Tooth disease 
A number of CMT families have been described in which men are affected more 
severely than women(41, 97-102). Features of both demyelinating(103), 
axonal(104), and purely motor(102) have been observed in forms of X-linked 
CMT (CMTX), as have both X-linked dominant(97, 101) and X-linked 
recessive(102, 104-106) modes of inheritance (table 34, appendix). It has been 
estimated that X-linked CMT account for 7-10% of all CMT cases(41). X-linked 
forms of CMT which fit into one of the CMT-I, -II, or dHMN subtypes may be 
mentioned more than once in this chapter. 
GJB1, or connexin32 (Cx32), is one of the connexin family of membrane-
spanning proteins that assemble to form gap junction channels which facilitate 
the transport of ions and small molecules between cells(103). It has been 
shown to be expressed in myelinated peripheral nerves in the paranodal myelin 
loops, and Schmidt-Lanterman incisures of myelinating Schwann cells(103, 
107). GJB1 mutations, responsible for CMT-1X result in variable CMT 
phenotypes, including a stroke-like presentation(108) and CNS 
involvement(109). 
CMT-X4 and CMT-X5 represent X-linked forms of CMT which present as part of 
a syndrome: Cowchock syndrome and Rosenberg-Chutorian syndrome, 
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respectively. Cowchock syndrome is characterised by a triad of slowly 
progressive axonal neuropathy, bilateral sensorineural hearing loss, and varying 
degrees of cognitive impairment, with childhood onset. Cowchock syndrome 
results from mutations in AIMF1, encoding a mitochondrial flavoprotein involved 
in caspase-independent cell death(41). Rosenberg-Chutorian syndrome is also 
characterised by a triad of symptoms: pre-lingual sensorineural hearing loss, 
followed by peripheral neuropathy and visual loss due to optic neuropathy at 
~10 years. Rosenberg-Chutorian syndrome is caused by mutations in a 
metabolic enzyme, Ribose-phosphate pyrophosphokinase 1 (PRPS1), which 
catalyses the synthesis of phosphoribosylpyrophosphate, essential for purine 
metabolism and nucleotide biosynthesis. Mutant PRPS1 has also been 
implicated in phosphoribosylpyrophosphate Synthetase Superactivity, 
characterised by hyperuricemia, neurodevelopmental abnormalities, 
sensorineural deafness, and gout(110), Arts syndrome, characterised by early 
onset hypotonia, ataxia, delayed motor development, intellectual disability, 
hearing impairment and optic atrophy(111), and X-linked deafness 1, a form of  
nonsyndromic hearing loss(112). 
 
1.7.1.5 The distal hereditary motor neuropathies 
The distal hereditary motor neuropathies (dHMNs), also known as spinal CMT 
or distal spinal muscular atrophy (dSMA), are a clinically and genetically 
heterogeneous group of diseases characterised by distal lower motor neurone 
dysfunction. The dHMNs share considerable phenotypic overlap with CMT-I and 
CMT-II, however are set apart in that they are predominantly motor and 
generally lack sensory abnormalities, and are thus considered a third CMT 
subtype. The most common characteristic features of these disorders include 
progressive distal weakness and wasting in the limbs, usually presenting in the 
extensor muscles of the toes and feet with later progression to the upper limbs, 
and foot deformities such as pes cavus and hammer toes. 
In 1993, Harding classified dHMN into seven subtypes (dHMN-I to VII) 
according to mode of inheritance and clinical features, including the distribution 
of muscle weakness, age of onset of the disease and clinical evolution(113). 
Since then, novel forms of dHMN have been reported and the classification of 
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the dHMN subtypes has evolved as the molecular and genetic basis of this 
group of disorders has become clearer. The presence of unusual characteristic 
features such as vocal cord paralysis, diaphragm paralysis, onset and 
predominance in the hands, and pyramidal tract signs can often be used to 
distinguish between subtypes (table 35, appendix). Due to difficulties in 
detecting sensory involvement in CMT-I and CMT–II, electromyography and 
nerve conduction tests are used to distinguish between CMT and dHMN. dHMN 
patients are generally considered to have normal or slightly reduced motor 
NCVs and normal sensory NCVs, where CMT-I and CMT–II patients show both 
motor and sensory involvement. However, the presence of or absence of 
sensory symptoms is no longer a distinctive feature of dHMN as a number of 
dHMN subtypes display minor sensory abnormalities. Mutations of the same 
gene (HSPB1, HSPB8, GARS, TRPV4, DYNC1H1) may be associated with 
either CMT-II or dHMN, and even the same mutation may cause both 
phenotypes(114). The dHMNs also have clinical and genetic overlap with other 
motor neurone diseases with proximal neuromuscular involvement amyotrophic 
lateral sclerosis (ALS), Kennedy’s disease, and spinal muscular atrophy (SMA), 
and these disorders are often considered to be encompassed by the term distal 
hereditary motor neuropathy.  
Despite successful identification of dHMN causing mutations in over 20 genes, 
it has been estimated that 80% of dHMN patients have mutations residing in as-
yet undiscovered genes(114, 115). The genes that have been implicated in 
dHMN encode a functionally diverse array of proteins, including 4 heat-shock 
proteins (HSPB8, HSPB1, HSPB3, DNAJB2) which are produced in response to 
cellular stress, proteins involved in RNA metabolism (IGHMBP2, SETX), 2 tRNA 
synthetase proteins (HARS, GARS), microtubules motor proteins or motor 
complex subunits (dynactin, cytoplasmic dynein heavy chain 1), cation channels 
and transporters (TRPV4, ATP7A), a lipid transporter (SIGMAR1), a 
ubiquitination enzyme (UBE1), and a mitochondrial protein (REEP1).  
This thesis describes two distinct groups of neurological conditions arising due 
to different mutations in the primary cholinergic transporter (CHT). Our data 
show that these conditions include autosomal dominantly inherited dHMNs, and 
autosomal recessively inherited infantile hypotonia, arise due to distinct disease 
mechanisms. A review of this this latter condition is provided in section 4.2. 
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2 MATERIALS AND METHODS 
 
2.1 Buffers, reagents and stock materials 
Table 3. Buffers, reagents and stock solutions and their constituents 
Agarose loading buffer 
 
40% ficoll, 0.2% xylene cyanol, 0.1% bromophenol blue 
ExoSAP For 1 millilitre: 50 U/ml Exonuclease I 50U/ml shrimp 
alkaline phosphatase (both bought from New England 
BioLabs), ddH2O to final volume 
 
Denaturing loading 
buffer (for PAGE) 
0.3% bromophenol blue, 0.3% xylene cyanol, 10mM 
EDTA 
 
Amipicillin 5mg/ml Amp in ddH2O sterilized using a 0.22μM filter unit 
 
Kanamycin 50mg/ml Kan in ddH2O sterilized using a 0.22μM filter unit 
 
Carbenicillin 50mg/ml Carb in ddH2O sterilized using a 0.22μM filter 
unit 
 
SOC medium For 1 litre: 2% (w/v) Bacto tryptone, 0.5% (w/v) Bacto 
yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 
20mM Glucose, ddH2O to final volume, then autoclaved 
 
Luia Bertani (LB) broth 
(Sigma-Aldrich) 
For 1 litre: 25g LB broth base (components: 10g/L 
tryptone, 5g/L yeast extract, 5g/L NaCl), ddH2O to final 
volume, then autoclaved 
 
LB Agar For 1 Litre: 25g LB broth base, 15g Agar, ddH2O to final 
volume, then autoclaved 
 
Phosphate buffered 
saline (PBS) (Life 
technologies) 
 
GIBCO® Dulbecco’s PBS without calcium and magnesium 
1X PBS/Ca2+Mg2+ 1mM MgCl2, 0.1mM CaCl2 in PBS 
 
1X 
PBS/Ca2+Mg2+/glycine 
1mM MgCl2, 0.1mM CaCl2, 100mM glycine in PBS 
 
Transfer buffer  25mM Tris-base, 192 mM glycin, 20% methanol, pH8.3 
TBS 150mM NaCl, 10mM Tris (pH8.0) in ddH2O, adjusted to 
pH8.0 with HCl 
TBST 0.1% Tween-20 in TBS 
 
Protease inhibitor 
(Qiagen) 
 
Protease inhibitor solution 
RIPA buffer 10mM Tris (pH7.4), 150mM NaCl, 1mM EDTA, 1% Triton 
X-100, 0.5% Na deoxycholate, 0.1% sodium dodecyl 
sulphate (SDS) in ddH2O 
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Sodium chloride-Tris-
EDTA (STE) buffer 
100mM NaCl, 10mM Tris (pH8), 1mM EDTA (pH8) in 
ddH2O 
Tris/CHAPS buffer 30mM Tris HCl, 150mM, NaCl, 1% CHAPS in ddH2O 
Low concentration 
Triton X-100 lysis (LCTL) 
buffer 
5mM Tris (pH7.4), 100mM NaCl, 0.5% Triton X-100 in 
ddH2O 
Hypertonic swell 
(SWELL) buffer 
10mM Tris (pH8), 1mM EDTA (pH8) in ddH2O 
Salt solution 1.5M NaCl, 10mM MgCl2 in ddH2O 
2X Laemmli buffer 
(Sigma) 
277.8mM Tris-HCl (pH6.8), 4.4% LDS, 44.4% (w/v) 
glycerol, 0.02% bromophenol blue 
 
4X Laemmli buffer  
(BIO RAD) 
277.8 mM Tris-HCl, pH 6.8, 4.4% LDS, 44.4% (w/v) 
glycerol, 0.02% bromophenol blue 
Krebs-Ringer 
bicarbonate buffer 
(KRHB) 
130mM NaCl, 1.3mM KCl, 1.2mM MgSO4, 2.2mM CaCl2, 
1.2mM KH2PO4, 10mM glucose, 10mM HEPES (pH7.4) 
 
Stripping buffer 200mM glycine, 3.5mM SDS, 1% Tween-20 in ddH2O, 
adjusted to pH2.2 with HCl 
 
2.2 Family recruitment and sample acquisition  
2.2.1 Ethical Approval 
Ethical approval for the research carried out at St. George’s Hospital 
laboratories was granted by the Wandsworth Research Ethics Committee 
(reference 04/Q0803/78, 05/Q0803/161). Research was carried out in 
compliance with the Code of Practice for Human Tissue and Research provided 
by the Human Tissue Authority (HTA), which defines human tissue as relevant 
material which consists of, or contains cells (HTA CoP 9). As this project 
involves the use and storage of blood samples, as well as subsequent DNA 
extraction, the blood must be stored on HTA-licensed premises and research 
must be carried out in accordance with the Human Tissue act 2004. 
The HT Act and the HTA’s code of practice states that informed consent must 
be obtained in order to: 
i. Store and use dead bodies 
ii. Remove, store and use relevant material from a dead body 
iii. Store and use relevant material from the living 
(HTA CoP 1) 
In accordance with the HTA’s code of practice, all subjects from which blood 
samples were taken for analysis were adequately informed about the purpose 
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of the research and how their blood samples would be stored and used. Only 
once a subject felt sufficiently informed and satisfied with the purpose of the 
research, were they asked to give signed consent. 
 
2.2.2 Data management 
On receipt of blood or DNA samples from their respective collection locations, 
each sample was assigned a sample ID, and this as well as clinical and 
molecular information was recorded in a password protected database. The 
vessels containing the samples were anonymised and labelled with the relevant 
sample ID. 
 
2.3 Molecular methods 
2.3.1 DNA extraction 
DNA was extracted and purified from whole blood lymphocytes using the 
Promega ReliaPrepTM Blood gDNA Miniprep system according to the 
manufacturer’s instructions (summarised below), or provided by St. George’s 
Hospital molecular diagnostic laboratory. 
On arrival blood samples were stored at -20°C. Prior to extraction, blood 
samples were thawed completely and mixed thoroughly for 10 minutes at room 
temperature on a rotisserie shaker. Filter pipettes and sterile microcentrifuge 
and collection tubes were used throughout the procedure in order to prevent 
contamination. For each sample, 20μl of Proteinase K was dispensed into a 
1.5ml microcentrifuge tube. 200μl of blood was added to the Proteinase K and 
triturated to mix. 200μl cell lysis buffer was subsequently added to the tube and 
the contents mixed by vortexing for 10 seconds and incubated at 56°C for 10 
minutes. Following incubation, 250μl of binding buffer was added to the tube 
and the contents mixed by vortexing for 10 seconds. At this point it was ensured 
that the lysate was dark green in colour. The contents of the tube were added to 
a ReliaPrepTM binding column placed in a collection tube and centrifuged at 
13,000rpm (max speed of microcentrifuge) for 1 minute. If the lysate was still 
visible at the top of the membrane following centrifugation, the column was spun 
for a further 1 minute. The column was moved to a fresh collection tube, and the 
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flowthrough from the old one was discarded as hazardous waste in a sharps 
bin. The column was then washed by adding 500μl of column wash solution to 
the column and centrifuging it at 13,000rpm for 3 minutes. If any of the solution 
remained visible on the membrane, the column was spun for a further minute. 
The flowthrough was discarded as hazardous waste. This wash step was 
repeated two more times to make a total of three washes. The column was then 
transferred to a clean 1.5 microcentrifuge tube and 50μl of 70°C nuclease free 
water added to the column which was centrifuged at 13,000rpm for 1 minute to 
elute the DNA. The binding column was discarded. The DNA concentration and 
purity of the elute was measured using the nanoDrop, and an aliquot of working 
stock of 10-30ng/μl was prepared by diluting the DNA with molecular grade 
water. 
 
2.3.2 RNA extraction 
Monocyte mRNA was extracted from whole blood collected in PAXgene Blood 
RNA Tubes (BRT) and purified for sequencing using the Qiagen PAXgene 
blood RNA kit according to the manufacturer’s instructions, described below. 
PAXgene BRTs were equilibrated to room temperature after storage at -20˚C 
and then stored at room temperature prior to commencement of the procedure. 
In order to avoid RNase contamination the lab work space, pipettes, tubes racks 
and gloves were cleaned with RNaseZAP® prior to starting the extraction, and 
filter tips were used throughout.  
Blood samples were centrifuged at 3000xg for 10 minutes in the PAXgene 
BRTs in a swing-out centrifuge. The supernatant was removed by pipetting, 
taking care not to disturb the pellet, and 4ml RNase free H2O was added before 
closing the tubes with BD Hemogard closures. The pellet was resuspended by 
vortexing the tubes, which were then centrifuged a 3000xg for a further 10 
minutes. The supernatant was completely removed and discarded. The pellets 
were dissolved in 350μl resuspension buffer and vortexed to ensure completed 
dissolution. The samples were then transferred to 1.5ml microcentrifuge tubes 
and mixed with 300μl binding buffer and 40μl proteinase K by vortexing for 5 
seconds. The samples were incubated at 55˚C for 10 minutes in the shaking 
incubator at 800rpm. The lysate was transferred into a PAXgene Shredder spin 
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column placed in a 2ml processing tube by pipetting and centrifuged for three 
minutes at maximum speed (13,000rpm) in a bench-top micro-centrifuge. The 
entire supernatant of the flow-through fraction was transferred to a fresh 
microcentrifuge tube, taking great care not to disturb the pellet in the processing 
tube. 350μl 100% ethanol was added to the sample and mixed by vortexing 
before briefly centrifuging in order to remove any drops from the inside of the 
lid.  
A 700μl volume of sample was pipetted into a PAXgene RNA spin column 
placed in a 2ml processing tube and centrifuged at 10,000xg for 1 minute. The 
PAXgene RNA spin column was placed in a fresh 2ml processing tube, and the 
flow-through in the old processing tube was discarded. 350μl wash buffer 1 was 
pipetted into the PAXgene RNA spin column and centrifuged at 10,000xg for 1 
minute. Again the spin column was placed in a fresh 2ml processing tube, and 
the flow-through discarded.  
In a 1.5ml microcentrifuge tube, 10μl DNase I stock solution was mixed with 
70μl DNA digestion buffer and mixed gently by flicking the tube before briefly 
centrifuging to collect the fluid at the bottom. The full volume (80μl) of this mix 
was then pipetted directly onto the PAXgene spin column membrane and 
incubated at room temperature for 15 minutes. 350μl wash buffer 1 was 
subsequently pipetted into the spin column and the column was centrifuged at 
10,000xg for 1 minute. The spin column was transferred to a new 2ml 
processing tube, and the flow-through discarded. 500μl wash buffer 2 was 
pipetted into the spin column and the column was centrifuged at 10,000xg for 1 
minute. The spin column was transferred to a fresh 2ml processing tube, and 
the flow-through in the old processing tube was discarded. Another 500μl wash 
buffer 2 was added to the spin column and the column was centrifuged at 
10,000xg for 3 minutes. The spin column was transferred to a fresh 2ml 
processing tube, the flow-through discarded, and the spin column was 
centrifuged for 1 more minute at 10,000xg. The processing tube containing the 
flow-through was discarded and the spin column was placed in a 1.5ml 
microcentrifuge tube. 40μl elution buffer was pipetted directly onto the PAXgene 
spin column membrane and the spin column was centrifuged at 10,000xg for 1 
minute in order to elute the RNA. Another 40μl elution buffer was pipetted 
directly onto the spin column membrane and the spin column was centrifuged at 
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10,000xg for 1 minute, keeping the spin column placed in the same 
microcentrifuge tube. The elute was incubated at 65˚C for 5 minutes in the 
shaking incubator to denature the RNA, and then chilled immediately on ice. 
RNA was stored at -80˚C and used in reverse transcription PCR (RT-PCR) 
followed by sequencing as described in sections 2.3.8 to 2.3.13. 
 
2.3.3 Reverse transcription PCR (RT-PCR) 
R-PCR is a technique used for the indirect amplification of RNA by first making 
a complimentary DNA copy for amplification and sequencing, from which the 
RNA sequence can be deduced.  
Prior to commencement of the procedure the workspace, including the bench 
top, pipettes, pipette racks, and filter-tip boxes, was cleaned first with 70% 
ethanol and then with RNaseZap (Ambion) to eliminate any traces of RNase. 
Filter tips were used throughout the procedure. RNA extracted from whole blood 
monocytes (see 2.3.2) and stored on ice was subjected to the Titanium one-
step RT-PCR kit (Clontech), according to the manufacturer’s protocol.  
Primers for RT-PCR were designed to anneal to exonic sequences separated 
by at least one intron using Primer3 software (version 0.4.0, available at 
(http://bioinfo.ut.ee/primer3-0.4.0/) and ordered from Sigma-Aldrich. The 
programme settings were altered so that primers were designed according to 
the following criteria: 
 Primers should be at least 22 bases in length (ideally 25-30) 
 Primer melting temperature should be ~70°C  
 Primer should have a GC content of 45-60% 
Primers were diluted to 45µM for use. A master mix was made for each control 
and experimental reaction comprising the constituents in table 4, and RNase 
free water was added to bring the total volume to 50µl. A negative control 
reaction containing RNase free water in place of RNA was included to control 
for contamination. When carrying out RT-PCR it is important to be confident that 
it is in fact RNA that is being amplified, and not genomic DNA. To control for 
this, an additional control reaction was prepared in which standard taq, used in 
PCR, was used in place of the Titanium taq and the RNA replaced with ddH2O. 
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A positive control reaction was also run containing mouse liver total RNA and 
primers specific to mouse β-actin (provided with kit). The reaction mixes were 
placed in a Eppendorf 96-well Mastercycler, thermal cycler machine and run 
through the heat cycling parameters detailed in table 5. 
Table 4. RT-PCR constituents and their volumes 
Component Volume (µl) 
 Positive 
control 
Experimental 
reactions 
10X One-Step Buffer 5 5 
50X dNTP Mix 1 1 
Recombinant RNase Inhibitor (40u/µl) 0.5 0.5 
Thermostabilising Reagent 25 25 
GC-Melt 10 10 
Oligo(dT) primer 1 1 
50X Titanium Taq RT Enzyme Mix 1 1 
Control mouse liver total RNA 1 - 
Control mouse β-actin primer mix 1 - 
Experimental RNA sample (1ng-1µg) - 1-5.5 
Experimental PCR primer mix (45µM) - 1 
RNase free H2O 4.5 To 50 
Total Volume 50μl 50μl 
 
Table 5. RT-PCR thermal cycling program 
Number of cycles Temperature (°C) Time  
1 50 1 hr 
1 94 5 min 
40 94 30 sec 
65 30 sec 
68 1 min 
1 68 2 min 
 
The size of the products were analysed by agarose gel electrophoresis (see 
2.3.11), on a 2.5% gel for 90 minutes. 
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2.3.4 Whole-exome sequencing in dHMN-VII family 
Whole-exome sequencing was performed by Dr Saeed Al-Turki and Dr Matthew 
Hurles at the Wellcome Trust Sanger Institute (WTSI), and also provided 
guidance and support with the analysis of the data. Whole-exome sequencing 
was carried out on a single affected member of the dHMN-VII family. Gene 
coding regions were captured using SureSelect All Exons Target Enrichment 
System (50Mb): an automatable and scalable platform, and target enrichment 
solutions which enrich the genomic region of interest, and sequenced on the 
Illumina HiSeq with 76pb paired ends. In order to call single nucleotide variants 
(SNVs), reads were mapped to the reference genome sequence (GRCh37), 
duplicate fragments were marked using Picard, and GATK (v1.0.130910) was 
used to recalibrate base qualities. GATK was then used to call indels using 
IndelGenotyper. Variants were called using GATK UnifiedGenotyper and poor 
quality sites were filtered out near indels using the following hard filters: QUAL < 
30.0 || AB > 0.75 && DP > 15 || HRun > 5 || SB > -0.10 || DP < 4 || DP > 2000". 
Samtools (v0.1.7) was used to call variants only from reads mapped in good 
pairs (correct insert size range) within the union of the bait and design target 
regions. Variants were filtered out if the read depth <4x or >1200x, if the 
consensus quality <20, or if the SNP quality <25. Dindel was run on a list of 
candidates in the union of the bait and design target regions +/-25bp. All 
variants were annotated using dbSNP (132), and the 1000 genomes pilot study. 
The effect variants on protein structure was predicted by SNP Effect Predictor 
(VEP v2.1) based on the Ensembl database (version 61). Both the SNVs and 
indels called by the mentioned programs were then merged in a single file for 
downstream analysis. 
The VCF file obtained from whole-exome sequencing underwent further custom 
filtering using the exome variant analysis suite (EVA) – now the family based 
exome variant analysis suite FEVA – a software tool developed at the Wellcome 
Trust Sanger Institute which applies custom filters to VCF files in order to select 
a subset variants of interest. In silico predictive analysis of the structural and 
functional outcomes of any candidate variants identified by whole exome 
sequencing was performed using PolyPhen 
(http://genetics.bwh.harvard.edu/pph2/), PROVEAN &SIFT 
(http://provean.jcvi.org/genome_submit_2.php), Mutation Taster 
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(http://www.mutationtaster.org/), VEP 
(http://www.ensembl.org/Homo_sapiens/Tools/VEP), and TMHMM (Tied 
mixture hidden Markov model) (http://www.cbs.dtu.dk/services/TMHMM/) online 
software. 
 
2.3.5 Targeted next-generation sequencing in dHMN-V family 
Sequencing libraries were prepared using the Illumina TruSight One™ 
sequence capture and were sequenced on an Illumina HiSeq 2500. With the 
use of a custom built cloud-based GATK genotyping bioinformatics pipeline 
offering targeted test panels from a 4800 gene menu, the following known motor 
neuropathy genes were analysed: ALS2, ANG, BSCL2, C9orf72, DCTN1, FIG4, 
FUS, GARS, HSPB1, HSPB3, HSPB8, IGHMPB2, DYNC1H1, SLC5A7, OPTN, 
REEP1, SETX, SOD1, SPAST, SPG20, TARDBP, TRPV4, UBQLN2, VAPB, 
CMTX. Next generation sequencing data was visualised using the Integrative 
Genome Viewer (IGV) software. Putative pathogenic mutations were confirmed 
with bi-directional Sanger sequencing. 
 
2.3.6 Whole-exome sequencing in Turkish hypotonia family 
Exome sequencing of this family was carried out in collaboration with Dr 
Sebahattin Cirak at Uniklinik Köln University Hospital, Germany. The exome 
was captured with SeqCap EZ Human Exome Library v2.0 kit (Roche 
NimbleGen). The finished libraries were sequenced on an Illumina HiSeq 2000 
with a paired-end 2x100 bp protocol as per the manufacturer’s guidelines. The 
Cologne Center for Genomics VARBANK pipeline v.2.12 
(https://varbank.ccg.uni-koeln.de/) was used for data analysis and filtering with 
Burrows-Wheeler Aligner-ALN plus hg19 for mapping of reads in combination 
with the GATK toolkit for base quality score recalibration (BQSR), local 
realignment, and variant quality score recalibration (VQSR). Variant 
prioritization and data filtering were conducted using the VARBANK database 
and analysis tools. 
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2.3.7 Whole-exome sequencing in Hispanic hypotonia family 
Exome sequencing of this family was carried out in collaboration with Dr. Omar 
Abdulrahman and Holly Zimmerman, based at the University of Mississippi 
Medical Center, USA. Coding regions were captured using the SureSelectXT 
Target Enrichment System for Illumina Paired-End Multiplexed Sequencing, 
additional probes for 1800 clinically relevant disease genes were included to 
improve the exome coverage. Finished libraries were sequenced on the Illumina 
HiSeq platform with a 100bp paired-end protocol, according to the 
manufacturers guidelines. Exome data was analysed using the Mercury 1.0 
next generation sequence analysis pipeline. Sequencing data were converted to 
bcl file by Illumina CASAVA 1.8 software, and mapped with the Burrows-
Wheeler Aligner (BWA) software (SourceForge). Variant calls were performed 
using the Baylor College of Medicine Human Genome Sequence Center (BCM-
HGSC) Atlas-SNP and Atlas-indel tools and variants were annotated using 
BCM-HGSC-SNP-anno and BCM-HGSC-indel-anno software. 
 
2.3.8 Primer design 
Genomic DNA sequences were obtained from the Ensembl Genome Browser 
(February 2009 and December 2013 assemblies) database. Primers were 
designed for a small section of DNA sequence (200-500bp) using online 
Primer3 software (version 0.4.0, available at (http://bioinfo.ut.ee/primer3-0.4.0/) 
and ordered from Sigma-Aldrich. The guidelines for primer design are as 
follows: 
 Primer length should be between 18-22 nucleotides.  
 Difference in melting temperature between the forward and the reverse 
primers should be no more than 1˚C, preferably between 55-65˚C.  
 Guanine-cytosine (GC) content should be between 40-60%.  
 Use of self-complimentary primers with inter or intra-primer efficiency 
extending more than 3 bases was avoided in order to prevent the 
formation of primer dimers and secondary structures, which would affect 
the PCR.  
 Primers must be 100% complimentary and unique to the region of 
interest to ensure only that region is amplified.  
70 
 
In silico PCR and BLAST analysis was carried out via the UCSC Genome 
Bioinformatics website to ensure primers were specific to the region of interest. 
To ensure that a primer is 100% complimentary to the area of interest, the 
corresponding sequence of DNA must not contain any single nucleotide 
polymorphisms (SNPs).  
 
2.3.9 Polymerase chain reaction (PCR) 
The PCR is a laboratory technique used to selectively and exponentially amplify 
specific DNA sequences in vitro, by up to 109 times. The reaction requires 
repeated temperature cycles, a buffering solution, forward and reverse primers, 
deoxynucleotides (dNTPs: dGTP, dCTP, dATP, dTTP), magnesium chloride 
(MgCl2), DNA, and Taq polymerase (Thermo Scientific). 
Primers, designed as described in 2.3.8, arrive as a solid dried pellet which is 
diluted to a 100ρM/μl stock solution and stored at -20˚C. The stock dilution is 
further diluted to a 5ρM/μl working solution for use in PCR. For each set of 
primer pairs, a master reaction mix is made up with all of the reaction 
components except for the DNA. The master mix volume is dependent on the 
number of reactions required. If using patient DNA, this is dictated by the 
number of samples (patients) plus positive and negative controls (See table 6 
for the constituents and their volumes required for each PCR mix).   
Table 6. PCR constituents and their volumes 
Component Volume (μl) Volume (μl) 
10x Dream Taq Buffer (15mM MgCl2, Thermo 
Scientific)  
1 2.5 
dNTPs (10mM, Invitrogen) 0.4 1 
ddH2O 6.9 17.25 
Forward Primer (5ρM/μl, Sigma-Aldrich) 0.4 1 
Reverse Primer (5ρM/μl, Sigma-Alsdrich) 0.4 1 
Dream Taq polymerase (5U/μl, Thermo Scientific) 0.1 0.25 
DNA 0.8 2 
Total Volume 10μl 25μl 
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The PCR mix was then run through a number of repeated heating and cooling 
cycles in order to melt the DNA (denaturation), bind the primer pairs to their 
complimentary sequence (annealing), and allow enzymatic replication of the 
region of interest (elongation). This was carried out in an Eppendorf 96-well 
Mastercycler, thermal cycler machine. 
A ‘touchdown’ PCR protocol was used, which is a method that helps to avoid 
amplification of regions other than that of interest by improving the specificity of 
the primer binding. This is achieved by incrementally lowering the annealing 
temperature by 2°C every two cycles from an initial temperature that is 4°C 
greater than that of the annealing temperature (Tm) until the desired Tm is 
reached (table 7).  
 
Table 7. Touchdown PCR thermal cycling program 
Number of cycles Temperature (°C) Time (Sec) 
1 95 (denaturation) 120 
2 
95 (denaturation) 
Tm plus 4 
72 (elongation) 
30 
45 
45 
2 
95 (denaturation) 
Tm plus 2 
72 (elongation) 
30 
45 
45 
35 
95 (denaturation) 
Tm (annealing) 
72 (elongation) 
30 
45 
45 
1 72 (elongation) 300 
 
Before use with subject DNA samples, PCR conditions were optimised for each 
primer pair using control DNA samples known to amplify well from their use in 
previous reactions. This allowed for determination of the optimum annealing 
temperature of the primer pair, as well as modification of the PCR reaction 
mixture if necessary (see section 2.3.10- optimisation of PCR primer conditions 
below). When carrying out PCR both with control and subject DNA, a negative 
(water) control was also run to ensure that the desired DNA template was being 
amplified, and not DNA from a contaminant in one of the reaction constituents.   
 
2.3.10 Optimisation of PCR primer conditions 
To determine the optimal annealing temperature for primer pairs, they were 
trialled using a 55-67°C temperature gradient. This was carried out by running 
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12 reactions for each primer pair through a touchdown PCR thermal cycle, each 
with a different annealing temperature which increased incrementally across the 
PCR block from 55°C to 67°C by approximately 1°C. If the temperature gradient 
produced weak or no products across the range of temperatures, often due to 
the GC content of one or both of the primers being above 60%, a second 
gradient was carried out with a 10% concentration of dimethyl sulfoxide (DMSO, 
Fisher Scientific)  in each reaction. DMSO is an organic sulphur compound 
which binds to cytosine residues on DNA, changing its conformity and making it 
more liable to heat denaturation. Should amplification still be inadequate for 
intended use, further temperature gradients were carried out which PCR 
mixtures containing varying concentrations of magnesium (1mM-3mM), in the 
form of magnesium chloride (MgCl2). Magnesium concentration was controlled 
by altering the amount of 10x Dream Taq Buffer and adding an appropriate 
volume of ddH2O to make up the total volume of the reacting mixture. 
 
2.3.11 Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique that uses an electric current to 
separate molecules according to their size. The gel forms a matrix through 
which smaller DNA molecules migrate faster and therefore further through the 
gel than larger molecules. This technique was used to visualize PCR products 
in order to assess the success of the PCR and whether amplification of the DNA 
is adequate for sequencing. 
A 1.5% Agarose gel was made by mixing 1.5g agarose powder (Sigma-Aldrich) 
with 100ml 1X tri-acetate EDTA (TAE) buffer and heating the mixture in a 
microwave for 3-4 minutes or until the powder had completely dissolved. 1μl of 
ethidium bromide (Sigma-Aldrich) was then added and the mixture left to cool 
for 15-20 minutes. Ethidium bromide is a DNA intercalating agent which 
fluoresces brightly when exposed to ultraviolet (UV) light. Rubber seals were 
used to close up the two open ends of the gel plate creating a sealed mould into 
which the gel could set. 28-toothed combs were placed at equal distances along 
the length of the gel plate to create loading wells in the gel. The molten gel was 
poured in to the gel plate and a cellophane cover was placed over it as it set to 
avoid light exposure as the ethidium bromide is UV sensitive. 
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Once the Agarose gel was set, the rubber seals were removed and the gel 
plate, containing the gel, was placed in an electrophoresis tank and submerged 
in 1X TAE buffer. 1μl DNA ladder (1Kb Plus, Invitrogen) was loaded into the first 
well of each row to allow assessment of the PCR product size. 5μl of each PCR 
product was mixed with 2μl agarose loading buffer, and loaded into one of the 
wells. A power pack was used to apply a 100V current across the gel for 20-30 
minutes. The gel was subsequently removed from the tank and the gel plate 
and placed on the illuminator (UV light box with a camera), where the ethidium 
bromide in the gel caused the PCR products to fluoresce under UV light. The 
column in which the negative control was loaded should not fluoresce, if 
products were seen in the negative control, all the PCR products were assumed 
to be contaminated and the reaction was repeated. 
For larger DNA fragments (>500bp), PCR products were run through a lower 
concentration agarose gel (0.8%-1.0%) prepared as above with a lesser amount 
(0.8g-1.0g) of agarose powder. 
 
2.3.12 PCR product purification 
Before sequencing of a PCR product can be carried out, any unincorporated 
dNTPs and primers that remain in the reaction mixture must be removed. For 
this ‘clean-up’ reaction, 2μl ExoSAP (Exonuclease-1 and shrimp alkaline 
phosphatase) was used to purify 5μl of each of the PCR products. The 
exonuclease 1 removes remaining primers and the shrimp alkaline phosphatase 
removes the dNTPs whilst allowing the PCR products to be salvaged.  The 
mixture was incubated at 37˚C for 30 minutes during which the two enzymes 
mentioned above were active, then at 95˚C for 5 minutes in order to deactivate 
the enzymes. 
 
2.3.13 Sequencing reaction 
Purified PCR products underwent a sequencing reaction in order to attach to 
them a fluorescent dye which is read by the sequencer machine. This was 
carried out using the BigDye® Terminator Cycle Sequencing Kit v3.1 (ABI 
PRISM®, Applied Biosystems). 
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A master reaction mix was made for each region of interest (each of the primer 
sets used in the PCR) and 7μl was aliquoted into appropriately labelled 0.2ml 
thermo-tubes. 3μl of the appropriate PCR product was then added to each 
thermo-tube. For each PCR sample, two sequencing reactions were performed 
with the forward and the reverse primers in separate reactions.  (See table 8 for 
the constituents and their volumes required for each sequencing reaction mix).  
Each of the 10μl reaction mixtures was placed into an Eppendorf 96-well 
mastercycler, thermal cycler machine and run through thermal cycle detailed in 
table 9 for a total of 25 cycles. 
 
Table 8. Sequencing reaction constituents and their volumes 
Component Supplier Volume (μl) 
BigDye Terminator Applied Biosystems 0.5 
BigDye Terminator Buffer Applied Biosystems 1.7 
Primer (forward or reverse) Sigma_Aldrich 0.5 
ddH2O  4.3 
Cleaned PCR product  3.0 
Total volume  10 
 
Table 9. Sequencing reaction thermal cycler program 
Number of cycles Temperature (°C) Time (Sec) 
25 
96 
50 
60 
30 
15 
240 
 
2.3.14 Sequencing reaction product purification 
In order to prepare the samples for automated DNA sequencing, they must first 
be purified. Purification of the sequencing reaction products was carried out 
using the BigDye® XTerminatorTM Purification Kit (Applied Biosystems) 
according to the manufacturer’s instructions, described below. 
The BigDye® XTerminatorTM Purification Kit removes unincorporated BigDye 
terminators, salts and other charged molecules from sequencing reactions that 
may interfere with base calling and electrokinetic sample injection (Applied 
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Biosystems). This clean-up reaction requires two reagents: XTerminatorTM 
Solution scavenges unincorporated dye terminators and other charged 
molecules; SAMTM Solution enhances the performance of the XTerminatorTM 
Solution and stabilises the post-purification reactions (Applied Biosystems).  
The sequencing reaction products were loaded into a 96-well plate. The 
XTerminatorTM Solution was vortexed briefly and 5μl was aliquoted into each 
well containing the sequencing reaction products. 30μl of SAMTM Solution was 
also added to each well. The plate was sealed using clear adhesive film 
(Thermo Scientific) and vortexed for 30 minutes then briefly centrifuged. The 
plate was then placed into a 16-capillary 3130xl Applied Biosystems® 
Automated DNA Sequencer for sequencing on a 36cm array POP7 polymer 
programme setting. 
 
2.3.15 Restriction digest 
A restriction digest is a method used to cleave DNA fragments by digestion of a 
given DNA molecule, at specific sites (restriction sites) recognised by a 
particular restriction enzyme. Polymorphisms which create or eliminate a 
restriction site are called restriction fragments length polymorphisms (RFLP). 
Restriction digest is a technique by which an RFLP can be detected by using a 
restriction enzyme specific to that variation to fragment a length of DNA. 
Resulting DNA fragments are then sized by agarose gel electrophoresis or 
PAGE as in 2.3.11 and 2.3.16, respectively. This was carried out to confirm the 
presence of the putative disease causing variants in affected subjects, and its 
absence their unaffected family members, as well as control populations. 
A restriction digest reaction mixture is constituted of PCR product (amplified 
DNA) of the area of interest, 10X buffer, the appropriate restriction 
endonuclease and ddH2O. The sequence containing the variant and the wild 
type sequence was entered into NEBcutter V2.0 online 
(http://tools.neb.com/NEBcutter2/) software to identify restriction enzymes that 
cut the two sequences differently, and these were selected for use. 
A restriction digest master mix was made with all the constituents, except for the 
PCR product, and 12.5μl was aliquoted into appropriately labelled 0.2ml 
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thermo-tubes. 2.5μl PCR product was then added to each tube, and the tubes 
were incubated at 37˚C overnight (8+ hours). Two methods were used to 
visualise the restriction digest products, agarose gel electrophoresis or PAGE. 
For agarose gel electrophoresis, a 3% Agarose gel was made (3g Agarose 
powder, 100ml 1X TAE buffer) as described in 2.3.11 and the restriction digest 
products loaded and run through it for 1 hour prior to being visualised in the 
illuminator. For PAGE see 2.3.16.  
 
2.3.16 Denaturing polyacrylamide gel electrophoresis (PAGE) 
PAGE was used in order to visualise the products from restriction digest 
reactions. Prior to running the restriction digest products on the PAGE gel, they 
were visualised by agarose gel electrophersis to determine the relative volumes 
of product and loading buffer required for page, according to the strength of the 
PCR/restriction digest product. 
An 8% denaturing acrylamide gel was made from the following components: 
25ml Gene Page 8% (Amresco), 40µl TEMED (N’N’N’N’-
tetramethylethylenediamine, Sigma-Aldrich) and 40µl 25% APS (ammonium 
persulphate, Sigma-Aldrich). The components were mixed for 30 seconds with a 
magnetic stirrer, then poured into a gel casting apparatus and left to set for 1 
hour. Once set, the gels were placed into an electrophoresis tank and the tank 
was filled with 1L 65°C 1X TBE. The restriction digest products were mixed with 
denaturing loading buffer (formamide, bromophenol blue, and xylene cyanol) 
and subsequently 1µl of the mixture was loaded into each well. These were 
electrophoresed at 100mA for an appropriate length of time to ensure sufficient 
separation of the different sized products. 
The gel was fixed with an aqueous fixing solution (10% ethanol (BDH), 0.5% 
glacial acetic acid (BDH)) for 15 minutes. It was then silver stained by 
submersion in an aqueous solution of 0.1% silver nitrate (Sigma-Aldrich) for 10 
minutes followed by submersion in an aqueous solution of 1.5% sodium 
hydroxide (BDH) and 0.15% formaldehyde (BDH) until visualisation of the bands 
had occurred (~10-15 minutes). The gel was finally fixed with an aqueous 
solution of 0.75% sodium carbonate (BDH) for 5 minutes. Between each of 
these steps the gels were rinsed thoroughly with distilled water. Following the 
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final wash with water the gel was wrapped in Saran wrap, appropriately labelled, 
and the bands analysed over a white light box. 
 
2.3.17 Bacterial culture: growth and maintenance 
Transformed DH5α competent Escherichia coli (E. Coli) cells were propagated 
both in Luria Bertani (LB) broth, and on agar plates, supplemented with 
antibiotic at 37°C overnight. Cells grown in liquid LB broth were used 
immediately for plasmid extraction once fully confluent. Cells grown on agar 
plates were stored at 4°C in sealed bags for later selection of colonies for 
further propagation. Frozen cell stocks were made by mixing 0.5ml of fully 
confluent liquid culture with 0.5ml 100% sterilised glycerol by vortexing, followed 
by storage at -80°C.  
 
2.3.18 Heat shock transformation of chemically competent bacteria 
Heat shock transformation is a process in which the membrane of chemically 
competent cells is made permeable by heating to allow ingestion of foreign DNA 
for propagation. This technique was used for propagation of pRK5α vectors 
containing gene constructs of interest for later use in function investigation in 
transiently transfected cell lines, and in sub-cloning (see 2.3.19) of wild type and 
mutant alleles for sequencing of separate strands from individuals with 
heterozygous frameshift variants. In both cases, plasmids were transformed into 
competent E. coli. 
Transformation with pRK5 vector: Preparation of this reaction took place in a 
fume cupboard. Chemically competent Subcloning Efficiency™ DH5α™ cells 
(Invitrogen) were thawed on ice. 0.5µg DNA (from site directed mutagenesis 
reaction, 2.3.20) was added to 80µl chemically competent cells, mixed gently, 
and incubated on ice for 30 minutes. The cells were heat shocked at 42°C in a 
water bath for 45 seconds and returned immediately to ice for 2 minutes for 
recovery. 100µl SOC was added to the cells and they were incubated at 37°C 
for 1 hour in the shaking incubator. Cells were then spread on an agar plate 
supplemented with 100µg/ml Ampicillin and incubated overnight at 37°C. 
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Transformation with pCR®2.1 vector (ligation mix): Preparation of this reaction 
took place in a fume cupboard. BL21(DE3) Singles™ Competent E. coli 
(Novagen) were thawed on ice. Once thawed, 2μl ligation reaction product was 
pipetted directly into 50µl cells and mixed gently before incubating on ice for 5 
minutes. The cells were subsequently heat shocked at 42˚C in a water bath for 
30 seconds. The cell were then immediately transferred to ice for 2 minutes to 
recover. 250μl of room temperature LB broth was added to each vial and the 
vials were shaken horizontally at 225rpm at 37˚C for 1 hour in a shaking 
incubator. 100μl cells was then evenly spread across pre-prepared agar plates 
supplemented with 50µg/ml Kanamycin, which were then incubated overnight at 
37˚C. 
The plasmid vectors used in the above transformation reactions contain 
antibiotic resistance genes to the respective antibiotics mentioned. Any cells 
that did not internalise a plasmid during the heat-shock would not contain the 
antibiotic resistant gene and therefore should not grow on the agar 
supplemented with antibiotic. The introduction of antibiotic resistance into the 
cells was necessary to ensure that all the colonies that grew on the agar plates 
contained the DNAs of interest. 
 
2.3.19 Sub-cloning of PCR products 
Sequencing data containing a frame-shift or compound heterozygous mutation 
appears as a double trace before or after the point of change depending on 
whether the forward or reverse primer was used during the sequencing 
reaction. Should a double trace be found in a sequencing file, the two individual 
strands (wild type and mutant) were separated for DNA sequencing by sub-
cloning. This involves incorporating a small (200 bases) length of single 
stranded DNA into the plasmid of chemically competent cells (transformation). 
Any cell that internalises a plasmid will take in only one copy of the region of 
interest, either the wild type or the mutant, because plasmids are single strands 
of DNA. This allows for clean, clear sequencing of the region of interest. Sub-
cloning requires two steps: an initial ligation reaction, described below, followed 
by a transformation reaction as described in 2.3.17. 
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A ligation reaction is a type of DNA amplification, similar to PCR that uses DNA 
ligase to link chains and amplify the template containing the sequence in 
question. DNA ligases are enzymes that catalyse the joining of two DNA 
molecules to form a double helix. This part of the sub-cloning incorporates the 
length of DNA of interest into a plasmid vector (See table 10 for the constituents 
and their volumes required for a ligation reaction). Sub-cloning was carried out 
using the pCR®2.1-TOPO® Vector (Invitrogen), and the TOPO® TA Cloning® 
Kit (Invitrogen). PCR of the sample to be sub-cloned was undertaken, as 
described in 2.3.8, to produce fresh (less than 1 day old) PCR products. A 
master reaction mixture containing all the reagents except for the PCR product 
was made and 8.5μl was aliquoted into appropriately labelled thermo-tubes 
(positive and control). 1.5μl of fresh PCR product and 1.5μl of water was then 
added to the positive tube and the control tube respectively. The reaction 
mixture was incubated at 14°C overnight, and then at 65°C for 10 minutes to 
heat inactivate the T4 DNA ligase before use of the products in the 
transformation reaction, as described in 2.3.18. 
Table 10. Ligation reaction constituents and their volumes 
Component Volume (μl) 
10x Ligation Buffer  1.0 
pCR®2.1 vector (25ng/μl) 2.0 
T4 DNA Ligase (4.0 Weiss units/μl) 1.0 
ddH2O 4.5 
Fresh PCR product 1.5 
Total volume 10 
 
In order to sequence the colonies of transformed cells from the agar plate, 
individual colonies were gently transferred to 0.2ml thermos-tubes containing 
50µl molecular grade water with the use of a sterile 10µl pipette tip. 12 standard 
PCR reactions were made up with the same primers that were used for the 
PCR reaction undertaken prior to the ligation reaction. 1µl was taken from each 
of the 0.2ml thermos-tubes containing sole colonies and added to 1 of the 12 
PCR mixes. PCR was carried out and its success analysed by agarose gel 
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electrophoresis, as described previously. All successful reaction products were 
sequenced by dideoxy Sanger sequencing (see 2.3.13) 
 
2.3.20 Site-directed mutagenesis (SDM) 
Site directed mutagenesis (SDM) is a molecular technique used to introduce 
specific and intentional sequence variations to a gene construct in a plasmid 
vector. SDM was carried out with the use of the QuickChange Lightning Site-
Directed Mutagenesis kit (Agilent) according to the manufacturer’s instructions 
(for SDM primer sequences see appendix 7.3.7), detailed below, in order to 
generate mutant gene constructs. 
Prior to carrying out SDM, mutagenic primer pairs were individually designed 
according to the desired mutation. Wild type gene cDNA sequences were 
obtained from the Ensembl Genome Browser (February 2009 GRCh37/hg19 or 
December 2013 GRCh38/hg38 assembly) database, and primers were 
designed by eye according to the following criteria:  
 Both the forward and reverse mutagenic primers must contain the 
desired mutation 
 Both mutagenic primers must anneal to the same sequence on opposite 
strands of the plasmid 
 Primers should be between 25 and 45 bases in length, and have a 
melting temperature of 78°C or greater 
 The desired mutation should be positioned in the middle of the primer 
with between 12 and 20 bases of correct sequence flanking each side 
 Primers should have a GC content ≥40% 
 Primers should terminate in one or more G or C bases 
A 50µl reaction mix was prepared for each pair of mutagenic primers comprising 
the constituents in table 11, and a 50µl control reaction mix was prepared with 
the constituents listed in table 12 on ice. 1 µl QuickChange Lightning Enzyme 
(derivative of PfuUltra™ High Fidelity DNA polymerase) was added to each 
reaction mix immediately prior to their being loaded in the thermal cycler and 
run through the heat cycling parameters detailed in table 13. 
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Table 11. SDM sample reaction constituents and their volumes 
Component Volume (µl) 
10x QuickChange Lightning Buffer 5 
pRK5 vector containing wild type gene cDNA (50ng/µl) 2  
Forward mutagenic primer (65ng/µl) 2 
Reverse mutagenic primer (65ng/µl) 2 
dNTP mix 1 
QuickSolution reagent 1.5 
ddH2O 37.5 
 
Table 12. SDM control reaction constituents and their volumes 
Component Volume (µl) 
10x QuickChange Lightning Buffer 5 
pWhitescript 4.5-kb control plasmid (5ng/µl) 5 
Oligonucleotide control Primer #1 (100ng/µl) 
5’ CCATGATTACGCCAAGCGCGCAATTAACCCTCAC 3’ 
1.25 
Oligonucleotide control Primer #2 (100ng/µl) 
5’ GTGAGGGTTAATTGCGCGCTTGGCGTAATCATGG 3’ 
1.25 
dNTP mix 1 
QuickSolution reagent 1.5 
ddH2O 34 
 
Table 13. SDM reaction thermal cycling program 
Number of cycles Temperature (°C) Time (Sec) 
1 95 120 
18 
95 
60 
68 
20 
10 
30/kb plasmid 
1 68 300 
 
Following amplification, 2µl DpnI restriction enzyme was added to each sample 
reaction and the control reaction. The tube contents were gently mixed briefly 
centrifuged prior to incubation at 37°C for 5 minutes. DpnI digests the parental 
supercoil dsDNA. The resultant plasmids were transformed into Chemically 
Competent Subcloning Efficiency™ DH5α™ cells (see 2.3.18).  
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The control reaction was used to test the efficiency of mutant plasmid 
generation. The pWhitescript 4.5-kb control plasmid contains a stop codon in 
place of a glutamine codon in the β-galactose gene, and the oligonucleotide 
control primers #1 and #2 create a point mutation which reverts stop codon 
back to the wild type sequence, reintroducing the glutamine residue to the β-
galactose gene product. Following transformation and propagation of 
transformed cells on agar plates, the presence of >100 colonies, of which >85% 
are blue as opposed to white, on the plate spread with the control reaction 
indicates successful mutagenesis.  
 
2.3.21 Plasmid preparation and sequence verification 
Following SDM and transformation, single, stand-alone colonies were picked 
from the agar plate using a sterile inoculating loop and transferred to 10ml LB 
broth supplemented with 100µg/ml Ampicillin and incubated at 37°C overnight 
in the shaking incubator. Once confluent, a frozen stock of each of the grown 
colonies was made, and the remaining cells were spun at 6000 xg for 15 
minutes at 4°C, and the supernatant removed. Plasmids were extracted with the 
Qiagen® Plasmid Mini kit according to the manufacturer’s instructions involving 
an alkaline lysis step and subsequent binding of plasmid DNA to an anion 
exchange resin under low salt and pH conditions. Medium salt washes are 
applied to remove impurities, followed by a higher salt solution wash to elute the 
plasmid DNA. Plasmid DNA was precipitated from the high salt buffer with 
isopropanol, desalted with 70% ethanol, and resuspended in 1x TE buffer. 
The plasmids were then sequence verified by dideoxy sequencing to ensure the 
desired mutations had been introduced, and that no additional variations were 
present. For plasmids found to be sequence verified, larger scale preparations 
were made by transferring a scrape of cells from the frozen stocks into 200ml 
LB broth supplemented with 100µg/ml Ampicillin and incubating at 37°C 
overnight in the shaking incubator. The plasmids were then extracted using the 
Qiagen® Plasmid Midi kit according to the manufacturer’s instructions. 
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2.4 In silico methods 
2.4.1 In silico sequencing data analysis 
The success of the sequencing was checked visually as a chromatogram using 
Finch TV 1.4.0 (created by Geospiza Inc. Avaialble at www.geospiza.com). 
Successful sequences were than compared to the wild type DNA sequence 
(available from the online Ensembl database) using alignment trees created in 
CLC Free Workbench sequence viewer 6.3 (created by CLC Bio A/S). 
 
2.4.2 Mutation Analysis 
The amino acid sequence was obtained for both the wild type and the mutant 
forms of the putative disease causing gene by entering the exonic DNA 
sequence into ExPASy software (https://www.expasy.org/). The amino acid 
sequences then were entered into Tied Mixture Hidden Markov Model 
(TMHMM) software (http://www.cbs.dtu.dk/services/TMHMM/) to produce 
graphs which predict probability of amino acid sequences forming 
transmembrane helices based on the hidden Markov model (HMM). 
 
2.4.3 Conservation Analysis 
The wild type and mutant amino acid sequences for the human disease gene of 
interest, and the wild type amino acid seuqences of the orthologues from 7 
other species (Pan troglodytes, Canis lupus familiaris, Bos taurus, Mus 
musculus, Rattus norvegicus, Gallus gallus, and Caernorhabditis) were entered 
into CLUSTAL W2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/), or CLUSTAL 
Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) software in FASTA format to 
create a multiple alignment. 
 
2.5 Cell culture techniques 
2.5.1 Cell culture 
HEK-293 cells previously found to be negative for mycoplasma infection were 
maintained in 5% CO2, at 37°C in growth medium: DMEM (with 4.5g/L glucose, 
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with L-glutamine without sodium pyruvate) (GIBCO®) supplemented with 1% 
penicillin-streptomycin, 1% L-glutamine, and 10% foetal bovine serum 
(GIBCO®).  
 
2.5.2 Freezing cell line stocks 
When fully confluent, HEK-293 cells cultured as described above were 
harvested and resuspended in freezing medium (growth medium with 15% 
DMSO) and transferred to CryoTubes. These were immediately placed into a 
Mr. Frosty™ Freezing Container in which they were stored overnight prior to 
long term storage in liquid nitrogen. 
 
2.5.3 Cell plating 
HEK-293 cells were plated in either 24-well plates with 100,000 cells/well in 1ml 
growth media, or in 6-well plates with 500,000 cells/well in 2ml growth media. 
The procedure was carried out under a sterilised cell culture hood, and all 
equipment was sprayed with 70% ethanol prior to being placed in the hood to 
avoid infection of the culture. 1X poly-D-lysine (PDL) was dispensed into each 
well in order to promote adhesion of the cells to the bottom of the wells. The 
cells were washed by rinsing 1X phosphate buffered saline (PBS) over the 
inside of the cell culture flask. The PBS was removed from the cell culture flask 
and the cells were trypsinised in 1X trypsin to detach the cells from the flask and 
to break up clumps of cells. The cells were then suspended in 10ml growth 
media (GIBCO®) and counted using a haemocytometer. The cells were then 
appropriately diluted in media in order to plate the appropriate number of cells in 
each well. Once plated, the cells were returned to incubation at 37°C, in 5% 
CO2 for 24 hours before transfection. 
 
2.5.4 Transient transfection of cultured cells 
The cells were transfected using TranIT®-LT1 transfection reagent (Mirus) in 
Opti-MEM® Reduced Serum Media (modification of Eagle's Minimum Essential 
Media, buffered with HEPES and sodium bicarbonate, and supplemented with 
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hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements, and 
growth factors, Invitrogen). For a 6-well plate plated with 500,000 cells/well, 1µg 
plasmid DNA was transfected in 3µl TranIT®-LT1 and 100µl Opti-MEM®. For 
24-well plates with 100,000 cells/well, 200ng plasmid DNA was transfected in 
1.5µl TranIT®-LT1 and 45µl Opti-MEM®.  
Appropriate volumes of TranIT ®-LT1 and Opti-MEM® for the number of well 
to be transfected were mixed in a 15ml BD Falcon tube and incubated at room 
temperature. Appropriate volumes of the DNAs (see tables 36 and 37 in the 
appendix) to be transfected were each transferred to separate BD Falcon tubes 
and the appropriate amount of TranIT®-LT1/Opti-MEM® mix was added to each 
before a 20 minute room temperature incubation. The transfection mix and 
DNAs were then pipetted directly onto the cell containing media in the wells and 
the plates were swirled to ensure mixing. The plates were returned to incubation 
at 37°C, in 5% CO2 for 24 hours before use in assays or for protein extraction. 
 
2.6 Protein methods 
2.6.1 Cell extract preparations 
In order to detect and analyse the protein products of mutant gene constructs 
transiently transfected into HEK-293 cells, the proteins were first extracted.  
The procedure was carried out on ice. Cells plated and transfected in 6-well 
plates as described were washed 2 times with warm (37°C) 1X PBS then 
solubilised in 400µl RIPA containing protease inhibitor on the shaker at 4°C for 
1 hour. Cell lysates were scraped from the wells and transferred to 1.5 
microcentrifuge tubes and spun at full speed (13,000rpm) for 20 minutes at 4°C. 
The supernatant was transferred to clean microcentrifuge tubes on ice, leaving 
the globby pellet of tissue debris behind. The protein content of the cell lysates 
was then quantified by a BCA protein assay. 
 
2.6.2 Bicinchoninic acid (BCA) protein assay 
A protein assay was carried out in order to quantify the amount of protein 
present in cell lysates of transiently transfected HEK-293 cells.  5ml BCA protein 
assay agent (Thermo Scientific) was prepared (BCA protein assay reagent 
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A:BCA protein assay reagent B , 50:1). In a 96-well plate, 10μl BCA standards 
(blank, 0.025mg/ml, 0.125mg/ml 0.25mg/ml 0.5mg/ml, 0.75mg/ml, 1mg/ml, 
1.5mg/ml, 2mg/ml) were loaded into wells with 200μl BCA protein assay agent. 
10μl of each of the protein samples obtained from the biotinylation was also 
loaded into wells with 200μl BCA protein assay agent. Following 20 minutes 
incubation at 37°C, the plate was loaded into a PHERAstar FS microplate 
reader (BMG Labtech) and the concentrations of each sample were calculated. 
Each sample was then diluted in RIPA buffer to meet the concentration of that 
of the lowest concentrated protein prior to their purification. 
 
2.6.3 SDS-PAGE 
A 10% SDS-PAGE running gel solution (see table 14 for SDS-PAGE running 
gel constituents and their volumes) was prepared and poured into a gel mould. 
Once set, a 10% SDS-PAGE stacking gel solution (table 15) was made and 
poured into the mould on top of the running gel. A 15 toothed comb was placed 
in the top of the mould to form the wells. Once the stacking gel had set, gel was 
placed in an electrophoresis tank containing 1X SDS-PAGE running buffer 
(24.8mM tris base, 192mM glycine, 0.1% SDS in ddH2O). Proteins extracted 
from cells and normalised for concentration as described, were mixed with 20µl 
2X Laemmli buffer and spun at maximum speed for 5 minutes. 10µl Spectra 
Multicolor Broad Range Ladder (Thermo Scientific) was loaded into one of the 
wells, and 20µl each protein sample was loaded into subsequent wells. The 
electrophoresis tank was connected to a power pack and a current of 125V was 
run across the gel for 1.5 hours. 
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Table 14. 10% SDS-PAGE running gel constituents and their volumes 
Component Supplier Volume 
(ml) 
ddH2O  4 
Acrylamide 
(30% at 29:1) 
Invitrogen 3.3 
1.5 Tris pH8.8  2.5 
10% SDS Invitrogen 100μl 
10% APS Invitrogen 50μl 
TEMED Invitrogen 5μl 
 
 
Table 15. 10% SDS-PAGE stacking gel constituents and their volumes 
Component Supplier Volume 
(ml) 
ddH2O  3.05 
Acrylamide 
(30% at 29:1) 
Invitrogen 650 
0.5 Tris pH6.8  1.25 
10% SDS Invitrogen 150μl 
10% APS Invitrogen 25μl 
TEMED Invitrogen 5μl 
 
2.6.4 Membrane transfer 
The proteins separated by SDS-PAGE were transferred onto Immobilin-P blot 
membrane (EMD Millipore). The membrane, cut according to the size of the 
SDS-PAGE gel was activated with 100% methanol, and two similarly sized 
sheets of blotting paper were soaked in transfer buffer. The gel was removed 
from the electrophoresis tank, placed in contact with the Immobilin-P blot 
membrane, and sandwiched between the two pieces of blotting paper. A test 
tube was gently rolled over the ‘sandwich’ to remove air bubbles. The sandwich 
was then placed in a transfer tank filled with transfer buffer and connected to a 
power pack, and current of 20V was run through the gel for 18 hours in the cold 
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room. During this time, the ladder and the proteins transfer from the gel to the 
Immobilin-P blot membrane. 
 
2.6.5 Western blotting 
Following transfer of the proteins onto the Immobilin-P blot membrane, the blot 
membrane was removed from the transfer tank and blocked with 3% bovine 
serum albumin (BSA) in 1X TBS with1% Triton (TBST) for 30 minutes at room 
temperature, with gentle agitation on the Belly Dancer® (Sigma-Aldrich). The now 
empty gel was discarded. The 3% BSA-PBST was poured of the membrane and 
the membrane was probed with mouse monoclonal anti-HA antibody (m.m. anti-
HA) (Abcam, ab18181) in 3% BSA-PBST (1:500) for 2 hours at room 
temperature on the belly dancer. The m.m. anti-HA was poured off and the 
membrane was washed three times in 1X TBST for 10 minutes at room 
temperature on the Belly Dancer. The membrane was probed with a secondary 
antibody, goat-anti-mouse-IgG-HRP (Abcam, ab6789) in 3% BSA-TBST 
(1:10,000) for 1 hour at room temperature on the Belly Dancer®. The membrane 
was then washed 3 times in 1X TBST for 10 minutes at room temperature on 
the Belly Dancer® and then submerged in 1X TBS until visualisation. 
Transferred proteins probed with goat-anti-mouse-IgG-HRP secondary 
antibodies were detected with the use of the Western Lightning® Plus-ECL, 
Enhanced ChemiluminescenceSubstrate Kit (Perkin Elmer) and developed on 
Amersham HyperFilm™ ECL (GE Healthcare Life Sciences) in a Konica Minolta 
SRX-101 A-Xray film developer. In the dark room, with the lights on, 2.5ml 
Western Lightning –ECL Enhance Luminol Reagent (Perkin Elmer) was mixed 
with 2.5ml Western Lightning –ECL Oxidising Reagent (Perkin Elmer). The 1X 
PBS was poured off the blot membrane and the Western Lightning mix was 
poured on for 1 minute.  The lights were then turned off. The membrane was 
removed from the Western Lightning mix and the excess fluid wiped off with a 
Kim-wipe. The membrane was placed in an exposure cassette with an 
Amersham Hyper-Film for varying exposure times (1minute, 30 seconds, 10 
seconds and 2 seconds) and the film was immediately placed into the Konica 
SRX-101A-Xray Film Developer. The membrane was wrapped in Saran wrap 
and placed in a C-DiGit® Blot Scanner (LI-COR®) for imaging. 
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2.7 Functional studies 
2.7.1 Cell surface biotinylation experiments in transiently transfected 
HEK-293 cells 
This work was carried out in collaboration with Dr. Randy Blakely and Jane 
Wright of Vanderbilt University School of Medicine.  
Biotinylation is a technique often used to detect and/or purify proteins by the 
process of attaching biotin to the proteins. The functional impact of the putative 
disease causing variants was investigated by heterologous expression of the 
mutant and wild type cDNAs in transiently transfected HEK-293 cells followed 
by biotin labelling of the wild type and mutant proteins produced. The proteins 
were visualised by western blotting.  
HEK-293 cells were plated in 6 well plates and incubated for 24 hours to allow 
the cells to adhere to the bottom of the wells. The cells were then transfected 
with the appropriate cDNAs and incubated for a further 48 hours at 5% CO2 at 
37°C. The cells were washed twice with cold 1X PBS/Ca2+Mg2+ (1mM MgCl2, 
0.1mM CaCl2 in 1X PBS) and incubated in 2ml/well NHS-SS-Biotin (12mg/ml 
Sulfo-NHS-SS-Biotin [EZ-LinkTM] in 1X PBS/Ca2+Mg2+) with gentle shaking at 
4°C for 30 minutes. The cells were then washed twice with 2ml/well 
PBS/Ca2+Mg2+/glycine (1mM MgCl2, 0.1mM CaCl2, 100mM glycine in 1X PBS) 
and quenched in 1ml PBS/Ca2+Mg2+/glycine at 4°C with gentle shaking for a 15 
minutes. The cells were washed again in 2ml/well 1X PBS/Ca2+Mg2+ and 
solubilised in 400µl RIPA buffer with protease inhibitor (Qiagen) on the shaker 
at 4°C for 1 hour. The contents of each well were transferred to 1.5 
microcentrifuge tubes and spun at 13,000rpm for 3 minutes. The supernatant 
was transferred to clean microcentrifuge tubes and the pellets discarded. A 
BCA protein assay was then carried out as described previously in order to 
determine the protein concentrations for normalisation.  
Streptavidin beads were used to purify the biotinylated proteins. Streptavidin 
beads were washed 4 times with RIPA buffer containing protease inhibitor. 50µl 
of the streptavidin beads was added to each of the lysates and the mixture was 
incubated at room temperature on a tilt plate for 1 hour. The samples were 
washed 4 times with 200µl RIPA buffer with protease inhibitor before 30µl 4X 
Laemmli buffer (277.8 mM Tris-HCl, pH 6.8, 4.4% LDS, 44.4% (w/v) glycerol, 
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0.02% bromophenol blue) was added to each and they were incubated again at 
4°C on the shaker for 30 minutes. The samples were then analysed by Western 
blot. 
 
2.7.2 Saturation analysis of choline uptake in HA-SLC5A7WT and HA-
SLC5A7K499N transfected HEK-293 cells 
This work was carried out in collaboration with Dr. Randy Blakely and Jane 
Wright of Vanderbilt University School of Medicine.  
Saturation analysis was carried out in order to determine the choline 
concentration at which the CHT WT and CHT p.K499Nfs*13 transporters uptake 
activity becomes saturated. This allows confidence that any differences in 
transport activity observed between the two isoforms arise due to differences in 
rate of transport of the molecules and not due to differences in choline 
concentration. 
Choline uptake assays were carried out as described in section 2.7.3 in HEK-
293 cells transiently transfected with HA-SLC5A7WT and HA-SLC5A7K499Nfs*13. 
In each assay cells were incubated in varying concentrations of a mix of [3H]-
choline chloride and cold choline chloride (100nM, 300nM, 1µM, 3µM, 7µM, 
10µM, 20µM, 30µM) at 37°C for 15 minutes prior to washing and scintillation 
counting. 
 
2.7.3 [3H]-choline uptake assay in transiently transfected HEK-293 cells 
[3H]-choline uptake was measured in transiently transfected HEK-293 cells in 
order to determine whether there was reduced CHT activity in these cells and, if 
so, whether that reduction was due to a reduction in choline transport VMAX as 
opposed to a change in choline KM. 
HEK-293 cells were plated and transfected as described above in 24-well plates 
as previously described. Parallel experiments were carried out in multiples of 6. 
Transport assays were performed 24 hours later. Cells were washed 2 times 
KRHB with (130mM NaCl, 1.3mM KCl, 1.2mM MgSO4, 2.2mM CaCl2, 1.2mM 
KH2PO4, 10mM glucose, 10mM HEPES: pH7.4) prior to a 15 minute incubation 
91 
 
at 37°C in 200µl KRHB. The KRHB was removed and replaced with 50µl 50nM 
[3H]-choline chloride (78.3 Ci/mmol) in KRHB and the cells were incubated at 
37°C for a further 15 minutes. The fluid was removed from the cells and 
disposed of as radioactive waste. The cells were washed 4 times with ice cold 
KRHB before being lysed in 400μl scintillation fluid on the Belly Dancer® at 
room temperature, for 1 hour. Contents of the wells were transferred to 
scintillation vials and accumulated radioactivity was quantified by scintillation 
spectrometry (HIDEX 300SL, LabLogic). Parallel assays were conducted with 
cells transfected with empty pRK5 vector in order to account for the cells own 
choline uptake activity. Parallel plating and transfection of cells with various 
constructs was also carried out. These cells were lysed and the average protein 
concentration/well was calculated in order to calculate the choline uptake per 
minute per microgram of protein produced. 
 
2.7.4 [3H]-Choline uptake assay in whole blood monocytes 
This work was carried out with the assistance of Dr. Ajith Sreekantan-Nair at St. 
George’s University of London. Choline transport was measured in whole blood 
monocytes collected in BD Vacutainer® CPT glass cell preparation tubes from 
affected individuals from the dHMN-VII_family (family 1) and from healthy 
control individuals. 
Cell preparation tubes containing blood samples were spun at 2,200rpm at 4°C 
for 20 minutes. Serum and buffy-coat were transferred to a fresh tube and made 
up to a 15ml volume with KRHB. The cells were then spun at 300xg for 10 
minutes and the pellet resuspended in KRHB before protein content was 
determined by BCA assay as described in chapter (2.6.2). [3H]-choline uptake 
assays were performed by incubating the cells at 37°C for 1 hour in 60nM [3H]-
choline chloride (85.5 Ci/mmol; Perkin Elmer) in KRHB as the substrate. 500µl 
ice cold KRHB was added to each sample and the cells were then pelleted and 
washed 3 times with KRHB. Accumulated radioactivity was quantified by liquid 
scintillation counting as described in Chapter 2.7.3 and counts per minute 
(CPM) were counted on a Beckman Coulter LS 6500 scintillation counter. 
Nonspecific [3H]-choline uptake was quantified is assays performed in parallel 
with 1µM hemicholinium-3 (HC-3), which was then subtracted from the total 
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accumulation to yield the specific uptake. All data were normalised to protein 
content. 
 
2.7.5 Co-immunoprecipitation of tagged SLC5A7 wild type protein 
products and SLC5A7 (NM_021815.2: c.1497delG; NP_068587.1: 
p.K499Nfs*13) mutant protein from transiently transfected HEK-
293T cells 
Unfortunately, due to the time constraints of my visit to Vanderbilt University, 
and because during the undertaking of these experiments Okuda and 
team(116) publish evidence that CHT forms a homo-oligomer on the cell 
surface, these experiments were not successfully completed. Methodology and 
results for these studies is included in the appendix. 
 
2.7.6 Pulse chase analysis of CHT-WT and CHT-K499Nfs*13 in transiently 
transfected HEK-293 cells 
Initial pulse chase analysis attempts in HEK-293T cells were unsuccessful, and 
due to the time constraints of my visit to Vanderbilt University further attempts 
were not able to be made. Methodology and results for these studies is included 
in the appendix. 
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3 READING FRAME ALTERATION OF THE SLC5A7/CHT C-
TERMINUS IS ASSOCIATED WITH dHMN PHENOTYPES VIA 
A DOMINANT-NEGATIVE DISEASE MECHANISM 
3.1 Introduction 
The dHMNs are a heterogeneous group of peripheral motor neurone disorders 
(see section 1.7.1.5 and table 35, appendix) that share a common feature of 
length-dependent neuropathy which results in progressive weakness and 
wasting of the distal limb muscles, which typically presents in the extensor 
muscles of the toes and feet, and later on progresses to the upper limbs(80). 
Unlike CMT-I and II, in dHMN there is no overt sensory involvement and motor 
nerve conduction velocities (mNCVs) are normal or slightly reduced. It has been 
hypothesised that the dysfunctional mechanisms underlying this group of 
diseases relate to the cell body of the neurone and not the axon(117). In 
addition to the progressive muscle weakness and atrophy of the distal limbs, 
foot deformities such as pes cavus and hammer toes, and diminished or no 
reflexes are the most commonly observed features of dHMN(117).  
Distal hereditary motor neuropathy type VII (dHMN-VII or dHMN-VIIA) was first 
described by Young and Harper in 1980, in a large Welsh kindred, in which they 
observed that the disease was of autosomal dominant inheritance and 
displayed a large age range of onset (11-31 years), although in most affected 
individuals onset was in the second decade(118). Pes cavus was also reported. 
Muscle weakness and wasting distribution was unusual and presented initially 
in the small muscles of the hands, occurring later in the lower limbs. The main 
characteristic noted in this family however, was the presence of unilateral or 
bilateral vocal cord paresis presenting as a husky voice and difficulty in raising 
the voice, and which was visible on laryngoscopy. Three other dominantly 
inherited neuropathies in which vocal cord paresis is characteristic have been 
described: CMT-IIC, scapuloperoneal spinal muscular atrophy (SP-SMA), and 
vocal cord and pharyngeal weakness with distal myopathy (VCPDM)(119). 
In a later study by Pridmore et al. (1992) a smaller dHMN-VII family, thought to 
be unrelated to that described by Young and Harper, was reported with 
hoarseness, slowly progressive wasting and weakness of the hands and distal 
forearms and later, weakness of the feet. Again, age of onset varied between 
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family members (4-21 years), as did the severity of the disease(120). This could 
be due to variable expressivity and lack of penetrance of the mutant gene(118).  
McEntagart et al. (2002) undertook linkage analysis on the two previously 
described dHMN-VII families and not only found them to be distantly related, but 
also mapped the dHMN-VII disease locus to chromosome 2q14(119). The 
authors noted that dHMN-VII shows considerable phenotypic overlap with CMT-
IIC (table 32, appendix), but can be distinguished by the lack of sensory 
involvement in dHMN-VII. The locus was further refined in 2008 by Dick et al. to 
two distinct regions of chromosome 2q14.2, one comprising of 9.2Mb defined by 
markers D2S3038-D2S160, and the second comprising of 4.3Mb defined by 
markers D2S2970-D2S2969 (figure 13)(121). 
In 2003, Puls et al. reported a family with a second form of dHMN-VII, dHMN-
VIIB(60). Similarly to the family described by Young and Harper, Pridmore et al,, 
and McEntagart et al., disease transmission followed and autosomal dominant 
mode of inheritance with onset in early adulthood, limb muscle weakness and 
atrophy presented and predominated in the small muscles of the hands, and 
vocal cord paralysis was present. Unlike in Young and Harding’s original dHMN-
VII family, in addition to weakness and atrophy of the hand muscles, the 
neuropathy in these subjects presented as breathing difficulty due to the vocal 
cord paresis, and progressive facial weakness. Using genome-wide linkage 
analysis, Puls et al. (2003) mapped the disease locus to a 4Mb region on 
chromosome 2p13 and, after sequencing of candidate genes within the critical 
region, identified a mutation in DCTN1 as underlying the disorder in this family. 
DCTN1 encodes the p150Glued subunit of dynactin, a large complex that 
interacts directly with dynein via the p150Glued subunit where it acts as an 
activator and binds cargos(122). Together, and with a number of other 
activators, the complexes form a microtubule-based motor protein required for 
cytoplasmic retrograde transport of vesicles and organelles along 
microtubules(122). Puls and colleagues found that the disease causing variant 
identified in this family significantly reduced (50%) microtubule binding 
preventing distal enrichment of dynactin thereby inhibiting the initiation of 
retrograde transport. The authors suggested that motor neurones may be 
particularly vulnerable to the resultant defects in axonal transport due to their 
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unusual size and metabolic activity, and their dependence on trophic factors 
delivered from the periphery. 
First described by Meadows and Marsden in 1969 and later classified as a 
subtype of the dHMNs, dHMN-V shares considerable phenotypic overlap with 
dHMN-VII with the exception of vocal cord paralysis(123). Similarly to dHMN-
VII, dHMN-V follows an autosomal dominant mode of inheritance; is variable in 
both age of onset which ranges from early childhood to the fourth decade, and 
disease severity; is usually slow to progress; weakness and atrophy presents 
and predominates in the small muscles of the hands, with lower limb 
involvement occurring later and at a lower degree in the disease course(123-
127). Several cases have been observed in which hand muscle weakness and 
wasting is confined exclusively to the thenar and/or interosseous dorsalis I 
eminences(124-126, 128). Foot deformities including pes cavus, pes planus 
and/or hammer-toes are often present, and less frequently, atrophy of the ankle 
extensors(129). dHMN-V canbe divided into two further subtypes, -VA and  -VB, 
based on genetic features. 
dHMN-VA is allelic with two phenotypically similar disorders, CMT-IID and Silver 
syndrome(85, 114, 128, 130, 131). CMT-IID (table 32, Appendix), an autosomal 
dominant form of axonal CMT which also presents and predominates in the 
hands with the addition of sensory involvement, shares with dHMN-VA, mutant 
GARS as it disease causing gene. GARS encodes Glycyl-tRNA synthetase, a 
class II aminoacyl synthetase enzyme that catalyses the synthesis of glycyl-
tRNA, required for the insertion of glycine during protein synthesis(132). Its 
secondary function is the synthesis of dinucleoside polyphosphates, which have 
been suggested to play a role in the regulation of cell functions(132). Silver 
syndrome, a rare complex form of spastic paraplegia characterised by unilateral 
or bilateral upper and lower limb muscle weakness and atrophy- often involving 
the thenar or hypothenar muscles, pes cavus, pyramidal tract signs, and lower 
limb hyperreflexia and hypertonia, is caused by autosomal dominant mutations 
in BSCL2(133). BSCL2 encodes the protein seipin, which plays an important 
role in adipocyte differentiation, its exact molecular function  remains unknown, 
as well as lipid homeostasis by promoting adipose tissue fat storage, via the 
regulation of intracellular calcium homeostasis(134). Autosomal recessively-
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acting BSCL2 mutations are also known to cause Bernardinelli-Seip congenital 
lipodystrophy type 2, one of the most severe lipodystrophy diseases(134). 
dHMN-VB is distinguishable from type-VA by genetic evidence only, and is 
caused by mutations in REEP1. REEP1 encodes receptor expression 
enhancing protein 1 (REEP1), which plays an important role in the formation, 
shaping and remodelling of the endoplasmic reticulum by linking endoplasmic 
reticulum tubules to the cytoskeleton(127, 135). It has also been suggested that 
REEP1 may enhance cell surface expression of odorant, or olfactory 
receptors(136), and play a role in long-term axonal maintenance via the 
endoplasmic reticulum-regulation of lipid droplets(137). Loss-of-function REEP1 
mutations have previously been identified in a dominant form of hereditary 
spastic paraplegia, SPG31, a disease associated with upper-motor neurone 
pathology(127). 
Here, genetic and molecular studies implicate an autosomal dominantly-
transmitted truncating mutation in SLC5A7, encoding the high-affinity choline 
transporter, as the cause of dHMN-VII in two families via a dominant-negative 
mode of action on transporter function.  Interestingly we also identified a third 
family with a truncating dominant-negative mutation without vocal cord paralysis 
(VCP), in which the phenotype is more in-keeping with that of dHMN-V. 
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3.2 Results 
PART A 
3.2.1 Identification of the disease causing mutation in SLC5A7 in a 
dHMN-VII family by whole-exome sequence analysis  
The data regarding the discovery and analysis of the causative gene mutation 
was published in The American Journal of Human Genetics (Barwick KES, 
Wright J, Saeed Al-Turki, McEntagart MM, Nair A, Chioza B, Al-Memar A, 
Modarres H, Reilly MM, Dick KJ, Ruggiero AM, Blakely RD, Hurles ME, and 
Crosby AH (2012): 91(6): 1103-1107): Defective presynaptic choline transport 
underlies hereditary motor neuropathy.  
3.2.1.1 History of clinical and pathological features of dHMN-VII family 
(family 1) members and previous genetic analysis 
Subject family 1_V:9 (figure 10) from Young and Harper (1980) (corresponding 
pedigree number: III 24 of the YH1 branch of the family) was born in 1929 and 
initially presented at the age of 14 with bilateral wasting of the palm muscles 
which caused stiffness and curling of his fingers(118). By 20 years of age his 
voice had become husky and he was neither able to sing nor shout, and at this 
point he reported that the muscle weakness and wasting he had experienced in 
his hands has progressed to the distal lower limb muscles. Another 10 years on 
and muscle weakness and wasting had progressed to a point at which it 
severely limited his activity as walking became painful and difficult. From the 
age of 40 he noticed increasing dyspnoea (laboured breathing), which in 
addition to his muscles weakness and atrophy, contributed to impaired exercise 
tolerance. At 50 years he was only able to walk for short distances, had difficulty 
driving, and could barely hold a pen, so was no longer capable of earning his 
living. On examination he showed marked distal wasting and atrophy of the 
lower limbs with the typical “inverted champagne bottle” appearance of the legs 
(figure 11) and bilateral pes cavus. He also had severe wasting of the small 
muscles of the hand, in particular those of the palm, and despite exhibiting full 
passive movements in both hands he was unable to extend the medial three 
digits in either. He lacked deep tendon reflexes in both his wrists and ankles 
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and showed a pronounced tremor in the hands when outstretched. No sensory 
deficits were observed.  
 
Figure 10. dHMN-VII family (family 1) pedigree 
 
In a later study by Pridmore et al. (1992) a smaller Welsh dHMN-VII family -
thought to be unrelated to that described by Young and Harper - was reported 
with hoarseness, slowly progressing weakness and wasting of the hands and 
distal forearms, and later weakness of the feet(120). Similarly to Young and 
Harper’s family, age of onset of the disease varied between family members (4-
21 years), as did the severity of the disease. Also as in Young and Harpers 
family, the disease was dominantly inherited and affected family member across 
at least three generations. With a diagnosis of peroneal muscular atrophy in the 
family history, the proband (family 1_VI:12, figure 10) was taken to hospital at 
the age of 6 by her parents who were concerned about her impaired hand 
function. The parents reported that onset of hand weakness was at age 5 when 
her ability to manipulate a pencil or a spoon became difficult, and she had had a 
slightly hoarse voice from the age of 4. On examination at age 6 family 1_VI:12 
was found to have a hoarse voice in absence of facial weakness, palatal palsy, 
tongue atrophy, or fasciculation. This was confirmed by laryngoscopy which 
revealed left vocal cord paralysis. Weak grip was reported with normal muscle 
tone and preserved reflexes, although these were depressed in the upper limbs. 
Nerve conduction velocities (NCVs) and electromyography (EMG) studies were 
normal (table 16). She had a normal gait but poor heel walking. On later 
examination (age 9 years) she showed mild weakness in her grip, finger 
extension, and wrist flexion, but still showed no muscle wasting. The family 
reported that her voice had become progressively more hoarse and her writing 
progressively more difficult. She had bilateral pes cavus and the poor heel 
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walking persisted, as did the normal tone and preserved reflexes with 
depression in the upper limbs. Sensation and NCVs were normal however EMG 
indicated early neurogenic change (table 16). 
Previous genetic studies by McEntagart et al. (2001) and Dick et al(2008) 
indicated that the gene responsible for dHMN-VII resides in either of two closely 
located genomic regions of 9.2Mb, flanked by microsatellite markers AC084377 
– AC115115 proximally, or 4.4Mb, D2 S437 – D2 S5347 distally(figure 13),  
resulting from an unusual series of recombination events in the P2 branch of the 
family (figure 12). 15 candidate genes within the locus were also excluded as 
being disease causing by dideoxy sequence analysis(121). Pedigree 
identification numbers for a number of individuals in this study have varied 
between studies over the years since their first description with the addition of 
new family members; for past subject ids see appendix. 
A summary of the clinical and electrophysiological findings of members from 
both branches of the family can be found in tables 16 and 17. 
 
Figure 11. Distal muscle wasting of family 1_V:9 in (A) the lower limbs giving an 
“inverted champagne bottle” appearance, and (B & C) small hand musculature 
giving a claw-like positioning of the hands.  Modified (Young & Harper, 1980 (118)) 
101 
 
Table 16: Electrophysiological findings from both branches of dHMN-VII family 1 
 Normal 
range 
family 
1_V:9 
family 
1_VI:6 
family 
1_V:4 
family 
1_VI:2 
family 
1_V:7 
family 
1_VI:4 
family 
1_V:12 
family 
1_VI:12 
family 
1_VI:13 
family 
1_V:19 
Age at testing  45y 20y 46y 14y 45y 21y/24y 42y 6y/9y 11m 12 
Sensory studies 
Sural nerve (post tibial) 
Velocity (m/s) 
Action potential (μV) 
       
28 
7 
  
48/51 
18/16 
 
53 
20 
 
Median nerve 
Amplitude (μV) 
Latency (ms) 
 Rt 
9 
3.8 
Rt 
30 
2.6 
 Rt 
Norm 
  Lft 
** 
   
Ulnar nerve 
Amplitude (μV) 
Latency (ms) 
 Rt 
12 
2.5 
Rt 
21 
2.1 
 
Norm 
 Rt 
Norm 
Rt 
Norm 
Rt 
Norm 
   
Motor studies 
Medial popliteal nerve 
Velocity (m/s) 
Distal latency (ms) 
Distal CMAP (mV) 
F wave latency (ms) 
 
 
 
 
25-32 
 Rt 
55 
4.0 
 
Lft 
50 
3.7 
      
 
3.5 
11 
27.5 
 
53 
5 
6 
35.5 
 
Median nerve (apb) 
Velocity (m/s) 
Distal latency (ms) 
Distal CMAP (mV) 
F wave latency (ms) 
  
NR 
NR 
 
  Rt 
56 
5.8 
  Lft 
43 
 
51 
3.5 
3.6 
24 
  
Ulnar nerve 
Velocity (m/s) 
Distal latency (ms) 
 Rt 
55 
3.6 
Rt 
57 
2.5 
 
41 
Rt 
56 
Rt 
44 
Rt 
31 
Rt 
52 
   
Lateral popliteal nerve (edb) 
Velocity (m/s) 
Distal latency (ms) 
Distal CMAP (mV) 
F wave latency (ms) 
    
28 
Rt 
38 
Rt 
44 
Rt 
26 
    
45 
5.5 
2.8 
52 
Common peroneal nerve 
Velocity (m/s) 
Distal latency (ms) 
  Rt 
40 
3.8 
        
Electromyography 
Abductor digiti minimi         ***    
Extensor digitorum communis          Early NC Normal  
First dorsal interosseous          Normal  
Tibialis anterior       *     
 Abbreviations and symbols: apb= abductor pollicis brevis; edb= extensor digitorum brevis; NR=No response; Rt=Measurement taken on right side; Lft= Measurement taken on left side; 
*Spontaneous fibrillation with reduced volitional activity; **Small, dispersed, delayed sensory action potentials; ***Spontaneous fibrillation and reduced interference pattern 
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Table 17: Clinical findings from both branches of dHMN-VII family 1 
Subject Sex Age on 
examination 
(y) 
Age at 
onset 
(y) 
Vocal cord 
changes 
Upper limb 
involvement 
Lower limb 
involvement 
family 1_V:9 M 50 14 Left cord 
fixed 
+ + + + + + 
family 1_VI:6 F 23 16 Hoarse 
voice 
+ + +  
family 1_V:4 M 57 14 Right cord 
fixed 
+ + + + +  
family 1_VI:2 F 25 12 Left cord 
fixed 
+ +  +  
family 1_V:7 F 57 11 Bilateral 
palsy 
+ + + + + 
family 1_VI:4 M 33 13 Bilateral 
palsy 
+ + + + 
family 1_V:12 F 42 31 Hoarse 
voice 
+ + + +  
family 1_VI:12 F 6 4 Left cord 
palsy 
+ +  + 
family 1_V:19 M 32 12 Bilateral 
palsy 
+ + + + 
family 1_V:21 F ? 21 Hoarse 
voice 
 - 
family 1_IV:9 M 63 Teens Hoarse 
voice 
 + + 
family 1_IV:8 F 62 ? Hoarse 
voice 
 - 
Abbreviations: F=Female; M=Male; + + +=Severe; + +=Moderate; +=Mild; -=Absent 
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↑ Figure 12. Family pedigree of large Welsh kindred 
in which dHMN-VII locus was refined. Shows the two 
branches of the family, YH1 and P2. 
Modified (Dick, 2008)  
 
 
←Figure 13. Schematic diagram of the refined 
dHMN-VII locus represented by microsatellite 
markers. Shows the boundary-defining double 
recombination event separating the two linked 
regions, defined by markers AC115115-D2S437, as 
well as the portions of the ancestral haplotype 
inherited by V:4 from the YH1 branch of the family, 
and by VI:13and V:21 from the P2 branch. 
Modified (Dick, 2008) 
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3.2.1.2 Exome sequencing identifies a mutation in SLC5A7 as the likely 
cause of dHMN-VII  
 
In order to identify the gene responsible for this condition, DNA from a single 
affected individual (family 1_VI:5) was subjected to whole-exome sequence 
analysis to generate a novel variant profile in collaboration with Dr Matt Hurles 
at the Wellcome Trust Sanger Institute. Coding regions were captured using 
SureSelect All Exons (50Mb) and sequenced by Illumina HiSeq. The VCF file 
obtained from whole-exome sequencing yielded 9.8Gb data (~130 million 
reads) corresponding to 91% coverage with a mean depth of 107x and 
identifying 52,806 variants. See table 18 for sequencing statistics. Exome 
sequence analysis identified four novel potentially pathogenic variants within the 
chromosome 2q14 locus (table 19). 
Table 18. Sequencing statistics 
 
Table 19. dHMN-VII family 1 loci variants 
Variant 
position 
Variation Affected 
gene 
Predicted 
outcome 
Cosegregates?  
Chr2:108627070 Single base 
deletion (G) 
SLC5A7 Non-synonymous 
coding 
p.Lys499Asnfs*13 
Yes 
Chr2:120404629 Single base 
deletion (T) 
+3 in 
intron 
splice of 
PCDP1 
Unlikely to affect 
splice site 
No 
Chr2:101924635 Single base 
substitution (T-C) 
RNF149 Non-synonymous 
coding 
p.Asn199Asp 
No 
Chr2:121107178 Single base 
substitution (A-G) 
INHBB Non-synonymous 
coding 
p.Asn318Asp 
No 
Legend: Novel likely deleterious varients within the dHMN-VII loci identified by whole-
exome sequencing, the genes in which they appear, their predicted outcome, and 
results of cosegregation analysis. 
Bases 9,877,091,850 (9.8 Gb) 
% Q20 bases 96.87% 
% Q30 bases 91.57% 
Reads used 131,694,558 
% Duplication 7.69% 
Reads mapped 120,632,748 (91.6%) 
Reads mapped (high mapping quality ≥ Q30) 103,839,839 (78.8%) 
Mean depth on target regions 107.5 
Array SureSelect All Exon 50Mb (solution) 
Mapped to GRCh37_53 (Human) 
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In order to determine which of these variants may represent the causative 
mutation, cosegregation analysis was performed on all four variants in the 24 
member family (for primer sequences see table 39 appendix). Only one likely 
deleterious variant was found to cosegregate with the disease phenotype (table 
19), a single base deletion located within the reading frame of the solute carrier 
family 5 (choline transporter), member 7 (SLC5A7) gene (c.1497delG: 
NM_021815.2), encoding the Na+/Cl- dependent, high affinity choline 
transporter (CHT). All SLC5A7 exons were well covered during the exome 
sequencing (data not shown) including the 9th exon that harbours the 
c.1497delG variant under study. There are fewer reads covering the first exon 
due to high GC content. 
The variant was found to be absent in all unaffected members of the family and 
present in all affected members of the family by both dideoxy sequence analysis 
(figure 14A), and by an Ssp1 restriction digest (recognition sequence AATATT) 
visualised by PAGE (figure 14B). The variant was shown to be absent in 151 
UK controls by Ssp1 restriction digest visualised by agarose gel electrophoresis 
(figure 45, appendix), and was absent from online genomic databases: National 
Center for Biotechnology Information’s (NCBI) dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/), 1000 Genomes Project 
(http://browser.1000genomes.org/), National Heart, Lung and Blood Institue’s 
(NHLBI) Exome sequencing project (ESP6500) via the Exome Variant Server 
(EVS) (http://evs.gs.washington.edu/EVS/), and Exome Aggregation 
Consortium (ExAC) (http://exac.broadinstitute.org/).  
The variant was also found to be present in monocyte mRNA of affected cases 
by dideoxy sequencing (PCR primers used for amplification of mRNA were 5’-
TGGTCTTGGTGCAGTTTCTGCTGCT-3’ and 5’-
GGTGAAAGTTGAGCTGAGGGTCATGC-3’) (figure 15). 
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Figure 14. dHMN-VII family 1 pedigree showing A) cosegregation analysis results 
for each of the variants in the dHMN-VII loci identified by whole exome 
sequencing. Only one variant cosegregates with the disease phenotype (red 
box). B) Confirmation of cosegregation of c.149delG in SLC5A7. The variant 
results in the creation of a novel Ssp1 restriction site allowing cosegregation 
analysis by restriction digest of exon 9 PCR products (PCR primers used for 
amplification of exon 9 genomic DNA were 5’-CCCTGGCTATTACCCTGATG-3’ 
and 5’-CACAAGTGCAAGTTCATCTAATTT-3’). Digest products were resolved by 
polyacrylamide gel electrophoresis (PAGE). The c.1497delG variant results in the 
digestion of the 218bp wild type product into two fragments of 198bp and 20bp 
(not shown). All unaffected subjects have only the undigested 218bp product. All 
affected subjects are heterozygous for the c.1497delG variant and thus have 
both the undigested 218bp products as well as the digested 198bp fragment. 
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Figure 15. Chromatogram showing DNA sequence around the c.1497delG variant 
showing wild type sequence (upper trace) and mutant (c.1497delG) strand from  
monocyte mRNA (middle trace) from an affected individual (family 1_V:9). 
 
3.2.1.3 In silico analysis of SLC5A7 c.1497delG 
The amino acid sequence was obtained for both the wild type and mutant 
molecules by entering the coding (exonic) DNA sequence into the online 
ExPASy translate tool (http://web.expasy.org/translate/). The wild type protein 
(CHT: NP_068587.1) consists of 580 amino acids predicted to comprise 13 
transmembrane domains, with an extra cellular NH2-terminus and an 
intracellular COOH-terminus(138, 139) (figure 16A). The SLC5A7 c.1497delG 
variant at the nucleotide level is predicted to result in premature truncation of 
the protein by 82 amino acids, causing near complete deletion of the proteins 
cytoplasmic C-terminus, and the inclusion of 12 aberrant amino acids 
(p.K499Nfs*13) (figures 17 and 16B). 
Conservation analysis indicates that the C-terminal corresponds to a region of 
the molecule that is highly conserved across many species (figure 46, 
appendix) and TMHMM analysis predicts that the c.1497delG  variant will 
profoundly affect transmembrane morphology of the 3’ terminus of the protein 
108 
 
(figure 47, appendix). Although it disputes the precise transmembrane topology 
of the SLC5A7 gene product, from the (TMHMM) analysis (online predictive 
software which uses the Tied Mixture Hidden Markov Model to predict the 
location and orientation of alpha helices in membrane spanning proteins) it is 
apparent that the mutation is likely to interfere with the number or orientation of 
transmembrane domains(139, 140). 
In silico mutation analysis programs, PROVEAN and Mutation Taster were used 
to create predictions of the impact of the SLC5A7 c.1497delG mutation on the 
structure and function of the protein product. PROVEAN predicted c.1497delG 
to have a deleterious effect on the function of the protein product with a score of 
-55.034. Mutation taster predicted the variant to be disease causing with a 
score of 1.  
SLC5A7 sequence analysis (for primer sequences see appendix) was also 
undertaken in two other unrelated families (figure 18) with dHMN-VII-like 
features. Both families displayed distal muscle weakness and wasting, as well 
as some degree of vocal cord paralysis. In the proband from dHMN-VII-like 
family 2 (family 2_II:2, figure 16A), onset of the disease occurred at 30 years of 
age with muscle weakness and wasting in the small muscles of the hands and 
the forearm muscles, with milder lower leg involvement and a hoarse voice. The 
second dHMN-VII-like family (family 3, figure 16B) display typically signs of 
dHMN-VII with the addition of myokymia (quivering muscles). Previous TRPV4 
screening had failed to detect mutations. No novel SLC5A7 sequence variants 
were identified in these subjects (data not shown) This indicates that another as 
yet undiscovered gene(s) is/are also responsible for this condition.  
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Figure 16. A) Diagram of the predicted secondary structure of the SLC5A7 gene 
protein product (CHT) showing 13 transmembrane domains with an extracellular 
N-terminus, and an intracellular C-terminus. Dark circles represent amino acids 
which are conserved across human CHT, mouse Cht1, and the C. elegans CHT 
ortholog, CHO-1. Dark circles containing the letter ‘P’ indicate potential protein 
kinase C phosphorylation sites, and light circles containing the letter ‘P’ 
represent potential protein kinase A phosphorylation sites. The fork-like 
structures represent potential N-glycosylation sites. B) Green circles represent 
the 12 ectopic amino acids encoded as a result of the c.1497delG variant, and the 
position of the first of these is the point from which the C-terminus is lost. 
Modified (Apparsundaram, 2000; Apparsundaram, 2001 (140, 141)) 
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Figure 17. Alignment of wild type and CHT K499Nfs*13 amino acid sequences 
showing premature truncation of the protein product, and the inclusion of 12 
ectopic amino acid residues (ClustalOmega –  
http://www.ebi.ac.uk/Tools/msa/clustalo/). 
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Figure 18. dHMN-VII-like family pedigrees A) family 2   B) family 3. Red arrows 
indcate affected individuals subjected to SLC5A7 sequencing. 
3.2.1.4 Functional investigation of CHT p.K499Nfs*13 
Experiments undertaken in collaboration with Prof Randy Blakely and Jane 
Wright in the United States.  
Investigation of the functional impact of the SLC5A7 c.1497delG 
(p.K499Nfs*13) variant on CHT was performed via heterologous expression of 
mutant (CHT p.K499N*fs13) and wild type (CHT WT) proteins in HEK-293 cells 
transiently transfected with the respective cDNA constructs (SLC5A7K499Nfs*13 
and SLC5A7WT) in a pRK5 vector (for cDNA transfection amounts see tables 36 
and 37 appendix). As existing CHT antibodies target the C-terminus of the 
molecule, a hemagglutinin (HA; amino acid sequence 5’-YPYDVPDYA-3’) tag 
was added to the N termini of both the mutant and wild type transporters by site 
directed mutagenesis using the Quick-Change kit, Stratagene. Cell surface 
biotinylation experiments and western blotting were carried out to investigate 
the expression and surface delivery of the two transporters, and [3H]-choline 
transport assays were performed in order to compare the choline transport 
ability of the wild type and mutant molecules when expressed both individually 
and in combination. Choline transport activity was also measured in whole 
blood monocytes natively expressing CHT WT and CHT p.K499Nfs*13 
collected from dHMN-VII affected individuals and healthy control individuals. 
 
3.2.1.4.1 SLC5A7K499Nfs*13 alters CHT expression levels and surface 
delivery 
Lysation of HA-SLC5A7WT and HA-SLC5A7K499Nfs*13 transfected HEK-293 cells, 
followed by SDS-PAGE and immunoblotting with anti-HA antibody, shows that 
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the wild type protein migrates through the cells as two broad bands; a 48kDa 
band which represents an immature, core glycosylated species, and a 56kDa 
band which represents the mature, more highly N-glycosylated species (figure 
19). CHT p.K499Nfs*13 is also shown to migrate as two species, however each 
as is of a smaller size than the wild type equivalent, confirming truncation of the 
mutant molecule (figure 19). For equivalent amounts of wild type and mutant 
cDNAs transfected, reduced levels of both the mature and immature protein 
products were observed in the HA-SLC5A7K499Nfs*13 transfected cells. Where 
double the amounts of transporter cDNAs were transfected, there is a 
comparable increase in CHT WT and CHT p.K499Nfs*13 protein, maintaining 
their relative differences in protein level.  
Cell surface biotinylation experiments analysed by Western blot show the 
mature more substantially glycosylated form to be enriched in cell surface 
extracts (figure 20). When expressed individually, the surface levels of CHT WT 
and CHT p.K499Nfs*13 are comparable, despite differences in total expression 
levels. However, when the wild type and mutant cDNAs were co-expressed, the 
levels of total and surface protein for each transporter were significantly 
reduced in comparison to when these cDNAs were transfected individually. The 
reduction in expression is ~30% of that calculated from a simple addition of 
levels from individual transfections (students unpaired t-test, p=0.001, n=5). A 
transfection titration was carried out prior to these experiments to account for 
saturation of the cell’s expression. 
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Figure 19. Total protein levels of HA-tagged CHT WT and CHT p.K499Nfs*13 in 
transiently transfected HEK-293 cells. Immunoblotting with anti-HA antibody of 
cell products run on SDS-PAGE confirms CHT p.K499Nfs*13 truncation and 
reveals reduced total protein expression of CHT p.K499Nfs*13 in cells 
transfected with both 2X (lanes 1 and 2) and 1X (lanes 3 and 4) cDNA (for 
amounts of DNA transfected see appendix). Stripping and blotting for β-actin 
reveals equal protein loaded across lanes. All experiments were conducted with 
the same total amount of transfected plasmid, balancing with pRK5 vector. 
 
 
Figure 20. Total and surface levels of CHT WT and CHT p.K499Nfs*13 protein are 
reduced in cells co-transfected with both cDNAs at 1X levels compared to cells 
transfected individually at 1X levels. Stripping and blotting for PP2Ac reveals 
equal protein loaded across all lanes. All transfection were performed with 
identical amounts of total plasmid, balanced by pRK5 vector.  
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3.2.1.4.2 The p.K499Nfs*13 mutation significantly reduces choline 
transport activity in both transfected and patient cells 
Saturation analysis of [3H]-choline transport in HA-SLC5A7K499Nfs*13 transfected 
HEK-293 cells compared with HA-SLC5A7WT transfected cells shows a 33.4% 
reduction in the choline transport activity of CHT p.K499Nfs*13. This reduction 
was accounted for by decrease in choline transport VMAX (rate of transport) as 
opposed to a change in KM ([
3H]-choline concentration) (figure 21). 
Choline uptake assays showed that CHT specific uptake in cells with dual HA-
SLC5A7WT and HA-SLC5A7K499Nfs*13 cDNA transfections was significantly 
reduced compared to what would be expected from the summation of transport 
activity from cells individually expressing either CHT WT or CHT p.K499Nfs*13 
(figure 22). Indeed, a far more severe impact of the c.1497delG variation arises 
when cells produce CHT proteins with mismatched C-termini, as is shown by 
the even further reduced CHT activity seen in cells co-expressing CHT WT and 
CHT p.K499Nfs*13 than that observed in cells transfected with CHT 
p.K499Nfs*13 alone. This suggests a dominant negative impact of the 
c.1497delG variant on CHT function. 
 
Figure 21. Saturation analysis of [3H]-choline transport activity in transfected 
HEK-293 cells demonstrates a significant reduction in transport activity for CHT 
p.K499Nfs*13 (CHT FS) compared to CHT WT. The reduced transport in CHT 
p.K499Nfs*13 transfected cells are accounted for by a reduction in choline 
transport VMAX (33.4% reduction, p=0.024, student’s unpaired t-test), and not a 
change in choline kM (WT=5.15+/-1.12μM, FS=6.12+/-1.72μM, p=0.66, student’s 
unpaired t-test). Specific choline uptake was determined by subtracting the 
uptake obtained in cells transfected with a mock vector (pRK5), from the uptake 
obtained from cells transfected with HA-SLC5A7WT and HA-SLC5A7K499Nfs*13  
cDNAs. Assays were conducted in parallel. 
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Figure 22. [3H]-choline transport activity is reduced in CHT p.K499Nfs*13 (FS) 
expressing HEK-293 cells compared to CHT WT (WT) expressing cells (*p=0.035, 
n=5, student’s unpaired t-test). The transport activity observed in cells co-
expressing CHT WT and CHT p.K499Nfs*13 (WT+FS(O)) falls significantly below 
that expected (WT+FS(e)) from a sum of the independent expression of these 
isoforms (*p=0.005, n=5, student’s unpaired t-test). 
 
Choline transport was measured in whole blood monocytes obtained from both 
affected subjects (n=4) and control individuals (n=11) in order to investigate 
whether a similar reduction in CHT activity exists in cells natively expressing 
CHT with the c.1497delG variant compared with cells natively expressing CHT 
WT (experiments carried out under assistance of Dr. Ajith Sreekantan-Nair, 
SGUL). Hemicholinium-3 (HC-3) sensitive choline transport was readily 
detected in CHT WT expressing cells from the control individuals (figure 23). In 
contrast, CHT activity was barely detectible in cells from affected individuals 
expressing CHT p.K499Nfs*13, a reduction even greater than that observed in 
the transfected cells. This is consistent with the severely reduced transport 
observed in cells co-transfected with cDNAs encoding both CHT WT and CHT 
p.K499Nfs*13, and supports the theory that the c.1497delG has a dominant 
negative impact on choline uptake activity. 
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Figure 23. HC-3 sensitive choline transport activity in whole blood monocytes 
natively expressing CHT WT (n=11) compared with that in whole blood 
monocytes natively expressing both CHT WT and CHT p.K499Nfs*13 (n=4) 
reveals a dramatic loss (to 7.6% of controls) in dHMN-VII subjects (*p=0.72x10-6, 
student’s one-tailed t-test) 
 
3.2.1.5 Electrophysiology recording in dHMN-VII subjects 
The congenital myasthenic syndromes (CMSs) are a well recognised group of 
genetically heterogeneous neuromuscular disorders known to result from 
mutations in genes encoding presynaptic, postsynaptic, and synaptic NMJ 
proteins. One key characteristic of CMS is fatiguing muscle weakness with a 
pathological decrement on repetitive muscle stimulation or abnormal jitter and 
blocking on single-fiber EMG. Despite there being considerable difference in 
phenotype between CMS and dHMN-VII, the involvement of the NMJ in the 
pathogenicity of dHMN-VII prompted us to undertake  specialist neuromuscular 
junction electrophysiology evaluation in two affected family members (table 20). 
This work was carried out by Dr. Meriel McEntagart, SGUL. Repetitive 
stimulation showed no significant decrement. EMG quantitative jitter studies 
showed an excess of jitter and blocking. This suggests disturbance of the NMJ 
but it is not clear if this is all secondary to reinnervation or if there is an element 
of primary disturbance of NMJ as well. The changes were less marked in the 
younger patient with less progressed disease. 
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Table 20. Fatigability and decrement EMG response 
Subject Age/Sex Repetitive stimuation Single fibre EMG 
family 
1_V:19 
56y/M Recording of right adm at 
rest and up to 1 min post 
activation showed no 
significant decrement. 
Right edc: no spontaneous activity, 
an excess of complex polyphasic 
units on volition, quantitative jitter 
studies showed an excess of units 
with jitter and blocking. 
family 
1_VI:13 
28y/M Recording of right adm at 
rest and up to 1 min post 
activation showed no 
significant decrement. 
Right edc: no spontaneous activity, 
an excess of stable polyphasic 
units noted on volition, quantitative 
jitter studies showed an excess of 
complex units with increased jitter 
and occasional blocking. 
Abbreviations: adm=adductor digiti minimi; edc=extensor digitorum communis; M=male. 
 
3.2.1.6 Identification of a second family (family 4), also from Wales, in 
which the same SLC5A7 c.1497delG truncating mutation 
underlies dHMN-VII 
Published in Practical Neurology: (Ingram G, Barwick KES, Hartley L, 
McEntagart MM, Crosby AH, Llewelyn G, Morris HR (2012): 0: 1-5): Distal 
hereditary motor neuropathy with vocal cord paresis: from difficulty in choral 
singing to a molecular genetic diagnosis.  
A 52-year-old woman, proband (family 4_II:2, figure 24) and her 20-year-old 
daughter (family 4_III:2), both keen singers, reported a change in their voices 
when singing between the ages of 12 and 13 years, as if their voices were 
‘breaking like a boys at puberty’. At age 15, the proband was diagnosed with a 
vocal cord nodule by an ear, nose and throat consultant and was referred for 
speech therapy. 2 years later her music college referred her for further ear, 
nose and throat review on the basis of hoarseness of voice and underwent 
partial thymectomy for a benign thymic tumour. However, her disorder 
continued to progress, and on more recent ear, nose and throat investigation 
family 4_II:2 was found to have a persistent glottic chink with poor opposition of 
the vocal cords due to bilateral vocal cord paralysis. Onset of motor problems 
did not occur until the proband was 27 years of age, following her first 
pregnancy when she experienced difficulty with tasks requiring manual dexterity 
such as changing her babies clothes and making him bottles of milk. 
Deterioration in hand function progressed gradually and later, she developed 
foot pain and calf cramps after walking as well as poor balance. Examination at 
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50 years after onset revealed hoarse voice but otherwise normal cranial nerves. 
She was also found to have bilateral weakness and atrophy of the small 
muscles of the hands with prominence at the thenar eminence (Figure 25), with 
no change in proximal strength, sensation or reflexes. High foot arches and 
clawing of the toes was present, but not true pes cavus. She displayed distal 
weakness of the lower limbs, especially on dorsiflexion, inversion and eversion.  
Motor symptoms occurred earlier for family 4_III:2 than her mother when she 
also experienced difficulty with manual dexterity and suffered with hands 
cramps at age 14. Similarly to her mother, she experienced gradual 
deterioration in hand function with later progression to the lower limbs, 
presenting as walking induced foot pain, calf cramps and loss of balance. Both 
the proband and her daughter have retained independent mobility. Nerve 
conduction studies showed small motor action potentials and electromyography 
showed changes of distal chronic denervation consistent with motor 
neuropathy. Sensory action potentials and sensory and motor NCVs were within 
normal range. The clinical phenotype in this family is consistent with that of 
dHMN-VII. 
Clinical review of the proband’s mother (family 4_I:2) revealed mild weakness of 
the right first dorsal interosseous muscle of the hand, but no overall hand 
wasting or weakness. She also had high foot arches and clawing of the toes, 
but was considered to be clinically distinct from the proband and her daughter. 
The maternal aunt (family 4_I:1) had relatively high arches with toe clawing but 
did not display any weakness or atrophy. The proband’s father (family 4_I:3) 
had right hand thenar wasting attributed to war injury problems in the left hand, 
feet or voice. He passed away in 1993 due to liver problems. 
 
3.2.1.7 Genetic studies 
Due to the diagnosis of dHMN-VII, the proband was screened and found to be a 
heterozygous carrier of the SLC5A7 c.1497delG mutation. Genetic testing was 
not performed on any further family members. 
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Figure 24. dHMN-VII family (family 4) pedigree 
 
Figure 25. (A & B) Distal muscle wasting of family 4_II:2 in the small hand 
musculature giving a claw-like positioning of the hands. C) High arched foot and 
clawing of the toes in family 4_II:2. Modified (Ingram, 2016 (142)) 
 
120 
 
PART B 
3.2.2 Identification of a likely pathogenic, distinct  SLC5A7 truncating 
mutation in a family with dHMN-V (family 5) by targeted next 
generation sequencing 
In preparation for publication: (Barwick KES, Wright J, Bower M,  Russell MA,  
Blakely RD, McEntagart MM, Baple EL, Walk D, Crosby AH (2016)): 
Dominantly-acting truncating mutations in SLC5A7 underlie adult onset dHMN 
Following our publication of SLC5A7 mutation in dHMN-VII, we were contacted 
by Dr David Walk (University of Minnesota Medical Center, USA) to help with 
the interpretation and investigation of a putative SLC5A7 sequence variant 
identified by clinical exome sequencing in a family under his care with 
individuals with a phenotype consistent with dHMN-V. 
 
3.2.2.1 History and clinical findings in dHMN-V family 5 members 
Clinical investigation of the dHMN-V family was carried out in collaboration with 
Dr David Walk, University of Minnesota Medical Center.  At 27 years of age, 
family 5_IV:1 (figure 26) was referred with possible ALS following a 1-2 year 
history of progressive weakness in the hands. Sensory symptoms were absent 
and she claimed no prior history of weakness, developmental delay, or 
peripheral neuropathy.  Neither was she aware of any family history of 
neurologic disease. Neurologic examination demonstrated normal mental state 
and cranial nerve examinations including voice were also normal. On motor 
examination family 5_IV:1 was found to have bilateral marked atrophy of the 
intrinsic hand muscles with normal tone and no fasciculations. On manual 
muscles testing (MMT), full strength was observed in all muscles required for 
shoulder abduction, elbow flexion, elbow extension, wrist extension,  hip flexion, 
knee extension, knee flexion and ankle plantar flexion, and weakness was 
present in distal muscles as follows on the Medical Research Council (MRC) 
scale (table 21):  bilateral mild loss of movement against resistance of the first 
dorsal interosseous (fdi) muscle involved in abduction of the index, middle and 
ring fingers from the midline of the hand; loss of rage of movement against 
resistance of the right abductor pollicis brevis (apb) muscle which functions as 
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an abductor of the thumb, and loss of range of movement both against gravity 
and resistance of the left; and a moderate loss of range of movement against 
resistance of the muscles responsible for ankle dorsiflexion. For manual muscle 
testing results please see table 22. She demonstrated normal perception to 
touch, vibration, and pinprick on sensory examination. Increased (brisk) reflexes 
were observed throughout, with vertical spread in the upper limbs. However, no 
clonus or Babinsky signs were present. Nerve conduction studies revealed 
markedly attenuated median and peroneal compound muscle action potentials 
(CMAPs) with normal conduction velocities and no focal motor conduction 
block, normal ulnar and tibial motor conduction studies, and normal sensory 
nerve action potential (SNAP) amplitudes. Needle electromyography 
demonstrated fibrillation potentials, reduced interference patterns, and high-
amplitude long-duration motor unit potentials in distal muscles. Together these 
provide evidence of a pure motor neurogenic process without conduction block, 
and did not demonstrate uniform involvement of all motor nerves (tables 23-26). 
Immune-mediated neuropathies such as multifocal motor neuropathy were 
excluded from diagnosis with the use of an anti GM-1 ganglioside antibody test. 
IV:1 also received one dose of intravenous immunoglobulin, 1 gm/kg with no 
immediate improvement and chose not to continue this intervention; supporting 
the evidence that the disorder is not immune-mediated. Hexosaminidase A 
deficiency, PMP22 and SOD1 mutations, and a number of other pathologies 
with similar presentations were omitted as possible causes by a range of tests 
including a urinary hexosaminidase-A assay, SOD1 sequencing, cervical 
magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) protein level 
measurements. The subject demonstrated no further progression of weakness 
over the following 6 years of follow up. 
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Figure 26. dHMN-V family (family 5) pedigree  
More than a decade later, the subjects mother (family 5_III:2, figure 26) (60 
years), presented with a 2-3 year history of gradually progressive bilateral 
weakness of plantarflexion of the ankle. Sensory symptoms, weakness of the 
proximal lower limbs, weakness of the upper limbs, and bulbar symptoms, were 
absent. Neurologic examination demonstrated normal mental state and cranial 
nerve examinations including voice were normal. On motor examination she 
was found to have slight atrophy of the intrinsic hand and feet muscles, with 
normal tone and no fasciculations. Similarly to family 5_IV:1, MMT revealed full 
muscle strength with the exception of the following: slight loss of range of 
movement against resistance of the left fdi, the left apb, and the left extensor 
digitorum communis (edc); moderate loss of range of movement in the right fdi 
and bilaterally in the muscles involved in ankle dorsiflexion; complete loss of 
range of movement against resistance but full range of movement against 
gravity of the left apb (table 22). Sensory examination of family 5_III:2 showed 
normal perception to touch and vibration, and demonstrated an ambiguous 
reduction in pinprick perception in her toes. Vertical reflex spread was observed 
in the upper limbs with no clonus, Babinski signs, or spasticity. Nerve 
conduction studies revealed weakened median, peroneal, and tibial CMAPs 
with normal conduction velocities and no focal motor conduction block, normal 
ulnar motor conduction studies, and normal SNAP amplitudes. Fibrillation 
potentials, reduced interference patterns, and high-amplitude long-duration 
motor unit potentials in distal muscles were demonstrated by needle 
electromyography. GM1 antibody, serum Lyme titer, vitamin B12 and copper 
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levels, cervical MRI, and CSF analysis were normal or negative. CSF analysis 
demonstrated a protein level of 42 mg/dl, glucose of 52 mg/dl, 2 white blood 
cells, 0 red blood cells, and negative oligoclonal bands. No paresis was 
observed and vocal cord function appeared normal on laryngoscopy. 
The proband and her mother have been followed for 14 years and 2 years, 
respectively.  With the exception of the development of median entrapment at 
the wrist, confirmed by electrodiagnostic study in family 5_IV:1, there were no 
clinically significant changes on examination in that time. 
The patients reported that their mother/maternal grandmother (family 5_II:3) 
had a hand deformity late in life. However, they describe the appearance of the 
deformity as being different from their own, and suspect it was due to arthritis 
rather than atrophy. Family 5_III:2 has three living brothers and one sister, three 
of whom (family 5_III:3-5) have undergone neuromuscular examination and 
genetic testing according to a protocol approved by the University of Minnesota 
Institutional Review Board. None were found to have neuromuscular symptoms 
or findings of dHMN on examination. One demonstrated clinical and 
electrodiagnostic evidence of a sensory-predominant polyneuropathy, with 
normal needle electromyography in both distal and proximal muscles. 
 
Table 21: Medical Research Councils manual muscle testing scale 
Grade Description 
5 Muscle contracts normally against full resistance  
4 Muscle strength is reduced but muscle contraction can still move joint 
against resistance 
3 Muscle strength is further reduced such that the joint can be moved only 
against gravity with the examiner’s resistance completely removed. As an 
example  
2 Muscle can move only of the resistance of gravity is removed 
1 Only a trace of flicker of movement is seen or felt in the muscle or 
fasciculations are observed in the muscle 
0 No movement is observed 
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Table 22: Manual muscle testing 
Muscle  ↓ Side Grade (0 to 5)  
Subject →  family 5_IV:1 family 5_III:2 
fdi Rt 4 4 
Lft 4 4.5 
apb Rt 2 3 
Lft 3 4.5 
Ankle dorsiflexion Rt 4 4 
Lft 4.5 4 
EDC Rt  5 
Lft  4.5 
Abbreviations and symbols: fdi= first dorsal interosseous; apb= abductor pollicis brevis; edc= extensor digitorum 
communis; Rt= measurement taken on right side; Lft= measurement taken on left side 
N.B. All recordings in below tables taken from the right side 
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Table 23: Motor nerve conduction in family 5_IV:1 
 Latency  
(ms) 
Velocity 
(m/s) 
Amplitude 
(mV) 
Distance 
(cm) 
Temp 
(°C) 
Median nerve 
Wrist - apb 
Elbow – wrist 
(normal range) 
 
3.6 
7.7 
 
 
47.6 
(49-64) 
 
0.54 
0.52 
 
8.0 
19.5 
32 
Right common peroneal 
Ankle - edb 
fh – ankle 
pf – fh 
(normal range) 
 
8.8 
15.5 
19.1 
 
 
33.0 
34.6 
(44+) 
 
0.33 
0.29 
0.32 
 
8.0 
25.4 
9.0 
30 
Tibial nerve 
Ankle - ah 
pf – ankle 
(normal range) 
 
3.6 
11.2 
 
 
48.2 
(41+) 
 
5.09 
3.4 
 
8.0 
36.6 
30 
Ulnar nerve 
Wrist – adm 
Be elb - wrist 
Ab elb – Be elb 
Axilla – Ab elb 
Erb – Axilla 
(normal range) 
 
3.2 
5.9 
7.5 
9.5 
13.2 
 
 
57.4 
64.4 
60.0 
73.0 
(49+) 
 
8.55 
7.03 
7.10 
6.59 
6.66 
 
 
15.5 
10.3 
12.0 
27.0 
33 
Abbreviations and symbols: apb= abductor pollicis brevis; edb= extensor digitorum brevis; fh= fibular head; pf= 
popliteal fossa; ah= abductor hallucis; adm= abductor digiti minimi; Ab elb= above elbow; Be Elb= below elbow; 
Erb= Erb’s point 
 
Table 24: F-wave analysis in family 5_IV:1 
Nerve F-Latency 
 Min F Max F Mean F 
Tibial nerve 
Ankle – ah 
 
50.2 
 
57.2 
 
51.6 
Ulnar nerve 
Wrist - adm 
 
25.5 
 
33.8 
 
29.5 
Abbreviations and symbols: Min F= minimum F-latency; Max F= maximum F-latency; Mean F= mean F-Latency; 
ah= abductor halluces; adm= adductor digiti minimi;  
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Table 25: Sensory nerve conduction in family 5_IV:1 
 
 Latency  
(ms) 
Velocity 
(m/s) 
Amplitude 
(mV) 
Distance 
(cm) 
Temp 
(°C) 
Median nerve 
Dig. II – wrist 
(normal range) 
 
2.4 
 
58.3 
(45-70) 
 
39.36 
 
14.0 
33 
Ulnar nerve 
Dig. V – wrist 
(normal range) 
 
1.9 
 
64.4 
(48-74) 
 
17.35 
 
12.5 
33 
Sural nerve 
Ankle –  
(normal range) 
 
2.5 
 
55.0 
(46-64) 
 
41.26 
 
14.0 
30 
Abbreviations and symbols: Dig= digit;  
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Table 26: Electromyography findings in family 5_IV:1 
 
Muscle 
(Innervation) 
 
Ins. act. 
Spontaneous 
action 
 
Amp. 
 
Dur. 
 
Poly. 
 
Recruit. 
 
Firing 
Fib/PSW Fasc. 
Rt Triceps  
(Radialis, c6 C7 c8) 
Incr. 1+ 2+ ++ ++ 0 Red. Norm. 
Rt Trapezius Incr. 0 1+ ++ ++ 2+ Mild red. Norm. 
Rt Biceps 
(Musculotaneous, C5 c6 
Incr. 1+ 1+ ++ ++ 1+ Red. Norm. 
Rt Paravert T4 Incr. 1+ 1+ ++ ++ 1+ Norm.  Norm. 
Rt Paravert T8 Incr. 0 1+ + + 1+ Norm. Norm. 
Rt Paravert T12 Incr. 0 1+ + + 1+ Norm. Norm. 
Rt Gastroc. caput med. 
(Tibialis, S1 s2) 
Incr. 1+ 2+ ++ + 1+ Norm. Norm. 
Rt Tibialis anterior 
(Peroneus profundus, l4 L5) 
Incr. 2+ 1+ ++ ++ 1+ Red. Norm. 
Rt Vastus lateralis 
(Femoralis, l2 l3 L4) 
Incr. 0 1+ + ++ 1+ Norm. Norm. 
Abbreviations and symbols: Rt= right; Gastroc. Caput med= Gastocnemius caput mediale; Ins. Act.= insertional action; Fib= fibrillation; PSW= positive sharp 
waves; Fasc.= fasciculation; Amp.= amplitude; Dur.= duration; Poly.= poly phasic potential; Recruit.= recruitment pattern; Incr.= increased; += mild abnormality ; 
++= moderate abnormality ; +++= severe abnormality; Norm= normal; Red.= reduced 
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3.2.2.2 Targeted next-generation sequence analysis identifies a novel 
likely pathogenic variant in SLC5A7 
In order to identify the gene mutation causative of this condition, family 5_III:2 
was subjected to next generation sequence analysis, the data from which was 
run through a custom built pipeline allowing the production and use of targeted 
test panels. Specific analysis was undertaken of the following genes: BSCL2, 
DCTN1, DNAJB2, GARS, HSPB1, HSPB3, HSPB8, IGHMBP2, PLEKHG5, 
REEP1, SLC5A7, and TRPV4.  Target regions were captured using the Illumina 
TruSight OneTM sequence capture and sequenced by Illumina HiSeq 2500. Of 
the 25 known motor neuropathy genes targeted for analysis, next generation 
sequencing identified only one potentially disease causing variant, a 
heterozygous 2 base deletion (c.1563_1564delCA: NM_021815.2) in SLC5A7 
(figure 27). Coverage across the exon harbouring the variant (exon 9) was 
>300x and about half of the reads contain the c.1563_1564delCA variant. 
Heterozygous presence of the mutation was confirmed in both family 5_III:2 and 
family 5_IV:1 by bi-directional di-deoxy sequencing (figure 28). 
 
Figure 27. Next generation sequencing data for individual family 5_III-2 
visualised in the integrative genome viewer (IGV).  Coverage across the area of 
interest is >300x and half the reads contain a 2 base pair AC deletion. 
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Figure 28. Chromatogram showing DNA sequence around the c.1563_1564delCA 
variant in (A) individual family 5_III:2 (forward strand); (B) individual family 5_IV:1 
(forward strand); (C) individual family 5_III:2 (reverse strand); (D) individual 
family 5_IV:1 (reverse strand). The overlapping traces indicate the position of the 
frameshift variant. 
 
3.2.2.3 In silico analysis of SLC5A7 c.1563_1564delCA 
As for c.1497delG, the amino acid sequence of SLC5A7 c.1563_1564delCA 
was obtained by entering the coding (exonic) DNA sequence into the online 
ExPASy translate tool. The SLC5A7 c.1563_1564delCA variant is also 
predicted to result in premature truncation of the protein at the C-terminus by 60 
amino acids with the inclusion of 1 aberrant histidine residue (p.H521Qfs*2) 
(figure 29 and 30B). Conservation analysis indicated that the portion of the C-
terminal that is lost contains residues that are highly conserved across many 
species (figure 49, appendix), and TMHMM analysis predicts a similarly 
profound effect on transmembrane morphology of the 3’ terminus of the protein 
as c.1897delG in that it too is likely to interfere with the number or orientation of 
transmembrane domains (figure 50, appendix). In silico mutation analysis 
programs, PROVEAN and Mutation Taster predicted the variant to have 
deleterious effects on the protein function with scores of -14.155 and 
0.999999999999999, respectively. SLC5A7 c.1563_1564delCA was absent 
from dbSNP, 1000 Genomes Project, EVS and ExAC. 
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Figure 29. Alignment of wild type and CHT H521Qfs*2 amino acid sequences 
showing premature truncation of the protein product, and the inclusion of 1 
(highlighted) ectopic amino acid residues (ClustalOmega - 
http://www.ebi.ac.uk/Tools/msa/clustalo/). 
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Figure 30. A) Diagram of the predicted secondary structure of the SLC5A7 gene 
polypeptide product (CHT) showing 13 transmembrane domains with an 
extracellular N-terminus, and an intracellular C-terminus. Dark circles represent 
amino acids which are conserved across human CHT, mouse Cht1, and the C. 
elegans CHT ortholog, CHO-1. Dark circles containing the letter ‘P’ indicate 
potential protein kinase C phosphorylation sites, and light circles containing the 
letter ‘P’ represent potential protein kinase A phosphorylation sites. The fork-like 
structures represent potential N-glycosylation sites. B) The blue circle 
represents the one aberrant amino acid encoded as a result of the 
c.1563_1564delCA variant followed by premature truncation of the cytoplasmic 
C-tail. Modified (Apparsundaram, 2000; Apparsundaram, 2001 (140, 141)) 
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3.2.2.4 SLC5A7H521Qfs*2 truncates CHT, alters expression levels and 
reduces choline transport 
In order to maintain experimental continuity, investigation of the impact of 
SLC5A7 c.1563_1564delCA (p.H521Qfs*2) variant on CHT function was 
performed via heterologous expression of mutant (CHT p.H521Qfs*2) and wild 
type (CHT WT) proteins in HEK-293 cells transiently transfected with the 
respective cDNA constructs (SLC5A7H521Qfs*2 and SLC5A7WT) in a pRK5 vector 
(for cDNA transfection amounts see tables 36 and 37 in appendix) in Prof 
Blakely’s laboratory. Mutant cDNA constructs were produced using the 
QuickChange Lightning Site-Directed Mutagenesis kit (for SDM primer 
sequences see appendix). These experiments were undertaken in parallel with 
those involving the SLC5A7 c.1497delG (p.K499Nfs*13) variant. Again, a HA-
tag was added to the N-termini of both the mutant and wild type transporters by 
site directed mutagenesis.  
Preliminary western blot analysis of cell lysates of HEK-293T and HEK-293 
cells transiently transfected with HA-SLC5A7WT, HA-SLC5A7K499Nfs*13, and HA-
SLC5A7H521Qfs*2 cDNAs, confirms truncation of the CHT p.H521Qfs*2 mutant 
indicates equal levels of products were produced for equivalent amounts of 
cDNA transfected (figure 31) (for amounts of DNA transfected into HEK-293 
cells see appendix). Two additional bands are present at a much higher 
molecular weight (between 120 and 140kDa for wild type) for both wild type and 
truncated proteins, especially visible in lysates from HEK-293T cells. These 
may represent CHT homodimers indicating that the ability of CHT to form 
homodimers is not affected by these mutations. 
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Figure 31. Preliminary western blot analysis of total protein levels of HA-CHT WT, 
HA-CHT p.K499Nfs*13 and HA-CHT p.H521Qfs*2 after SDS-PAGE and 
immunoblotting with anti-HA antibody of lysates from transiently transfected (A) 
HEK-293T and (B) HEK-293 cells. Truncation of HA-CHT p.H521Qfs*2 is 
confirmed. In A, two faint bands are visible for all proteins, between 120 and 
140kDa in the wild type and between 80 and 100kDa in the lanes loaded with 
truncated proteins (indicated by arrows) which may represent CHT homodimers. 
 
Preliminary choline uptake assays showed that CHT specific uptake in cell 
transfected with HA-SLC5A7H521Qfs*2 cDNA is ~50% of that in cells transfected 
with SLC5A7WT (figure 32), similar to the reduced uptake activity observed in 
cells expressing HA-CHT p.K499Nfs*13. 
 
 Figure 32. Preliminary choline uptake assay in HEK-293 cells transiently 
transfected with wild type and CHT p.H521Qfs*2 cDNAs. [3H]-choline transport 
activity is reduced in CHT p.H521Qfs*2 expressing HEK-293 cells compared to 
CHT WT expressing cells by ~50% (p=0.199, n=3, students unpaired t-test). This 
data is preliminary. Experiments are still underway. 
134 
 
3.3 Discussion 
Whole-exome sequencing of one affected member of dHMN-VII family 1 with 
individuals with dHMN-VII identified novel variants within four genes (SLC5A7 
[MIM 608761], PCDP1 [MIM N/A], RNF149 [MIM N/A], INHBB [MIM 147390]) 
located within the critical region. Following cosegregation studies, four of the 
sequence variants identified could be excluded as each had not been inherited 
by at least one affected family member, indicating that each was present on the 
alternate (non-disease) allele in the individual investigated. Only one of the four 
variants was found to cosegregate with the disease phenotype and considered 
likely to be the pathogenic mutation, a single base deletion, c.1497delG, in 
SLC5A7 encoding the Na+/Cl- dependent, high-affinity choline transporter 
(CHT). As well as other possible mutations located within the chromosome 2 
locus that may have been missed by whole exome sequencing, an unlikely 
possibility also exists that there is a second region located elsewhere on the 
genome that also cosegregates with the disease phenotype and contains a 
pathogenic mutation. To exclude this possibility, whole-exome sequence 
analysis of a second affected subject was undertaken by Prof M Reilly and Prof 
H Houlden at the MRC Centre for Neuromuscular Diseases, Department of 
Molecular Neurosciences, UCL Institute of Neurology and National Hospital for 
Neurology and choline transport was measured in whole blood monocytes 
obtained from both affected subjects (n=4) and Neurosurgery (data not shown). 
This confirmed the c.1497delG variant as the only variant identified by both 
analyses, and strongly indicates that it is causative. Identification of a second 
Welsh dHMN-VII family (family 4) as carrying the c.1497delG mutation provides 
further evidence of this genetic variation as being causative of the disorder and 
indicates that both families are likely to be distantly related. These findings 
provide an important additional genetic test for patients with upper limb 
dominant distal hereditary neuropathy with vocal cord involvement, in addition 
to screening for BSCL2 and TRPV4 mutations. 
SLC5A7 screening of families displaying dHMN-VII-like features (family 2 and 
family 3, figure 16) already found to be negative for TRPV4 and BSCL2  
mutations, failed to detect novel sequence variants, indicating the existence of 
as yet undiscovered gene(s) that is(are) also responsible for this condition. 
Whole exome sequencing is now being undertaken in these families.  
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Targeted next generation sequence analysis run through a custom built test 
panel was carried out on one affected member of a third family (family 5) in the 
laboratory of Dr David Walk. Affected family members displayed a phenotype 
related to dHMN-VII present in the Welsh families (family 1 and family 4)), 
presenting with a dHMN-V which does not display vocal cord paralysis. This 
identified a second SLC5A7 frameshift mutation (c.1563_1564delCA) which 
cosegregates with the disease phenotype and results in partial loss of the C-
terminus of CHT.  
CHT is a protein which consists of 580 amino acids predicted to comprise 13 
transmembrane domains with an extracellular –NH2 terminus and an 
intracellular –COOH terminus(138, 143). CHT is enriched in motor neurones 
and nerve terminals(144) and is localised at the cell membrane(138). This 
Na+/Cl- dependent, high-affinity choline transporter is sensitive to 
hemicholinium-3(139) and is responsible for the choline uptake at NMJs, the 
rate limiting step in acetylcholine (ACh) synthesis(138, 139). 
The SLC5A7 c.1497delG variant is predicted to result in a translational frame-
shift substituting lysine at amino acid position 499 for asparagine and going on 
to encode an additional 11 aberrant amino acids prior to a premature stop 
codon (p.K499Nfs*13). This alteration results in premature truncation of the 
protein, eliminating the transporter’s ultimate 82 amino acids which is a near 
complete deletion of the protein’s cytoplasmic C-terminus. The SLC5A7 
c.1563_1564delCA variant is also predicted to cause in a DNA reading 
frameshift resulting in the substitution of histidine at position 521 to glutamine 
followed immediately by a premature stop codon. This represents the loss of the 
ultimate 59 amino acids, partially eliminating the proteins C-terminus. The C-
terminus amino acid sequence is highly conserved across species and encodes 
residues known to regulate surface trafficking(145): both evidence that loss of 
this domain is likely to have profound consequences on the transporter’s 
function. 
Online TMHMM software is a programme which uses the Hidden Markov model 
to predict the location and orientation of alpha helices in membrane spanning 
proteins. In silico TMHMM analysis of CHT WT compared with CHT 
p.K499Nfs*13 and CHT p.H521fs*2 suggests that both variants are likely to 
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alter the number of transmembrane domains of the protein, which, if the protein 
acts as a monomer, may change the orientation of the 3‘-terminus of the 
protein. Further evidence that these frameshift mutations are likely to have 
profound functional consequences. 
Both frameshift mutations located in the last exon of the gene and therefore the 
transcript may not be subjected to nonsense-mediated mRNA decay (NMD). 
The NMD pathway mediates rapid down regulation of aberrant mRNAs that 
terminate translation upstream of the last splice junction(146). Following 
splicing, a multi-protein exon-junction complex (EJC) is deposited 20-24 
nucleotides upstream of each exon-exon junction, which are then removed by 
the first translation event(146).If translation terminates >50-55 nucleotides 
upstream of the last exon-exon junction, one or more of the EJC‘s will remain 
associated downstream of the termination complex triggering rapid decay of the 
mRNA(146). If, as is likely the case in the c.1497delG and c.1563_1564delCA 
variants, translation is terminated <50-55 nucleotides upstream of the last exon-
exon junction, no EJC‘s will remain associated and therefore NMD may be 
averted, potentially allowing the synthesis of the mutant molecule. While more 
accurate evaluation of this could be undertaken by quantitative PCR evaluations 
of cDNA generated from RNA extracted from patient cells, our sequencing of 
mRNA extracted from the blood of an affected dHMN-VII subject revealed the 
presence of the variant in the cDNA in approximately equimolar amounts (figure 
14), providing supporting evidence that the c.1497delG variant may escape 
NMD and be translated to produce mutant protein. 
The functional impact of the c.1497delG variant was investigated in HEK-293 
cells transiently transfected with human SLC5A7 WT and SLC5A7 c.1497delG 
cDNAs. Unfortunately the only anti-CHT antibodies available target the C-
terminus of the transporter, preventing their use in this investigation due to loss 
of the C-terminus associated with the CHT mutations. Consequently, an HA-tag 
was added to the N-termini of both the CHT WT and CHT p.K499Nfs*13 
constructs in order to detect the proteins using western blotting. The wild type 
protein migrates as two species: an immature 48kDa core-glycosylated species 
and a mature 56kDa N-glycosylated species. The CHT p.K499Nfs*13 
transporter can also be seen to migrate as two distinct species, which as 
expected are smaller (~38kDa and ~47kDa), confirming expression of the 
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truncated protein in these cells. For equivalent amounts of cDNA transfected, 
both at 1X and 2X, reduced levels of both the mature and immature species 
were observed in CHT p.K499N*13 expressing cells compared with the CHT 
WT expressing cells, indicative of reduced translation or stability of the CHT 
p.K499Nfs*13 transporter. The [3H]-choline uptake assays revealed a 
significant reduction in choline transport activity in heterologous CHT 
p.K499Nfs*13 expressing HEK-293 cells compared with the wild type 
expressing cells. This was accounted for by a reduction in choline transport 
VMAX (CHT activity) and not choline KM (a variation in choline concentration), 
confirming that the c.1497delG variant has a negative impact on CHT 
p.K499Nfs*13 transporter function. Interestingly, CHT activity observed in the 
uptake assays undertaken on HEK-293 cells co-expressing the two isoforms 
was found to be reduced significantly below that expected from the summation 
of transport activities from cells independently expressing CHT WT and CHT 
p.K499Nfs*13. This suggests that the CHT p.K499Nfs*13 exerts a dominant-
negative impact on total and surface protein for both CHT isoforms. Activity 
seen with dual transfection was reduced even when compared to activity in cells 
transfected with SLC5A7 c.1497delG alone, showing that the severity of the 
functional effect of the c.1497delG variant increases when the cells produce 
CHT proteins with mismatched C-termini. When the mutant and wild type 
cDNAs were co-transfected in equal amounts (1X), the combined surface levels 
of the two transporters were reduced greatly compared to that expected from 
the summation of the levels observed when the same amount of the two cDNAs 
were transfected individually, providing further evidence for a dominant-negative 
impact of the c.1497delG variant on CHT function. 
When measuring choline transport in whole blood monocytes natively 
expressing the SLC5A7 c.1497delG variant, obtained from affected subjects, 
choline transport was impacted even more significantly and barely detectable 
compared with that in whole blood monocytes of unaffected control individuals. 
This is consistent with the greatly reduced transport observed in HEK-293 cells 
co-transfected with both SLC5A7 WT and SLC5A7 c.1497delG. This, coupled 
with our studies in transiently transfected HEK-293 cells, provides robust 
evidence that the c.del1497 variation is the disease causing gene mutation in 
dHMN-VII, and that there is a dominant-negative impact of the mutation on 
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transporter function as opposed to the effects expected due to 
haploinsufficiency alone. 
Preliminary choline uptake assays in HEK-293 cells individually transfected with 
wild type CHT cDNA, and CHT cDNA encoding the p.H521Qfs*2 mutant 
identified in dHMN-V family (family 5) revealed a reduction in choline uptake 
activity of CHT p.H521Qfs*13 to ~53% of that of the wild type, similar to that 
seen in cells individually transfected with CHT p.K499nfs*13 cDNA. Choline 
uptake assays in cells dually transfected with wild type and p.H521Qfs*2 cDNAs 
are currently ongoing. However, due to the phenotypic similarity between the 
dHMN-VII and dHMN-V families, the similarity in the predicted outcome of the 
two truncating mutations, and the similarity in functional effect observed in these 
preliminary studies, it is likely that there will be a similar outcome in cells dually 
transfected with wild type and p.H521Qfs*2 cDNAs as that seen in cells 
transfected with CHT wild type and CHT p.K499Nfs*13 cDNAs. Consequently 
the p.H521Qfs*2 mutant molecule may also be likely to exert a dominant-
negative mode of action leading to a greater reduction in choline uptake activity 
compared to single transfections. In light of the slightly milder phenotype 
observed in the dHMN-V family (family 5) compared to the dHMN-VII families 
(families 1 and 4), and our knowledge that CHT p.H521Qfs*2 mutation spares 
residues of the proteins C-terminus that CHT p.K499Nfs*13 does not, perhaps 
the H521Qfs*2 mutation permits for slightly greater transporter activity, resulting 
in the milder phenotype lacking VCP. Unfortunately we are unable to test this in 
whole blood monocytes as patient material is not available. 
In 2012, Okuda and colleagues found that co-expression of wild type CHT with 
partially inactive mutants N301Q and I89A revealed inhibition of wild type 
uptake activity in a dominant-negative manner. Although these residues do not 
reside in the C-terminal tail like the CHT p.K499Nfs*13 and p.H521Qfs*2 
mutations, this supports our findings that mutant CHT molecules can interfere 
with the wild type molecule when expressed heterozygously, which may be 
explained by evidence that CHT functions as a homo-dimer(116). Deletion of 
CHT amino acid residues 499, 502, and 503 at the N-terminus of the C-tail 
leads to a decrease in CHT activity (30, 35, and 75% of wild type, 
respectively)(147). All of these are lost as a result of the SLC5A7 
c.1497delG/p.K499Nfs*13 mutation which eliminates the transporters 
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cytoplasmic C-terminus reducing CHT activity by ~50% of the wildtype in 
transfected cells, and resulting in the dHMN-VII phenotype with VCP in human 
carriers. On the other hand, deletion of residue 510 and 550 both result in an 
increase in uptake activity (120%)(147). These residues are lost as a result of 
both dHMN causing SLC5A7 mutations. The authors have not commented on 
the effects of the above variants when expressed with the wild type. However, 
the increase in uptake activity associated with their deletion seems at odds with 
the loss of uptake activity resulting from partial or complete loss of the C-
terminus, although it is not possible to draw strict correlations due to the 
different nature of each mutation. These findings indicate the necessity of 10 or 
less amino acids located at the stem of the cytoplasmic C-terminus for choline 
uptake activity(147). Evidence also suggests a negative effect on uptake of 
residues located closer to the C-terminus. CHT harbours a motif on the its C-
terminus (I530,L531) similar to an acidic residue-flanked dileucine motif on the 
cytoplasmic C-terminus of VAChT, on which VAChT internalisation and sorting 
to the synaptic-like microvesicles (SLMVs) in PC12 cells is dependent(32). As it 
is also present on the membrane of a subpopulation of VAChT-positive synaptic 
vesicles, it is likely that CHT and VAChT share this common structural motif, 
and possibly more, for endocytic targeting to synaptic vesicles. This motif is 
eliminated from both the truncated proteins underlying dHMN and it is thus 
possible that disrupted endocytosis and vesicular sorting contribute to the 
dHMN phenotype. 
Ruggiero et al. (2012) identified two sequences in the hCHT C-terminus that 
drive constitutive endocytosis(3). A primary endocytic motif (SEENMDKTILV-1° 
Motif) between CHT amino acids S522 to V532 contains a dileucine-type motif 
and is essential for CHT dynamin-dependent endocytosis(3). A secondary motif 
(DELAL-2° Motif) between D540 and L544 supports enhanced surface 
expression of CHT but doesn’t exhibit a dominant capacity for surface 
trafficking(3). Both the CHT truncating mutations we have identified in dHMN 
result in the complete elimination of both SEENMDKTILV-1° and DELAL-2° 
motifs suggesting that these mutations may lead to impaired choline uptake due 
to the loss of dynamin-dependent endocytosis. It has also been suggested that 
residues 560-577 within the C-tail, also lost in dHMN subjects, may be involved 
in internalisation of CHT from the cell surface and in recycling of internalised 
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CHT back to the surface(147); possibly these residues represent a motif 
required for protein kinase C (PKC)-dependent CHT internalisation and thus 
another possible contributing factor to the reduction of CHT activity in dHMN 
subjects. 
NMJ dysfunction has not previously been implicated in the distal hereditary 
motor neuropathies. However, it is a well-recognised cause of a genetically 
heterogeneous group of neuromuscular disorders known as the congenital 
myasthenic syndromes (CMS). CMS is known to result in mutation in genes that 
encode pre-, post and synaptic proteins at the NMJ such as choline 
acetyltransferase (CHAT), ACh receptors (AChRs), receptor associated protein 
of the synapse (RAPSN), and downstream of kinase 7 (DOK7)(148-152). CMS 
does not share any apparent phenotype with dHMN-VII or dHMN-V. Features of 
CMS include opthalmoparesis, ptosis and bulbar weakness and as suggested in 
the name, onset of CMS is usually at or before birth. The lack of phenotypic 
overlap between CMT and dHMN subjects is unexpected and prompted us to 
carry out electrophysiology (table 20) studies in two affected dHMN-VII family 
members (family 1_V:19 male 56y; family 1_VI:13 male 28y, figure 10). 
Repetitive stimulation did not show a significant decrement and single fibre 
EMG showed an excess of jitter and blocking which is suggestive of disturbance 
of NMJ function (data not shown) but such changes could also be secondary to 
reinnervation. The changes were less marked in the younger of the two subjects 
who has less progressed disease. Vocal cord paresis, presenting as congenital 
stridor (a harsh grating or vibrating sound when breathing) is a feature of CMS 
that is associated with mutations in DOK7, and less often with CHAT(153, 154). 
This suggests that it is possible that the differences between dHMN-VII and 
CMS may involve differences in the contribution made to NMJ signalling 
between CHT and the CMS related NMJ proteins. 
Two forms of NMJ exist (see chapter 1.4.2.2), of which the en plaque twitch 
fibres have a role for CHT in sustained, high frequency ACh signalling. It is 
possible that the synapses affected in dHMN-VII and dHMN-V are more 
dependent on CHT due to a requirement for sustained, high frequency ACh 
release. Model system studies with HC-3 demonstrate a suppression of ACh 
release and cholinergic signalling only with sustained or higher frequency 
stimulation(32). 
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In summary, convincing genetic and functional evidence has been provided that 
a dominantly-acting SLC5A7 mutation that results in near complete loss of the 
CHT transporter C-terminus underlies dHMN-VII in the families investigated. 
Moreover, we have identified a second dominant SLC5A7 mutation, which also 
affects the C-terminus, resulting in partial loss of the ultimate 59 amino acids, as 
underlying dHMN-V. This gives rise to a possible novel disease mechanism in 
which CHT has role in idiopathic motor neuropathies. Knowledge of these 
mutations underlying dHMN-VII and -V provides a genetic test for disease risk 
in affected families, and may permit the development of targeted 
pharmacotherapies (see chapter 5). 
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CHAPTER FOUR 
 
N-TERMINAL AUTOSOMAL RECESSIVELY-ACTING 
SLC5A7/CHT MISSENSE MUTATIONS ASSOCIATED 
WITH SEVERE CONGENITAL HYPOTONIA 
4 
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4 N- TERMINAL AUTOSOMAL RECESSIVELY-ACTING 
SLC5A7/CHT MISSENSE MUTATIONS ASSOCIATED WITH 
SEVERE CONGENITAL HYPOTONIA 
 
4.1 Introduction 
Hypotonia is a term used to denote diminished tone of skeletal muscle in the 
limbs, trunk, or craniofacial muscles, associated with reduced resistance of 
muscles to passive stretching(155). Hypotonia is not however, a specific 
diagnosis, but part of a great number of distinct disorders, and its severity is 
extremely variable depending on the underlying aetiology. In clinical practice, 
the differential diagnosis of neonatal and infantile hypotonia is extremely broad 
and presents a diagnostic challenge, yet is crucial for prognosis, management 
and treatment(156). Infantile hypotonia can present due to abnormalities at all 
levels of both central and peripheral nervous systems including anterior horn 
cell disorders, congenital motor or sensory neuropathies and NMJ disorders; 
muscle abnormalities such as congenital myopathies and muscular dystrophies; 
and metabolic disorders affecting multiple systems (figure 33). As hypotonia is 
often the presenting sign for many benign and serious multisystem and nervous 
system diseases, a detailed history combined with full systemic, neurological 
and often genetic examination are critical in obtaining an accurate diagnosis. 
Despite extensive clinical and genetic examination, a lack of information 
regarding the genes and their respective pathways involved in neuromuscular 
function means a significant proportion of patients remain undiagnosed.  
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Figure 33. Schematic diagram of the anatomical-clinical correlation of infantile 
hypotonia, illustrating differential diagnosis. Modified (Leyenaar, 2005 (156)) 
When investigating the underlying cause of hypotonia in an infant, it is important 
to first distinguish whether the diminished muscle tone results from an 
abnormality in the CNS, the PNS, or an abnormality involving both 
systems(155). Clinical findings, in additional to hypotonia, suggestive of a CNS 
abnormality may include hyperreflexia, cognitive developmental delay, normal 
strength and seizures, where as those suggestive of PNS involvement or 
neuromuscular origin may include muscle weakness, muscle atrophy, lack of 
antigravity movements, fasciculations and diminished reflexes, usually with 
normal cognitive function(155). Genetic disorders associated with either 
congenital central, peripheral or combined hypotonia, their salient distinguishing 
features, and their genetic aetiology are detailed in the appendix. Loss of 
function mutations in PRPS1, causative of peripheral neuropathy CMT-5X 
(Rosenberg-Chutorian syndrome), have also been reported to cause Arts 
syndrome, a characteristic of which is congenital or early onset central 
hypotonia(157). 
This chapter describes two consanguineous families affected by a severe 
congenital neuromuscular disorder presenting as combined (predominantly) 
central and peripheral hypotonia that have not previously been described in the 
literature, and provide genetic and molecular evidence implicating two 
autosomal recessive missense mutations in SLC5A7 that result in complete 
elimination of CHT choline transport as being causative. 
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4.2 Results 
 
4.2.1 Identification of a autosomal recessive mutations in SLC5A7 in two 
consanguineous families with severe congenital hypotonia 
In preparation for publication: (Wang H, Barwick KES, Wright J, Zimmerman 
HH, Karakaya M, Stüve B, Weis J, Russell MA, Wirth B, Abdul-Rahman OA, 
Blakely RD, Baple EL, Cirak S, Crosby AH (2016)): Recessively-acting choline 
transporter mutations associated with severe neurodevelopmental delay and 
congenital hypotonia. 
4.2.1.1 History and clinical pathological features in Turkish hypotonia 
family (family 6) 
A 2.5 year old female presented with severe developmental delay (family 
6_IV:1, figure 34). Born at 32 weeks from gestation because of pathologic 
cardiotocography- a similar technology to echocardiography in that Doppler 
ultrasound is used to provide information on foetal heart rate- after an 
uneventful pregnancy. Birth weight was 1676g (50th centile), and head 
circumference was 30cm (60th centile). During postnatal period, respiratory 
insufficiency and lack of spontaneous movements, especially in the distal 
extremities were noted. In addition to diffuse hypomotoric activity, lack of eye 
movements and difficulties in swallowing suggested in involvement of the 
cranial nerves. On examination, severe generalised central hypotonia and 
muscle atrophy were present. Due to bulbar and respiratory insufficiency 
tracheostomy and gastrostomy were required during the first month of life. The 
child did not demonstrate any milestones within the speech, cognitive or motor 
domains. Remarkably, she had some spontaneous and nonpurposeful 
antigravity movements although she is unable to follow objects with her eyes, or 
react to stimuli. Metabolic work up including serum and urine amino acids, 
serum acyl-carnitine profile, serum creatine and cerebro-spinal fluid lactate 
levels were normal. No cardiac involvement or organomegaly (unusually large 
organs) were noted on echocardiography and abdominal ultrasound. The 
electroencephalogram showed reduced brain activity but no pathological 
discharges, and studies of evoked potentials were normal. Nerve conduction 
studies with repetitive stimulation revealed no responses from both median and 
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tibialis nerves.  Cranial magnetic resonance imaging in the newborn period 
showed general atrophy of the brain (data not shown). A muscle biopsy showed 
myopathic changes with increased connective tissue and atrophic fibres 
together with core-like areas on electron microscopy (data not shown). This 
shows that despite the clinical presentation being dominated by central 
hypotonia, there is a degree of muscular weakness due to transmission defect 
on the presynaptic membrane of neuromuscular junction. The child is now 
almost 4 years of age. 
 
Figure 34. Turkish hypotonia family (family 6) pedigree 
 
4.2.1.2 History and clinical pathological features in Hispanic hypotonia 
family (family 7) 
A Hispanic male (family 7_V:3, figure 35) was born with a severe 
neuromuscular disorder and passed away aged 5 months. He displayed poor 
respiratory effort requiring a tracheotomy and ventilation. Brain magnetic 
resonance imaging (MRI) was normal (figure 36). Electromyography (EMG) 
indicated possible neuromuscular junction (NMJ) disorder with possible severe 
myopathy. Repeat EMG with a subdermal needle demonstrated widespread 
fibrillation in limb and trunk muscles with no voluntary motor unit activity. 
Metabolic testing, including amino acids (performed on plasma, urine and CSF), 
lactate and pyruvate (blood and CSF), creatinine/GAA (blood and urine), 
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carnitine/acylcarnitine, urine organic acids, and urine s-sulfocysteine, was 
normal or nondiagnostic. A neurochemistry panel was normal. Copy number of 
the SMN1 gene was also normal. A SNP array of this patient revealed 
excessive homozygosity at 6% of the genome, consistent with the known 
consanguinity of the parents. 
The family reported a similarly affected female sibling (family 7_V:1, figure 35) 
who was born a few years prior to family 7_V:3and passed away aged 10 
months.  
The family also reported a cousin to have a similar phenotype, however this 
patient is unfortunately also deceased and no clinical or genetic data available. 
For the clinical phenotypes of subjects family 7_V:1, family 7_V:3 and affected 
cousin, see table 27. 
 
 
Figure 35. Hispanic hypotonia family (family 7) pedigree 
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Figure 36. Brain MRI of family 7_V:3. Examination is degraded by patient motion. 
No significant intracranial abnormality is identified. 
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Table 27: Clinical phenotypes of family 7  
 Proband (family 7_V:3) 
homozygous for  
SLC5A7 c.335T>A 
Full sister (family 
7_V:1) 
homozygous for 
SLC5A7 c.335T>A 
Cousin  
(NOT TESTED) 
Hypotonia + + + 
Stridor + +  
Poor respiratory 
effort/Respiratory 
support needed 
+ + + 
Seizures + + + 
CK 198 168 20 
EEG Abnormal Abnormal Abnormal 
EMG Neuromuscular junction 
defect 
Neuromuscular 
transmission defect 
Neuromuscular 
transmission 
defect in UE and 
LE; diffuse 
myopathy 
Head imaging Normal MRI Normal HUS Normal HUS; 
initial brain MRI 
showed 
increase signal 
in the pituitary; 
f/u MRI showed 
cavum septum 
pellucidum 
Muscle biopsy Muscle atrophy Muscle atrophy myopathy 
Death 6.5 months 11 months 11 months 
Autopsy Consistent with 
neuromuscular disorder 
N/A  
Other details Bowel 
perforation/obstruction 
Bowel perforation nystagmus 
Previous Work-up 
(normal) 
SNP array showed AOH 
(~6%); normal plasma 
amino acids, normal 
lactate/pyruvate, normal 
urine organic acids, 
normal urine s-
sulfocysteine, normal 
creatine/ 
guinodinoacetate, normal 
carnitine/acylcarnitine, 
normal neurochemistry 
panel, normal SMA 
Normal newborn 
screen, normal 60K 
array, normal plasma 
amino acids, normal 
urine organic acids, 
normal 
lactate/pyruvate, 
normal SMA 
Normal echo 
Abbreviations: CK= Creatine kinase; EEG= Electroencephalogram; EMG= Electromyography; + = present; MRI= 
Magnetic resonance imaging; HUS= Head ultrasound scan; AOH= Absence of heterozygosity; SMA= spinal 
muscular atrophy. 
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4.2.2 Exome sequencing and mutation identification 
In order to define the disease causing mutation in each family, a single affected 
individual (family 6_IV:1, figure 34) from the Turkish hypotonia family, family 6, 
and three individuals (family 7_V:3, family 7_IV:3 and family 7_IV:4) from the 
Hispanic hypotonia family, family 7, were subjected to whole-exome sequencing 
analysis to generate novel variant profiles. Exome sequencing of these families 
was carried out in collaboration with Dr Sebahattin Cirak at Uniklinik Köln 
University Hospital, Germany and Dr. Omar Abdulrahman and Holly 
Zimmerman, based at the University of Mississippi Medical Center, USA, for the 
Turkish and Hispanic families, respectively.  
The exome from family 6_IV:1 was captured with SeqCap EZ Human Exome 
Library v2.0 kit (Roche NimbleGen) and sequenced on an Illumina HiSeq 2000 
with a paired-end 2x100 bp protocol. On average, this resulted in >68 million of 
mapped unique sequences with a mean coverage of 92 i.e., 20x coverage for 
92.9% of target sequences. Following filtering for homozygous variants and 
exclusion of all those with allele frequencies >0.1% in the population that do not 
occur within one of the homozygous intervals identified, one candidate variant 
was identified in family 6_IV:1; A single base substitution at chromosome 
2:108608665 (SLC5A7 c.282T>A) (figure 37A), encoding CHT.  
The exome of family 7_V:3 and his parents, family 7_IV:3 and family 7_IV:4, 
was captured using the SureSelectXT Target Enrichment System for Illumina 
Paired-End Multiplexed Sequencing with the addition of 1800 clinically relevant 
disease genes, and sequenced on the Illumina HiSeq platform with a 100bp 
paired-end protocol. The following quality control metrics of the sequence data 
are generally achieved using this protocol: >70% reads aligned to target, >95% 
target bases covered at >20X, >85% target bases covered at >40X, >100X 
mean coverage of target bases. Whole-exome sequencing data was compared 
to Illumina HumanExome 12vI array data to assess sequencing quality, 
achieving >99% SNP concordance to genotype array. Exome sequencing 
identified a single base substitution at chromosome 2:108609470 (SLC5A7 
c.335T>A) that was present homozygously in family 7_V:3, and heterozygously 
in family 7_IV:3 and family 7_IV:4 (figure 37B). Dideoxy sequence analysis of 
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the affected sister of family 7_V:3, family 7_V:1, revealed homozygosity for the 
SLC5A7 c.335T>A variant.  
Each substitution cosegregates in each family consistent with an autosomal 
recessive mode of inheritance, and, whilst regional control samples remain to 
be investigated, neither variant is present in genomic databases: National 
Center for Biotechnology Information’s (NCBI) dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/), the National Heart, Lung and Blood 
Institue’s (NHLBI) Exome sequencing project (ESP6500) via the Exome Variant 
Server (EVS) (http://evs.gs.washington.edu/EVS/ , Aggregation Consortium 
(ExAC) server (http://exac.broadinstitute.org/), or 1000 genomes database 
(http://www.1000genomes.org/). 
 
Figure 37. Chromatograms showing DNA sequence around A) the homozygous 
SLC5A7 c.282T>A variant in an affected individual (family 6_IV:1), and  B) 
the homozygous SLC5A7 c.335T>A variant in affected individual (family 7_V:3), 
acquired by dideoxy-sequencing of genomic DNA. 
 
4.2.3 In silico analysis of SLC5A7 missense mutations 
As previously, the amino acid sequence for the mutant protein was obtained 
using ExPASy translate software. At the nucleotide level, the SLC5A7 c.282T>A 
variant is predicted to result in an amino acid substitution from serine at position 
94 to arginine (p.S94R) (figure 38) affecting a residue in the third 
transmembrane domain of CHT (figure 39). The SLC5A7 c.335T>A variant is 
predicted to result in an amino acid change from valine at position 112 to 
glutamic acid (p.V112E) (figure 38) affecting a residue located on the second 
intracellular loop between transmembrane domains 3 and 4 (figure 39). 
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Conservation analysis indicates that both substituted residues display high 
evolutionarily sequence conservation (figure 51, appendix).  
In silico mutation analyses on the predicted effect of both variants on the 
structure and function of CHT show high damage prediction but do not predict a 
change in structure. PROVEAN predicted both variants c.282T>A and 
c.335T>A to have a deleterious effect on the function of the protein products 
with scores of -4.90 and -5.606, respectively. PolyPhen and Mutation Taster 
also predicted damaging or disease causing effects on protein function for both 
variants (table 28).   TMHMM analysis predicted no effects of these variants on 
the transmembrane morphology of CHT (figure 52, appendix).  An amino acid 
substitution at position 112 from valine to alanine (V112A) is reported in ExAC, 
however at an extremely low frequency (8.25e-06) and there are no reports of 
homozygous cases.  
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Figure 38. Alignment of wild type and CHT p.S94R and p.V112E amino acid 
sequences showing single residue substitutions S94R and V112E, respectively 
(ClustalW2).  
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Figure 39. Diagram of the predicted secondary structure of the SLC5A7 gene 
protein product (CHT) showing 13 transmembrane domains with an extracellular 
N-terminus, and an intracellular C-terminus. As in the previous chapter, dark 
circles represent amino acids which are conserved across human CHT, mouse 
Cht1, and the C. elegans CHT ortholog, CHO-1. Dark circles containing the letter 
‘P’ indicate potential protein kinase C phosphorylation sites, and light circles 
containing the letter ‘P’ represent potential protein kinase A phosphorylation 
sites. The fork-like structures represent potential N-glycosylation sites. CHT 
p.S94R is indicated in red, and CHT p.V112E is indicated in purple. Modified 
(Apparsundaram, 2000; Apparsundaram, 2001 (140, 141)) 
 
Table 28: Online In silico mutation analysis software results for CHT 
p.S94R and p.V112E 
Variant  PolyPhen 
(HumDiv) 
PolyPhen 
(HumVar) 
Mutation Taster PROVEAN 
S94R 1.000 – probably 
damaging 
0.996 – 
probably 
damaging  
0.999999968819884 
– disease causing 
-4.90 – 
deleterious  
V112E 0.996 – probably 
damaging 
0.979 – 
probably 
damaging 
0.999999999840146 
– disease causing 
-5.606 – 
deleterious 
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4.2.4 Functional investigation of CHT p.V112E and CHT p.S94R 
To investigate the functional impact of the SLC5A7 c. 282T>A (p.S94R) and 
c.335T>A (V112E) variants on CHT, similarly as with the dHMN truncating 
mutations, heterologous expression of mutant (CHT p.S94R and CHT p.V112E) 
and wild type (CHT WT) proteins in HEK-293 cells transiently transfected with 
the respective cDNA constructs was performed (for cDNA transfection amounts 
see appendix) in collaboration with Prof Randy Blakely; USA, and Dr Sebahattin 
Cirak, Germany. In order to maintain experimental continuity, SLC5A7S94R and 
SLC5A7V112E constructs were produced in the same plasmid vector (pRK5) and 
with the HA-tag included at the N-termini, as used in previous expression and 
uptake studies undertaken with the HA-SLC5A7K499Nfs*13 and HA-
SLC5A7H521Qfs*2. Mutant cDNA constructs were produced using the 
QuickChange Lightning Site-Directed Mutagenesis kit (for SDM primer 
sequences see appendix). Two additional sets of CHT constructs containing 
these variants were produced in Dr Sebahattin Cirak’s laboratory. The SLC5A7 
cDNA was purchased from Origene in pCMV6-Entry vector, one with myc/DDK 
tag in the C-terminal and the other with C-terminal double myc- and FLAG-tags, 
and the missense mutations were introduced with the use of the Q5® Site-
Directed Mutagenesis Kit (NEB). Cell surface biotinylation experiments and 
western blot analysis were performed in order to investigate the expression and 
surface delivery of the two transporters, as in the previous chapter. [3H]-choline 
transport assays were also performed to compare the choline transport ability of 
the two mutant molecules to that of the wild type molecule when expressed 
individually to mimic their expression in affected homozygous mutant gene 
carriers. Due to the unavailability of fresh blood samples from affected 
individuals, it has not been possible to measure choline transport activity in 
whole blood monocytes natively expressing CHT p.S94R and CHTp.V112E as 
was done previously in dHMN-VII subjects. 
 
4.2.4.1 SLC5A7S94R and SLC5A7V112E reduce surface, but not overall, 
CHT expression 
Western blot analysis of the lysates of HEK-293 cells transfected with myc-CHT 
WT, myc-CHT p.S94R and myc-CHT p.V112E cDNAs shows that for equivalent 
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amounts of cDNA transfected, equal levels of products were produced, 
suggesting that these variants do not alter translation or protein stability (figure 
40A). This was confirmed by assessment of protein levels by ELISA (figure 
40B). Similar result were obtained on preliminary Western blot analysis of cell 
lysates of HEK-293T and HEK-293 cells transiently transfected with HA-
SLC5A7WT, HA-SLC5A7S94R, and HA-SLC5A7V112E cDNAs also shows equal 
levels of products were produced for equivalent amounts of cDNA transfected 
(figure 41). Furthermore, two additional bands are present between 120 and 
140 kDa, possibly representing CHT homodimers. Myc-CHT proteins were 
isolated from the cell surface of HEK-293 cells transfected with myc-CHT WT, 
myc-CHT p.S94R and myc-CHT p.V112E cDNAs by biotinylation followed by 
NeutrAvidin agarose pulldown and quantified by Western blotting, and surface 
levels were quantified by ELISA. This showed reduced surface expression of 
both mutant proteins in contrast to the wild type (figure 42). Quantification of the 
cellular localisation of myc-CHT WT, myc-CHT p.S94R and myc-CHT p.V112E 
was carried out by immunofluorescent staining of the proteins in HEK-293 cells 
(figure 43). Compared to cells expressing wild type CHT, in cells expressing the 
S94R and V112E mutant proteins, a large fraction of CHT immunoreactivity 
showed an abnormal expression (figure 43B) pattern with large CHT 
aggregates in the cell body (figure 43A). These data suggest that although the 
CHT p.S94R and CHT p.V112E do not influence overall CHT expression, the 
surface localisation of the mutant proteins is reduced, and the mutants exhibit 
an abnormal expression pattern. 
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Figure 40. Western blot analysis of A) total protein levels of myc-CHT WT, myc-
CHT p.S94R and myc-CHT p.V112E expressed in HEK-293 cells, after SDS-PAGE 
and immunoblotting with anti-myc. The α-Tubulin level was detected in stripped 
membrane as loading control.  B) The total SLC5A7 protein level was assessed 
by ELISA as described in (Bogatcheva, 2007). Protein level is shown in arbitrary 
units (AU) as a ratio of specific horseradish peroxidase (HRP) activity of mutant 
to wild type SLC5A7 after anti-myc antibody binding.  Results are presented as 
means ± SE (n = 3). (Kindly provided by Dr Cirak, Uniklinik Köln University 
Hospital, Germany). 
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Figure 41. Preliminary western blot analysis of total protein levels of HA-CHT WT, 
HA-CHT p.S94R and HA-CHT p.V112E after SDS-PAGE and immunoblotting with 
anti-HA antibody of lysates from transiently transfected (A) HEK-293T and (B) 
HEK-293 cells. Both provide supporting evidence of equal expression levels of 
wild type and mutant proteins. The band at ~46kDa in A likely represents the 
immature less glycosylated species of CHT described in chapter 3. The broad 
band at 50kDa in B possibly represents both the immature and mature species. 
In both A and B two faint bands are visible for all proteins between 120 and 
140kDa which may represent CHT homodimers. (Kindly provided by Prof Randy 
Blakely and Mrs Jane Wright). 
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Figure 42. A) Surface protein level of SLC5A7 WT and mutants, after cell surface 
biotinylation, total surface protein fractions are isolated using surface isolation 
kit (pierce), following detection of surface SLC5A7 by SDS-PAGE and anti-myc 
antibody. CD49e (α5 integrin) or CD29 (β1 integrin, data not shown) level was 
detected in stripped membrane as loading control. B) Quantification assessed by 
ELISA is displayed as ration of mutant to WT of the myc antibody signal 
normalized to control protein signal. Means ± SE (n = 3). (Kindly provided by Dr 
Cirak, Uniklinik Köln University Hospital, Germany). 
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Figure 43. A) Immunostaining of transfected HEK-293T cells using anti-myc 
antibody shows abnormal expression of myc-CHT p.S94R and myc-CHT p.V112E 
compared to myc-CHT WT. Examples of cells displaying normal expression are 
marked with a solid white arrow, while cells displaying abnormal expression are 
marked with a dashed arrow. Scale bar 10µm. B) Statistical countering of cells 
with abnormal SLC5A7 expression (orange) and cells with normal SLC5A7 
expression (blue). Means ± SE (n = 2). (Kindly provided by Dr Cirak, Uniklinik 
Köln University Hospital, Germany). 
 
4.2.4.2 SLC5A7S94R and SLC5A7V112E abolish choline transport activity in 
transfected cells 
To investigate the outcome of the missense sequence variants on CHT 
transporter activity, [3H]-choline transport assays were performed in order to 
compare the choline transport ability of the mutant and wild type molecules in 
transiently transfected HEK-293 cells. These studies are currently still 
underway, and the following data is preliminary. Importantly, preliminary choline 
uptake assays revealed complete abolishment of choline uptake activity in cells 
expressing mutant molecules (0%) compared to those expressing the wild type 
(figure 44) 
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Figure 44. Preliminary choline uptake assay in HEK-293 cells transiently 
transfected with wild type and CHT p.S94R and p.V112E cDNAs. Choline 
transport activity is significantly reduced when comparing WT-CHT with CHT 
p.S94R (p=0.019, n=3, students unpaired t-test) and CHT p.V112E (p=0.014, n=3, 
students unpaired t-test). Choline uptake activity of both mutant proteins is 0% 
of that of the wild type, completely abolished. Specific choline uptake was 
determined by subtracting the uptake obtained in transfected cells with that of 
mock (vector) transfected cells obtained in assays conducted in parallel. This 
data is preliminary. Experiments are still underway. 
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4.3 Discussion 
Investigation of the genetic cause of severe congenital, predominantly central 
hypotonia in two consanguineous families by whole-exome sequencing 
identified distinct N-terminal CHT homozygous autosomal recessively acting 
SLC5A7 mutations as the likely pathogenic mutations. A single base 
substitution (c.282T>A) was identified in a family of Turkish origin with one 
affected female infant and results in a single amino acid substitution at position 
94 from serine to arginine (p.S94R), affecting a residue in the third 
transmembrane domain of the choline transporter (CHT). In a Hispanic family 
with two affected infants, one male and one female who are both deceased, a 
single base substitution (c.335T>A) was identified resulting in an amino acid 
substitution from valine to glutamic acid at position 122 (p.V112E). This 
substitution affects a residue located in the second intracellular loop between 
the third and fourth transmembrane domains of CHT. Comparison of exome 
sequencing data and SNP array data confirmed that this variant resides within a 
region of homozygosity in the proband. Each variant cosegregates with the 
disease phenotype across each respective family, and whilst regional control 
samples remain to be investigated neither variant is present in genomic 
databases. In silico analysis of the variants predicted a profound impact of both 
on the function of CHT, but did not predict any changes in structure of the 
protein. Both variants affect residues in the transmembrane spanning region of 
CHT (figure 39). Expression studies indicated that neither variant has an effect 
on overall CHT expression, however abnormal cellular localisation and reduced 
surface expression were observed. Most importantly however, CHT transporter 
assays revealed complete abolition of transporter activity in transfected cells 
compared to wild type expressing cells.  
The mechanisms underlying the genotype-phenotype relationships between the 
truncating and missense mutations reported in this thesis and their respective 
disorders, is yet to be fully elucidated. Comparison of our current knowledge of 
phenotypic, genetic and proteomic features of the truncating SLC5A7 mutations 
described in chapter 3 and the missense mutations described here can be 
found in table 29. Our studies suggest the truncated p.K499Nfs*13 and 
p.H521Qfs*2 mutant proteins interfere with the wild type molecule exerting a 
dominant negative effect on transporter function due to its functioning as a 
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homodimer, requiring the inheritance of only one mutant allele for disease 
penetrance. Conversely, the lack of phenotype found in carriers of  p.S94R or 
p.V112E missense mutations indicates that these mutations do not exeter such 
a dominant-negative interference effect on the wild type molecule. However due 
to time constraints, measurement of choline uptake activity in cells co-
transfected with both wild type and p.S94R or p.V112E mutant cDNAs to 
investigate this further have not yet been undertaken. The severe phenotypes 
resulting from the missense CHT mutations in homozygous gene carriers, 
combined with the complete abolition of CHT transport activity and its reduced 
surface expression (figure 42) in SLC5A7 p.S94R or p.V112E transfected cells, 
points towards roles in trafficking, internalisation, or constitutive endocytic 
recycling of CHT of the affected residues. As CHT choline transport is critical for 
ACh synthesis and signalling at all cholinergic synapses, it is interesting that 
while the hypotonia cases exhibit global effects of cholinergic dysfunction, 
neuro-dysfunction and degeneration in the dHMN cases is restricted to a 
specific subpopulations of neurones. This selective neuronal vulnerability may 
be a result of differences in the required levels of ACh synthesis to replenish 
stores following transmission between different subsets of cholinergic neurones, 
or differences in CHT expression levels. 
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Table 29: Comparison of SLC5A7/CHT mutations investigated in this study, their structural and functional effects on the 
choline transporter, and their associated conditions 
 Truncating mutations Missense mutations 
p.K499Nfs*13 p.H521Qfs*2 p.S94R p.V112E 
Phenotype 
Associated disorder dHMN-VII dHMN-V Severe hypotonia Severe hypotonia  
Onset 11-31 years 25-57 Congenital Congenital 
Characteristic features -Progressive length-
dependent motor 
neuropathy 
-presents in upper limbs 
-VCP 
-Progressive length-
dependent motor 
neuropathy 
-presents in upper limbs 
 
-Severe predominantly 
central hypotonia  
-Postnatal respiratory 
insufficiency 
-DD 
-Brain atrophy 
-Severe predominantly 
central hypotonia  
-Postnatal respiratory 
insufficiency 
-Normal brain MRI 
-Infantile death 
Genetics 
MoI AD AD AR AR 
Mutation type Frameshift Frameshift Missense Missense 
Exon 9 (ultimate). 
Avoids NMD 
9 (ultimate). 
Avoids NMD 
2 3 
Protein 
Structural changes Truncation. 
 
Truncation. 
 
None predicted  
aa substitution in 
membrane spanning 
region 
None predicted  
aa substitution in 
membrane spanning 
region 
Affected domain  C-terminus eliminated C-terminus partially 
eliminated 
Membrane spanning 
domain. 
(3rd transmembrane 
domain) 
 
Membrane spanning 
domain. 
(2nd intracellular loop) 
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Effect on expression in 
transfected cells 
Reduced overall 
expression compared WT 
in singular transfections, 
and reduced overall and 
surface expression in co-
transfected cells 
Reduced (less so than 
p.K499Nfs*13) overall 
expression compared WT 
in singularly transfected 
cells, 
No change in overall 
expression. Reduced 
surface expression to 
~70% of WT 
No change in overall 
expression. Reduced 
surface expression to 
~40% of WT 
Functional 
consequence 
Reduced choline transport 
(by ~50% in singularly 
transfected cells, by ~75% 
in co-transfected cells and 
by ~90% in patient cells) 
by a dominant negative 
mode of action 
Reduced choline transport 
(by ~50% in singularly 
transfected cells) 
Abolishes choline transport  Abolishes choline transport 
Knowledge of affected 
amino acid residues  
Loss of residues/motifs 
with suggested roles in: 
- Uptake activity 
regulation 
- Endocytic targeting to 
synaptic vesicles 
- Constitutive endocytosis 
Loss of residues/motifs 
with suggested roles in: 
- Endocytic targeting to 
synaptic vesicles 
- Constitutive endocytosis 
Nothing known w/i C-terminal tyrosine-
based sorting motif (YxxΦ; 
Y111VTM114) required for 
protein sorting to 
organelles and specific 
membrane regions 
including the 
somatodendritic domain of 
neurones 
Abbreviations: MoI= mode of inheritance; DD= developmental delay; MRI= magnetic resonance imaging; AD= autosomal dominant; AR= autosomal recessive; NMD= nonsense mediated decay; 
WT= wild type; w/i= within 
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Much work has focused on the identification of CHT residues that are required 
for choline binding and uptake, its translocation from the cell body to the 
synaptic vesicles and the cell surface, its interaction with other proteins and 
molecules, and its internalisation from the cell surface and recycling(3, 116, 
147, 158-162). V112E is located within a carboxyl-terminal tyrosine-based 
sorting motif (Yxxφ; Y111VTM114)(147). Tyrosine-based signals fitting the Yxxφ 
motif are known to mediate sorting of transmembrane proteins to endosomes, 
lysosomes, the basolateral plasma membrane of polarised epithelial cells, and 
the somatodendritic domain of neurones(163). Similarly to our CHT-V112E 
expressing HEK-293 cells, Y111A and M114A mutants have supposedly been 
found to eliminate CHT choline uptake activity [Unpublished work of Yamada 
H., reported by Haga (2014)](147), indicating that the residues that form this 
motif are necessary for choline uptake, however their specific functional role is 
unknown. The abnormal cellular localisation, and aggregation of CHT p.V112E 
in the cell body could be explained by sorting of the mutant protein due to 
disruption of the Yxxφ motif. The S94R amino acid substitution does not reside 
in any known motifs, and the residue affected has not been subject to 
investigation in any studies other than those pertaining to this thesis. However, 
both variants affect residues in the transmembrane spanning domain of CHT, 
which has been found to harbour residues required for choline and HC-3 
binding only (E45)(147), choline uptake and binding (D48, D242, D349, D411), 
choline uptake but not for binding (D158, E451, R466), N-glycosylation and 
thus, translocation to the cell surface (N301)(116). 
CHT is concentrated in cholesterol-rich lipid rafts at nerve terminals, and 
decreasing membrane cholesterol reduces CHT choline uptake activity and cell 
surface expression, diminishing cholinergic transmission by restricting the 
choline available for ACh synthesis(161). The association of CHT with 
cholesterol-rich lipid rafts is, thus, critical to CHT function. The amino acid 
residues required for binding to cholesterol-rich lipid rafts are not yet known. It is 
possible that the reduced surface levels of CHT p.S94R and CHT p.V112E 
compared to the wild type protein in transiently transfected HEK-293 cells, 
despite equal total protein expression levels, may be due to disrupted 
association with cholesterol-rich lipid rafts. 
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Choline uptake is regulated primarily by increasing the number of transporters 
on the presynaptic membrane, rather than altering the activity of existing 
transporters to support a biosynthetic response to neuronal excitation(3, 164). 
Data from our functional investigation of CHT p.S94R and p.V112E mutant 
transporters suggest that although the mutant proteins do not influence overall 
CHT expression, the surface localisation of the mutant proteins is reduced and 
the mutants exhibit an abnormal expression pattern. These mutations may 
therefore impact choline transport regulation and subsequent ACh synthesis. An 
important role of adaptor proteins (e.g. adaptor protein-3, AP-3) for CHT 
trafficking has been demonstrated(165), thus it is possible that these missense 
mutations exert their effects on surface delivery of the transporter by disrupting 
interactions with other molecules.  
Ferguson et al. (2004) examined CHT‒/‒ and CHT+/‒ mice for evidence of 
impaired cholinergic transmission(5). The CHT‒/‒ mice were born in the 
Mendelian ratios that were expected but become immobile, have irregular 
breathing, appear cyanotic (blue colouration of skin/mucus membranes due to 
low oxygen), and did not live longer than an hour after birth; resembling the 
phenotype observed in our cases. This provides support to our conclusion that 
the severe phenotype in these families results from the abolition (or near 
abolition) of choline uptake by CHT. 
It is an unlikely possibility that an alternative disease causing variant exists in 
each of the affected families that was missed by whole-exome sequencing, 
however existence of two SLC5A7 mutations in families presenting with similar 
phenotypes, coupled with data indicating a profound functional impact of these 
mutations on CHT function, provides strong evidence that these mutations are 
in fact, causative of the phenotype presenting in these families. Thus, this study 
defines a new cause of severe congenital hypotonia.  
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5 dHMN-VII MOUSE MODEL 
 
5.1 Introduction 
5.1.1 Animal  models of human disease 
Animal models of neurodegenerative disease have existed for almost six 
decades, since resperine was used to deplete dopamine and cause a 
Parkinson-like phenotype in animals in 1957(166). However, until more recently 
human disease could only be mimicked in animals by creating lesions in 
specific brain regions, primarily with the use of toxins; or studies were carried 
out on mouse strains in which spontaneous mutations had occurred(166). In the 
last 2 decades, the use and importance of animal models in the elucidation of 
human disease mechanisms has both changed and increased drastically. The 
mouse has become an invaluable model system for the study of human 
genetics and disease, owing to its many genetic and physiological similarities, 
genetic malleability, and short generation time(167). Many mouse models of 
human genetic disorders have offered insight into anatomical, neurochemical, 
and behavioural effects of aberrant gene expression(168). Nevertheless, yeast, 
fly, worm, sheep, pig and primate neurodegenerative disease models have also 
been produced(166).  
Animal models allow for different disease processes to be explored throughout 
the entire disease course, from a preclinical stage to the most advanced stages 
of disease. They also allow for testing of phenotype modifying agents and 
experimental therapies as a prelude to clinical trials with human subjects(166). 
We are able to alter environmental conditions to establish the intersection of 
genetics and environment, and study how much phenotypic variability can be 
accounted for by the disease causing gene mutation, and how much is due to 
influence from modifying genes. Animal models have even created opportunity 
to track specific proteins in vivo, and, with contribution from advancing 
technology, have provided researchers with the capacity to extract and analyse 
individual neurones, and even determine directly how different disease proteins 
behave in specific cell types(166). This may help us finally understand selective 
neuronal vulnerability. 
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5.1.2 The importance of animal models of motor neurone disorders 
Whilst there are a number of inherited MNDs (5–10 % of all patients having a 
clear family history of MND), the cause of most remains unknown(169). In 
‘sporadic’ cases of MND where there is no evidence of family history of the 
disorder, underlying factors involved may include an unknown genetic 
alteration, environmental factors, viral infection, or exposure to toxic 
substances. No consistent environmental risk factor(s) of MND have as yet 
been identified, suggesting the possibility that such factors may only trigger 
disease in genetically susceptible individuals(169). Over 100 genes have now 
been implicated in the causation of MND, some of which result in a very precise 
and consistent clinical phenotype, and others which result in more than one 
form of MND, even within related individuals who share the same gene 
mutation(169). It is therefore likely that there is significant overlap of the 
biological basis of many different types of MND. Despite our growing knowledge 
of the genetic and molecular basis of this group of disorders, at present 
treatment is largely palliative. Having identified the genetic basis of a form of 
MND in a particular group of patients, further investigation of the pathological 
mechanism by which the gene mutation results in the disease phenotype is 
often essential for the better understanding of the disease progress, and for the 
possibility of the development of tailored or targeted treatment strategies. As we 
are unable to take a biopsy of the brain or spinal cord of living MND subjects in 
order to better understand disease processes, the creation of mouse models 
allows us a way in which to do so in a biologically comparable species. There 
have been many successful mouse models of human disease, including 
neurodegenerative disorders such as PD via mutation of the mouse 
homologues of human disease genes, Snca encoding α-synuclein and 
Lrrk2(170), and HD via mutation of the huntingtin homologue Htt(171), the 
generation of which has proven invaluable for the study of these diseases. In 
addition to providing insight into the eitiology and progression of human genetic 
disease, animal models have proven a useful tool in the identification of targets 
of therapeutic drugs(172). It is important however, when trialling 
pharmacotherapies in animal models, to remember that drugs that successfully 
treat a disease in an animal model do not always translate to human clinical 
trials. Animal models may not always recreate all aspects of a human disease, 
172 
 
in particular mouse models for neurodegenerative diseases as these often 
involve cognitive deficits that mice are unable to express(172). 
 
5.1.3 CHT-related disease treatment hypotheses 
As described in chapter 3.3, CHT is a hemicholinium-3 (HC-3) sensitive, Na+/Cl- 
dependent, high affinity choline transporter responsible for the uptake of choline 
at the NMJ. CHT mediated choline uptake represents the rate-limiting step in 
ACh synthesis at the NMJ and is thus, essential for normal cholinergic 
transmission (figure 53, appendix). Our discovery that dominant-negatively 
acting SLC5A7 frame-shift mutations underlie dHMN has enabled a better 
understanding of the disease mechanism whereby choline uptake activity is 
significantly reduced and thus, following synaptic activity there is likely 
insufficient ACh synthesis to support further depolarisation (figure 54, 
appendix). As there are currently no therapeutic agents in medical use that 
augment CHT-mediated choline uptake activity, we hypothesise that 
intervention at the post synaptic cleft with approved and available therapeutic 
agents might be successful in aiding cholinergic signalling at the neuromuscular 
junction of affected patients, thereby alleviating symptoms of dHMN-VII. On this 
basis, we identified two possible treatment options to trial in a dHMN-VII mouse 
model as a prelude to patient clinical trials: 
(i) Treatment with a nicotinic acetylcholine receptor (nAChR) agonist 
may raise the resting potential of the postsynaptic muscle cells 
membrane potential, allowing the reduced amount of nAChR binding 
by ACh released from the presynaptic nerve terminal to increase the 
membrane potential to the action potential threshold (see 5.1.3.1). 
(ii) Treatment with an acetylcholine esterase inhibitor (AChE) inhibitor 
(e.g. edrophonium, neostigmine or pyridostigmine) may prolong the 
presence of ACh in the synaptic cleft by inhibiting breakdown by 
AChE and therefore promote binding to nAChRs to allow the 
postsynaptic membrane action potential threshold to be accomplished 
(see 51.3.2). 
In addition to the above treatments, the possibility of treatment with choline was 
also discussed in order to address the issue of reduced intracellular choline in 
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the presynaptic nerve cell. However, because increasing the intracellular 
choline concentration has been found to have an inhibitory effect on CHT-
dependent ion flux(3) and increasing extracellular choline rapidly decreases 
cell-surface CHT expression(173), it is possible that administration of choline 
may further exacerbate clinical symptoms. Should targeted inhibition of clathrin-
mediated and dynamin-dependent CHT endocytosis be achievable in the future, 
treatment with such an agent of dHMN subjects in which CHT is still partially 
active, might retain the higher level of CHT at the presynaptic plasma 
membrane following an increase in extracellular choline concentration. Thus, 
choline uptake activity might be sustained sufficiently to replenish ACh stores. 
Extensive studies have been carried out on endocytosis, including the 
investigation of key molecules and mechanisms that modulate dynamin 
dependent GTPase activity and clathrin- and dynamin-dependent vesicle 
formation(174, 175). A number of chemical, pharmacological and genetic 
inhibitors of endocytosis have been identified which target both clathrin 
(hypertonic sucrose, phenothiazines, pitstop, clathrin Hub mutant) and dynamin 
(dynasore, dynamin K44A mutant)(176). Unfortunately, most have also been 
reported to exert effects elsewhere in the cell including interference of 
macropintocytosis, phagocytosis, actin cytoskeleton and clathrin- and dynamin- 
independent endocytic pathways, as well as cell toxicity and changes in gene 
expression(176). 
 
5.1.3.1 Treatment with a nAChR agonist 
In 2013, Rilstone et al. reported an autosomal recessive disease presenting as 
infantile-onset movement disorder (parkinsonism and non-ambulation), sleep 
and mood disturbance, autonomic instability, and developmental delay as being 
caused by a SLC18A2 c. 1160C→T mutation resulting in a proline to leucine 
amino acid substitution at position 387 of the vesicular monoamine transporter 2 
(VMAT2)(177). VMAT2 is similar to CHT in that it is a membrane spanning 
transporter present on neurotransmitter containing synaptic vesicles. It 
translocates biogenic amines (dopamine, serotonin, adrenaline and 
noradrenaline) into synaptic vesicles and is essential for motor control, stable 
mood, and autonomic function(177). Similarly to the CHT p.K499Nfs*13 and 
p.H521Qfs*2 mutations responsible for dHMN, the authors reported the VMAT2 
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p.P387L mutation results in dramatically decreased, but not totally abolished, 
transport activity compared to the wild type molecule in transiently transfected 
COS-7 cells(177). The authors thus concluded that defective monoamine 
loading into synaptic vesicles, and therefore defective neurotransmission 
underlie the phenotype described. Affected family members had previously 
been treated with levodopa–carbidopa, which has dopamine receptor 
antagonistic properties, on the basis of Parkinsonism and diminished urinary 
dopamine. However this resulted in major deterioration and was discontinued. 
The authors gave one affected family member pramipexole, a direct dopamine 
receptor agonist, which resulted in in dramatic and sustained disappearance of 
Parkinsonism and dystonic attacks, and improvement in other symptoms(177). 
Other affected family members were also treated and showed continuing 
improvement with more substantial recovery observed in younger subjects, and 
minimal side effects(177). The similarity in pathogenic mechanism between 
dHMN-VII and the disorder investigated by Rilstone and colleagues, prompted 
us to hypothesis that treatment with a nAChR agonist may elicit a similar 
improvement in disease state of dHMN-VII animal models and human subjects 
(figure 55, appendix).  
Two types of Ach receptor exist within the mammalian nervous system: i) 
muscarinic ACh receptors (mAChRs), G-protein coupled receptor complexes 
which display higher sensitivity to the agonistic molecule muscarine than to 
nicotine and exhibit a slow and prolonged response to stimulation. These occur 
primarily in the CNS but are also present peripherally on postganglionic 
membranes of the sympathetic and parasympathetic nervous systems, and ii) 
nAChRs which are ligand-gated ion channels that mediate fast signal 
transmission at synapses. These are composed of multiple subunits that 
combine to form many different receptor subtypes that can be of either 
neuronal, or muscle type. Different nAChR subtypes are involved in a wide 
range of physiological processes including cognitive function, learning and 
memory, arousal, reward, motor control, and analgesia. Muscle type nAChRs 
are localised to the postsynaptic muscle cell membrane at the NMJ and are 
composed of  subunits. Ideally, for nAChR agonist treatment of 
dHMN-VII, an agonist that is specific to adult muscle nAChRs would be 
administered in order to reduced action at other cholinergic sites causing 
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adverse side-effects. Unfortunately however, there are currently no NMJ 
specific nAChR agonistic therapeutic agents available. For this reason we 
propose currently available, more globally acting yet safety approved 
pharmacological agents for which a therapeutic and safety window has already 
been established, such as the smoking cessation drug Varenicline (Champix®) 
or nicotine products used for smoking cessation. 
 
5.1.3.2 Treatment with an AChE inhibitor  
AChE inhibitors are drugs that inhibit the hydrolysis of ACh by AchE, whose 
action can be reversible, irreversible, or partially irreversible. Medicinally AChE 
inhibitors are used to treat myasthenia gravis and myasthenic syndromes(178), 
cognitive impairments associated with schizophrenia(179), ADi(180), PD(181), 
and dementia with Lewy bodies(182), as well as glaucoma(183), and to 
enhance rapid eye movement (REM) sleep in autistic children(184). We 
propose that treatment of dHMN-VII animal models and human subjects with 
reversible AChE inhibitors whose main site of action is the NMJ (edrophonium, 
neostigmine or pyridostigmine)(185) might maintain ACh levels in the post 
synaptic cleft following depolarisation and ACh release such that sufficient 
amounts remain to elicit a response despite depleted ACh pools on subsequent 
depolarisations (figure 56, appendix). The mentioned anticholinesterase drugs 
exhibit short to medium durations of action (10 minutes, 1-2 hours, and 2-3 
hours respectively) and thus, all should be trialled in order to distinguish which 
is more effective in treating dHMN(185). 
 
5.2 Generation of dHMN-VII mouse line, and results of preliminary 
phenotyping 
Mouse studies were designed by Dr Darren Logan and Dr Sebastian Gerety 
based at the Wellcome Trust Sanger Institute in house after discussion of the 
human phenotype with both myself and Professor Crosby. The analysis was 
performed by Ms Eve Coomber, while I observed much of this work.  
A patient-specific knock-in mouse model carrying the SLC5A7 c.1497delG 
mutation identified in dHMN-VII family 1 (chapter 3) was generated using 
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CRISPR/Cas9-mediated gene editing. For methodology for the generation of 
the dHMN-VII mouse line, see appendix 7.5.2. Confirmation of expression of the 
patient-specific Slc5a7indelAC allele was obtained by sequencing of mRNA 
extracted from spinal cord biopsy of animals found to carry the genetic 
alteration heterozygously that were sacrificed under the schedule 1 procedure 
of the Home Office Animals (Scientific Procedures) Act 1986.  For methodology 
and results for the assay for the knock-in allele expression, see appendix 7.5.3. 
 
5.2.1 Open field and grip strength testing 
Animals aged 18-22 weeks were subjected to 20 minutes open field testing to 
assess differences in distance covered (figure 58, appendix), average velocity, 
or time spent moving between either Slc5a7indelAC/+ or Slc5a7+/TM1A and their 
littermates. There were no measurable differences observed for any of the open 
field measurements. For methodology and results data for open field testing, 
see appendix 7.5.4. Grip strength measurements were taken from wild type 
control and mutant mice at 18-22, 23-26 and 27-31 weeks of age in order to 
assess difference in muscle strength between Slc5a7indelAC/+ or Slc5a7+/TM1A and 
their respective wild type littermates. For data from grip strength testing 
methodology, see appendix 7.5.5. 
 
5.2.2 Grip strength results for Slc5a7indelAC/+ mice 
In general, a trend can be observed whereby animals heterozygous for the 
patient-specific mutation (Slc5a7indelAC/+) have reduced mean forepaw and all-
paw grip strength compared to wild type littermates (Slc5a7+/+) at almost all time 
points in both sexes (figure 59, appendix 7.5.5.1). This reduction is only 
statistically significant however in two specific comparisons: female 
Slc5a7indelAC/+ mice had significantly less all-paw grip strength than Slc5a7+/+ 
mice (Mean difference=44.75; p=0.0334) at time point 1 (18-22 weeks), and 
male Slc5a7indelAC/+ mice had significantly less all-paw grip strength than 
slc5a7+/+ matched controls (Mean difference=41.12; p=0.0411) at time point 2 
(23-26 weeks). At other times points, the differences in grip strength visible on 
the graphs when comparing Slc5a7indelAC/+ and Slc5a7+/+mice are not 
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statistically significant (tables 42 and 43, appendix 7.5.5.1). Female 
Slc5a7indelAC/+ mice demonstrated a statistically significant increase in all-paw 
grip strength between time points 1 and 3 (mean difference=35.97; p=0.0418; 
figure 59A and table 42, appendix 7.5.5.1). This may explain why the difference 
seen between Slc5a7indelAC/+ and slc5a7+/+ females at time point 1 is not seen at 
time point 3.  
Mean forepaw grip strength decreases significantly between time points 1 and 3 
across both sexes and both phenotypes (female Slc5a7indelAC/+ mean 
difference=22.45; p=0.0459, female Slc5a7+/+ mean difference=20.63; 
p=0.0495, male Slc5a7indelAC/+ mean difference=32.05; p<0.0001, male slc5a7+/+ 
mean difference=20.03; p=0.0261; tables 42 and 43, appendix 7.5.5.1), 
suggesting that although there is no clear difference between Slc5a7indelAC/+ and 
slc5a7+/+ mice in forepaw grip strength, all animals between 18 and 31 weeks 
appear to lose forepaw strength. 
 
5.2.3 Grip strength results for Slc5a7+/TM1A mice 
No difference can be observed between Slc5a7+/TM1A and Slc5a7+/+ mice of 
either gender at any time point. No significant difference was observed between 
heterozygous null (Slc5a7) mice and their wild type littermates (Slc5a7+/+) in 
forepaw or all-paw grip strength at any time point in either of the sexes. As in 
the Slc5a7indelAC/+ animals, A significant decrease in forepaw grip strength in 
male Slc5a7+/TM1A mice can be seen between time points 1 and 3 (mean 
difference=33.48; p=0.0008, figure 60A and table 45, appendix 7.5.5.2). In 
addition to this, there is a significant decrease in male Slc5a7+/TM1A forepaw grip 
strength between time points 2 and 3 (mean diff=31.38; p=0.0019, figure 60A 
and table 45, appendix 7.5.5.2). This was not seen in slc5a7+/+ male or either 
genotype of female mice. The only significant difference observed in the female 
animals was an increased in all-paw grip strength of Slc5a7+/+ females between 
time points 1 and 3 (mean difference=54.86; p=0.0012, figure 60D and table 44, 
appendix 7.5.5.2) but this was not seen in the slc5a7+/TM1A littermates. There is 
no difference at any time point between Slc5a7+/TM1A and Slc5a7+/+ mice of 
either gender. 
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5.3 Discussion 
While in-depth neurological phenotyping remains to be undertaken, preliminary 
phenotyping data indicates that  Slc5a7indelAC/+ display only a very mild motor 
phenotype involving reduced mean forepaw and all-paw grip strength at all time 
points. Due to the lack of detailed phenotypical data, it is not possible to draw 
direct comparisons between Slc5a7indelAC/+ mice and human subjects with 
dHMN-VII. The apparently milder phenotype presenting in mice compared to 
human dHMN-VII subjects expressing the same mutated protein may be due to 
a number of reasons, elucidation of which requires far more rigorous 
neurophenotyping as well as molecular investigation in biopsied tissues.  
Different neuronal cells within the same organism display variable vulnerability 
to factors contributing to neurodegeneration. It is thus possible that human 
neuronal cells affected by defective CHT also differ in their vulnerability when 
compared to those neuronal cells in Slc5a7indelAC/+ mice, that would be 
considered to be representative with respect to their anatomical location and the 
tissues which they innervate. Another possibility is that the CHT choline 
transport activity of Slc5a7indelAC/+ mice is not reduced comparably to that of our 
dHMN subjects such that cholinergic signalling is better supported. Anatomical 
distribution of cholinergic neurones and thus, CHT, has been found to be 
consistent between humans and mice(141). It is therefore unlikely that the 
difference in severity of phenotype is due to differences in CHT distribution. It 
has been reported that >20% of human essential genes have nonessential 
mouse orthologues(186). Although CHT has been shown to be essential for 
mouse survival(187) it is likely that mice express different proteins involved in 
the trafficking and regulation of CHT to humans, and that deletion of the 
transporters C-terminus is not as detrimental to these essential interactions. It 
has been reported that the phenotype of a given single gene mutation in mouse 
models is often modulated by the genetic background of the strain to which the 
mutation is introduced(188). This phenotypic variability has been attributed to 
the presence of different “modifier-genes” in the genomes of different inbred 
laboratory mouse strains, which act in combination with modified gene(188). If 
such differences arise between different strains of the same species, it is not 
surprising that a number of influencing factors and thus the phenotype may 
differ between human and mice harbouring orthologous mutations. It is also 
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possible that cholinergic signalling at the mouse NMJ does not require the same 
rate of choline reuptake activity to replenish ACh stores following transmission. 
Although wild type and Slc5a7indelAC mRNA were found to be expressed at 
equivalent levels in Slc5a7indelAC/+ animals, without specific measurement of the 
CHT protein levels in neuronal tissue from these animals the possibility that the 
milder phenotypic presentation in mice may also be due to reduced expression 
of the mutant protein during translation also exists. 
The weaker grip strength observed in Slc5a7indelAC/+ mice than in Slc5a7+/+ mice 
at time point 1 indicate that 18 weeks is likely too late for commencement of 
phenotyping. The onset of loss of grip strength in Slc5a7indelAC/+ mice may occur 
earlier than 18 weeks of age, while age related loss of all-paw grip strength in 
Slc5a7+/+ mice reaches a similar level to that of the Slc5a7indelAC/+ animals at 
around time point 2. Despite this, considering the progressive nature of dHMN-
VII, one may have expected significant findings at all tested time points with a 
progressively worse presentation of Slc5a7indelAC/+ mice compared to age and 
sex matched wild type littermates. However, the presence of neurological 
outcome clearly indicates that mild neurological features are present in this 
model that should be explored in more detailed phenotypical assays.  
Overall, the motor-phenotyping results demonstrate that mice of all genotypes 
(Slc5a7indelAC/+, Slc5a7+/TM1A, and Slc5a7+/+) within our cohort display a degree 
of loss of forepaw grip strength between the ages of 18 and 31 weeks. As 
mentioned above, it is possible that a greater difference exists between younger 
animals than those tested, which might better represent the teenage onset of 
dHMN-VII in human patients. Repetition of the tests carried out in this study on 
the same models post-exercise may also reveal a phenotypic difference 
between genotypes, however licencing restrictions do not permit for these 
further tests to be undertaken. 
 
5.3.1 Future work- creation of a hypomorphoc compound heterozygous 
Slc5a7indelAC/TM1A 
Discussions are currently ongoing with partners at the University of Exeter 
Medical School animal unit and Prof Blakely’s group at Vanderbilt University to 
undertake more detailed phenotypical assessments of Slc5a7indelAC/+ mice. An 
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additional avenue of animal model development to recapitulate the patient 
dHMN(-VII) phenotype, is to create animals with hypomorphic choline transport 
by a combination of existing mutant alleles. Given the putative disease 
mechanism, this may provide an additional suitable substrate for testing the 
pharmacotherapies described in section 5.1.3. This work has commenced, 
however is still in early stages. Intercrossing of Slc5a7indelAC/+ and Slc5a7+/TM1A 
mice resulted in the birth of compound heterozygous animals (Slc5a7indelAC/TM1A) 
at expected ratios, confirmed by genotyping in 3-week old pups. From the initial 
litter 4 Slc5a7+/TM1A pups were born, which displayed a strong phenotype ~10 
weeks of age. This included a reduction in body weight of 30% compared to 
their wild type littermates (table 30), as well as reduced activity in their home 
cage, ataxia, abnormal gait, tremors, reduced rearing, poor posture, and rapid, 
heavy breathing. These animals were culled prior to any motor-phenotyping for 
humane reasons. Additional Slc5a7indelAC/TM1A animals are currently under 
observation as they approach 10 weeks.  These preliminary results are an 
encouraging indication that the Slc5a7indelAC/TM1A mice might indeed be showing 
phenotypes representative of that seen in dHMN-VII patients. Follow-up studies 
are required in order to confirm these findings. 
Table 30. Genotyping and initial phenotyping of litter born from 
intercrossing Slc5a7indelAC/+ and Slc5a7+/TM1A mice  
MOUSE ID SEX GENOTYPE WEIGHT PHENOTYPE 
SGAQ17.1a male slc5a7
indelAC/TM1A 19.3g YES 
SGAQ17.1b male slc5a7
indelAC/+ 28.7g NO 
SGAQ17.1c male slc5a7
indelAC/TM1A 19.6g YES 
SGAQ17.1d male slc5a7
+/+ 27.9g NO 
SGAQ 17.1e female slc5a7
indelAC/TM1A 16.2g YES 
SGAQ 17.1f female slc5a7 
+/TM1A 22.6g NO 
SGAQ 17.1g female slc5a7
 +/TM1A 23.6g NO 
Should open field and grip strength phenotyping of Slc5a7indelAC/TM1A support a 
disease state comparable to dHMN, we plan to carry out further phenotyping, 
molecular investigation of the disease mechanism, and exploration of 
phenotype improvement with potential treatments. Further phenotyping 
analyses are likely to include treadmill testing to assess stamina and the 
maximum velocity at which mutant mice are able to move, rotarod testing to 
assess balance, motor coordination and endurance, and in vivo compound 
action potential recordings to assess nerve function. Careful observation for 
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signs of onset of the disease in Slc5a7indelAC/TM1A pups will be made from birth, 
important information when considering at what point in the animals life to 
administer trial treatments. Biochemical analyses will provide additional 
important insight into disease pathogenesis and will include western blotting for 
CHT in protein extracts of mouse neuronal tissue to analyse expression levels, 
measurement of ACh and CHT levels, assessment of CHT trafficking in nerve 
terminal preparations, and measurement of CHT activity. As discussed in 
section 5.1.3, we hypothesise that treatment with either a nAChR agonist or and 
AChE inhibitor might prevent and or alleviate symptoms caused by cholinergic 
dysfunction in this animal model of dHMN. We plan to trial these treatments in 
Slc5a7indelAC/TM1A animal in order to establish which, if either, is the more 
successful in treating symptoms with minimal side effects. This will also 
establish the most beneficial time to commence treatment (prenatally, from 
birth, shortly before disease onset, or at onset), and whether administration at a 
progressed disease stage alleviates symptoms or if the benefits are limited to 
early administration. Should trials be successful in animals, this will provide the 
scientific basis and impetus to potentially carry out a clinical trial for the 
appropriate treatment with our dHMN subjects. 
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6 FINAL DISCUSSION AND FUTURE WORK 
The work in this thesis describes two distinct classes of novel SLC5A7 
mutations resulting in divergent clinical outcomes;  an autosomal dominant 
adult-onset form of distal hereditary motor neuropathy, as well as autosomal 
recessive severe congenital predominantly central hypotonia with respiratory 
insufficiency, seizures and usually, infantile death. Genetic mapping, traditional 
and next generation sequencing techniques were applied in order to identify the 
location of the disease causing gene, and the respective mutations for these 
disorders. Following genetic verification, the causative mutations were 
subjected to in silico and molecular functional analyses to elucidate the 
structural and biomolecular effects of each mutation on the protein product. 
These findings were of significant enough scientific and medical impact to 
warrant the generation of a range of  mouse models by our colleagues at WTSI, 
with a view to confirm pathogenicity of the truncated CHT protein, and trial 
putative treatment options as a prelude to clinical trials with human subjects. 
This section provides an overview of the findings of this thesis and relates these 
to the current literature, highlighting areas of future research. 
 
The identification of the biomolecular basis of neurological disease provides 
information crucial for the specification of putative treatment options to alter the 
disease course. Approximately 5% of the world’s population are estimated to be 
living with a ‘rare’ disease, with over 7000 having been reported, of which over 
1150 are neurological(189). Thus, these disorders collectively pose a 
substantial clinical and financial burden. Importantly, due to the overlap of many 
of the biological pathogenic pathways implicated in many neurological diseases, 
discoveries of the biological basis of a particular (rare) disease will likely provide 
far more wide-ranging benefits for other conditions with a similar biological 
cause. Thus, treatment benefits of knowledge of one of these disorders is likely 
to extend far more widely, and provide a platform from which broader research 
might be directed.  
The findings presented in this thesis has provided important new insights into 
NMJ dysfunction, and defined two novel human disorders that arise due to 
varying degrees of defective choline transport. ACh has well-defined 
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widespread actions as a neurotransmitter within the mammalian central, 
peripheral, and autonomic nervous systems. It is responsible for the normal 
functioning of a wide range of physiological and behavioural functions, including 
movement, cardiovascular activity, gut motility, arousal, attention, and memory. 
Within the CNS, ACh functions as a modulator of cognitive and appetitive 
processes including arousal, attention, memory and reward(32, 144). 
Cholinergic neurones of the CNS include motor neurones of the spinal cord, 
neurones within the basal forebrain, and interneurones in the caudate 
nucleus(147). Within the autonomic nervous system (ANS), ACh controls the 
output of many organs, including the heart, lungs, exocrine and endocrine 
glands, gut, and bladder, by mediating chemical signalling by both sympathetic 
and parasympathetic preganglionic neurones, and acting as a neurotransmitter 
at parasympathetic postganglionic synapses(32). ACh is also the principal 
neurotransmitter at the mammalian neuromuscular junction (NMJ) where it is 
critical for the control of muscular contraction. Our findings indicate that severe 
deductions (approaching 90%) of CHT activity may be tolerated and result in no 
(or only very late onset) neurological disease, which seems at odds with the key 
biological role of this molecule. Indeed our findings in dHMN, in which clinical 
signs appear to be restricted to motor neurones (specifically those innervating 
the distal limb muscles), indicate that it is the NMJ role of ACh that is impacted 
initially as CHT transporter activity is reduced. It is only with yet more severe 
reductions in CHT activity that the core CNS functions of ACh appear to be 
affected, resulting in a more severe central hypotonia phenotype. In addition, it 
will be interesting to investigate further whether the specific truncating mutation 
(p.H521Qfs*2) associated with dHMN-V lacking vocal cord involvement (family 
5) permits slightly more CHT activity than the truncating mutation 
(p.K499Nfs*13) resulting in dHMN-VII associated with VCP. A slightly less 
severe impact on transporter function of p.H521Qfs*2 may account associated 
with the dHMN-V phenotype, and provide further insight into the pattern of 
selective neuronal loss and clinical outcome in these conditions. 
As cholinergic neurotransmission supports a wide range of physiological and 
behavioural functions, it is not surprising that genetic variation and/or deficits in 
components of cholinergic signalling have been associated with a range of 
disorders, including  myasthenias, cardiovascular disease, attention-deficit 
186 
 
hyperactivity disorder (ADHD), ADi, schizophrenia, addiction, and depression(1-
3). It has been well established that basal forebrain cholinergic neurones are 
involved in learning and memory processes, and that impairment of cholinergic 
transmission contributes to the cognitive deficit in ADi(32, 190). Thus, 
enhancement of cholinergic transmission with the use of acetylcholinesterase 
AChE inhibitors is used, although with limited success, as a therapy for 
managing Alzheimer’s related cognitive decline(1, 3). Although useful in some 
instances, medications used in the treatment of these disorders are often 
insufficiently specific resulting in global side-effects, they may also exhibit dose-
limiting side effects, and usually act independently of neuronal activity(3). AChE 
inhibitors have not previously been trialled for the treatment of motor neurone 
degenerative disease, however they have been considered, and rejected, as a 
tool for the diagnosis of progressive muscular atrophy and amyotrophic lateral 
sclerosis(191). Our findings may provide an explanation for this and indicate 
that these treatments may only be of relevance in forms of MND in which ACh / 
CHT malfunction is the biological basis of the disease.  
The elimination of CHT in transgenic mice produces time-dependent eradication 
of cholinergic signalling presenting as immobility, failure to feed and cyanosis 
that is incompatible with life(187, 192). Consistent with this, our data indicates 
that elimination of CHT activity in human subjects results in a similar outcome. 
However, as we have not yet been unable to explore choline uptake activity in 
cells natively expressing CHT mutants, we are unable to conclude whether the 
longer lifespan of the Turkish hypotonic children (family 6) may result  from a 
slightly increased CHT transport activity of p.S94R mutant protein compared 
with p.V112E.  Furthermore, although CHT+/- mutant animals exhibit features 
consistent with reduced CNS and autonomic levels of ACh(193), the deficits of 
both the dHMN-VII and dHMN-V subjects investigated in this project are more 
severe than in hemizygous Slc5a7 mice. This is supportive of our finding of a 
dominant negative mode of action of truncated CHT on the wild type molecule, 
and this aspect may be further illuminated by assessment of NMJ morphology 
in the affected endplates of individuals with dHMN-VII and dHMN-V and studies 
in Slc5a7indelAC/+ and Slc5a7indelAC//TM1A transgenic mouse models.  
In addition to CHT, two additional families of choline transporter exist: the 
intermediate-affinity choline transporter-like (CTL) family, and the organic action 
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transporters (OCTs). The three families of choline transporters, although similar 
in that they comprise a single homogeneous glycoprotein with multiple 
transmembrane domains, differ in their specific structure, affinity for choline, 
and the fate of the choline translocated(147). Where CHT is dedicated to 
providing choline for ACh synthesis in cholinergic nerve terminals, more widely 
expressed choline transporters support other aspects of choline metabolism. 
The ubiquitously expressed intermediate-affinity choline transporter-like (CTL1) 
transports choline for the production of membrane lipid phosphatidylcholine, the 
body’s most abundant choline metabolite, constituting ~50% of the total cell 
membrane lipid content(190). This is thus unlikely to act as a compensator for 
defective CHT choline transport. OCTs 1-3 operate as polyspecific uniporters 
which mediate facilitated diffusion of organic cations, weak bases and some 
neutral compounds in both directions across the plasma membrane, including 
choline(194). OCT2, although predominantly expressed in basolateral 
membrane of the proximal tubules of the kidney, has also been reported to be 
localised on the synaptic vesicles of presynaptic cholinergic neurone terminals 
surrounding motor neurones at the spinal cord and NMJ. This suggests a 
possible role for this transporter in cholinergic neurones as well as a possible 
collaboration between OCT2 and CHT(195). There is no evidence however, 
suggesting a compensatory role of OCT2 in the absence or reduction of CHT 
activity.  
Although efficacious treatments exist for acquired neuropathies such as chronic 
inflammatory demyelinating polyneuropathy (steroids, IVIg, or plasmapheresis) 
and multifocal motor neuropathy (IVIg)(196), to date no cure has been 
developed for hereditary motor neuropathies. Intervention for these hereditary 
disorders including CMT and HNPP is restricted to the management of 
symptoms, such as physical and occupational therapy, and orthotic 
devices(196). Having gained mechanistic insight into the course of dHMN, we 
have been able to hypothesise putative treatment interventions (chapter 5.1.3) 
which may augment cholinergic signalling in affected subjects and we plan to 
trial these putative treatments in transgenic mice as a prelude to clinical trials. If 
successful, this will be the first MND for which knowledge of the genetic and 
molecular basis of the disease has led to the identification of pharmacological 
intervention. Further, a number of molecules and molecular complexes are 
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involved in the ACh cycle at cholinergic terminals with roles ranging from the 
regulation of ACh vesicle formation and membrane fusion, to ACh synthesis 
and hydrolysis, and the transport and maintenance of its various components. 
In this regard, genetic variation and/or deficits in components of cholinergic 
signalling have been associated with a range of disorders including 
myasthenias, cardiovascular disease, attention-deficit hyperactivity disorder 
(ADHD), ADi, schizophrenia, addiction, and depression(1-3). Myasthenia Gravis 
and the congenital myasthenic syndromes can arise from mutations in one of 
multiple genes encoding proteins expressed at the NMJ. These include AChR 
subunits (CHRNE, CHRNA1, CHRNB1, CHRND), AChE subunits (COLQ), ion 
channels subunits (SCN4A), as well as genes encoding proteins with roles in 
ACh synthesis (CHAT), AChR clustering (MUSK) and stabilisation (RAPSN), 
and NMJ development (AGRN)(148, 149, 197). Interestingly, CHAT mutations 
have been associated with hypotonia and respiratory failure at birth, similar to 
the cases seen in families 6 and 7. Myasthenias are most commonly treated 
with AChE inhibitors (pyrosigmine) which are largely beneficial(198, 199).  
There are however certain subtypes such as the DOK7-related myasthenias 
that show no improvement or even deteriorate with AChE inhibitors(198). CHT 
polymorphisms have been associated with ADHD(2) and it has been well 
established that basal forebrain cholinergic neurones are involved in learning 
and memory processes, and that impairment of cholinergic transmission 
contributes to the cognitive deficit in ADi(32, 190). Although useful in some 
instances, medications used in the treatment of these disorders are often 
insufficiently specific resulting in global side-effects, and they may also exhibit 
dose-limiting side effects and usually act independently of neuronal activity(3). 
Thus should intervention of the ACh cycle at cholinergic terminals prove to be 
successful in the treatment of dHMN subjects, this will likely provide a platform 
from which investigation may be taken into developing treatment interventions 
targeted to different aspects of cholinergic signalling which form the basis of 
these other ACh-associated disorders. 
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7.1 APPENDIX CHAPTER 1 
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7.1.1 Table 31. Demyelinating CMT subtypes, their distinguishing features, and their associated genes and their 
functions 
Demyelinating 
CMT subtype 
Mode of inheritance & 
Distinguishing 
characteristics 
Average 
mNCVs 
(m/s) 
Gene name (symbol) 
chromosomal location 
Protein function 
CMT-IA AD.70-80% of CMT-I cases. Less 
severe than CMT-IB. Onset in 1
st
-
2
nd
decade. 
Accounts for ~50% all CMT patients. 
15-20 Peripheral myelin protein-22 
(PMP22) 17p12 
Comprises 2-5% of peripheral myelin. 
Expressed predominantly in Schwann 
cells and plays a role in Schwann cell 
development. 
CMT-IB AD. More severe than CMT-IA. Onset 
from birth to second decade. 
<20 Myelin protein zero 
(MPZ or P0) 1q23 
Comprises 50% of peripheral myelin. 
Expressed in Schwann cells and is the 
major myelin structural protein. 
CMT-IC AD. Distinguishable from other types 
of CMT-I by genetic evidence only. 
16-25 Lippolysaccharide-induced 
tumour necrosis factor alpha 
factor (LITAF) 16p13.13 
Associated with p53, known to regulate 
apoptosis pathways. Expressed in 
Schwann cells and 3 other cell types. 
May play a role in protein degradation 
pathway. 
CMT-ID AD. Distinguishable from other types 
of CMT-I by genetic evidence only. 
26-42 Early growth response 2 
(EGR2) 10q21.3 
Induces essential myelin genes in 
Schwann cells. 
CMT-IE AD. CMT associated with deafness 29-43 Peripheral myelin protein-22 
(PMP22) 17p12 
See CMT-IA above 
CMT-IF AD. Increased severity compared with 
other CMT-I subtypes. Onset from 1-
13 years. 
9-20 Neurofilament protein, light 
polypeptide (NEFL) 8p21.2 
Interacts with MTMR2 which is 
expressed in both myelin-forming and 
non-myelin forming Schwann cells, and 
both sensory and motor neurones. 
HNPP AD. Onset usually in second or third 
decade. Tomacular (sausage shaped) 
swellings cause repeated focal 
pressure neuropathies, eg. Peroneal 
palsy with foot drop. 
 Peripheral myelin protein-22 
(PMP22) 17p12 
Comprided 2-5% of peripheral myelin. 
Expressed predominantly in Schwann 
cells and plays a role in Schwann cell 
development. 
CMT-IX X-linked dominant. Affects 
heterozygous females more mildly 
than homozygous males. Stroke like 
presentation has been reported. 
 
 
Males: 30-50 
Females: 31-
52 
Gap junction protein, beta 1 
(GJB1) Xq13.1 
Also known as connexin-32 (CX32). 
Transmembrane channels that cluster in 
gap junction to allow diffusion of low 
molecular weight materials between 
cells. 
CMT 
as yet 
unclassified 
X-linked. Onset ~50 years. Absent 
sural and superficial peroneal sensory 
response. Normal reflexes accept 
36-48 Dystrophin-related protein 2 
(DRP2) Xq22.1 
Interacts with periaxin (see CMT-4F) 
and dystroglycan and plays a role in the 
maintenance of Cajal bands of 
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absent ankle jerks. Relatively rapid 
progression. 
myelinating Schwann cells 
CMT-4A AR. Severe neuropathy with onset 
before 2 years. Rapidly progressive 
weakness and wasting. Basal laminal 
onion bulbs. 
30 Ganglioside-induced 
differentiation-associated 
protein 1 (GDAP1) 8q21.11 
Regulator of mitochondrial dynamics 
that are vital for the function of 
myelinated peripheral nerves by 
promoting mitochondrial fission. 
Expressed in both Schwann cells and 
neurones. May be involved in neuronal 
development. Regulates glutathione 
metabolism, sensitivity to apoptosis, and 
reactive oxygen species levels. 
CMT-4B1 AR. Focally folded myelin sheaths. 0-17 Myotubularin-related protein 2 
(MTMR2) 11q21 
Phosphate that acts on lipids and 
phosphoinositol headgroup. 
CMT-4B2 AR. Onset 5-8 years. Focally folded 
myelin sheaths. Juvenile-onset or 
congenital open-angle glaucoma may 
be present 
<20 Myotubularin-related protein 
13 or SET binding factor 
(SBF2) 11p15.4 
Guanine nucleotide exchange factor 
(GEF) which may activate RAB28. 
CMT-4B3 AR. Onset 5-11 years. Focally folded 
myelin sheaths, few onion bulbs and 
occasional regenerating clusters of 
axons. 
<38 Myotubularin-related protein 5 
or SET binding factor (SBF1) 
22q13.33 
Possible pseudophosphatase. May 
function as a guanine nucleotide 
exchange factor activating RAB28. 
CMT-4C AR. Classic CMT often with early 
onset severe scoliosis, often requiring 
surgery. Onset from infancy to 37 
years. Highly variable phenotype. 
19-30 SH3 domain and 
tetratricopeptide repeat-
containing proteins 2 
(SH3TC2) 5q32 
Involved in Rab11 regulation of 
recycling of internalised membrane and 
receptors. Contains a SOX10-CREB 
binding element that functions as an 
enhancer. 
CMT-4D AR. Classic CMT with onset in 
1
st
 decade and deafness developing 
by the 3
rd
 decade. Kyphoscoliosis may 
be present 
Progressively 
reduced till 
unattainable 
after 15 
years 
NMYC downstream-regulated 
gene 1 (NDRG1) 8q24.22 
May play a role in growth arrest and cell 
differentiation, and Schwann cell 
signalling. Upregulated in hypoxic cells. 
Expression is particularly high in 
Schwann cells. 
CMT-4E AR. Onse from birth to 7 years. 
Congenital cases show respiratory 
distress. Scoliosis, chest deformities, 
and pes equinovarus may be present.  
0-3 Early growth response 2 
(EGR2) 10q21.3 
 
See CMT-ID 
 
Myelin protein zero 
(MPZ or P0) 1q23 
 
See CMT-IB 
CMT-4F  AR. Variable age of onset from 
infancy to adulthood. When onset is in 
infancy, characterised as Dejerine-
Sottas syndrome. Slowly progressive, 
 3-15 Periaxin (PRX) 19q13.2  Required for myelin sheath 
maintenance. May specifically affect the 
internodal length, but not other 
parameters. 
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onion bulb formation, focal myelin 
swelling 
CMT-4G  AR. aka Russe-type HMSN. Severe 
CMT with onset by or in teenage 
years. Prominent sensory loss. Foot 
and hand deformities. Occasionally 
scoliosis is present. 
 25-37 Hexokinase-1 (HK1) 10q22.1 Allosteric enzyme involved in hexose 
metabolism. 
CMT-4H  AR. Early onset with variable severity. 
Slow rate of progression. Hypoplasia 
or hypotrophy of hypothenar muscles. 
Distal sensory loss. Myelin out-
foldings. Frequent scoliosis 
 8-13  FGD1-related F-actin-binding 
protein, FRABIN (FGD4) 
12p11.21 
 GDP/GTP exchange protein for CDC42 
and possesses actin filament binding 
activity. Role in PNS unclear. Induces 
CDC42-mediated cell shape changes in 
Schwann cells, suggesting Rho GTPase 
signalling is required for myelination of 
peripheral axons. 
CMT-4J  AR.- Compound heterozygous 
mutation identified. Childhood onset. 
Progressive proximal weakness and 
evidence of chronic denervation in 
both proximal and distal muscles. 
Severely diminished or absent 
sensory NCVs. 
 0-16  Polyphosphoinositide 
phosphatase (FIG4) 6q21 
 Plays a role in the biogenesis of 
endosome carrier vesicles / 
multivesicular bodies transport 
intermediates from early endosomes. 
CMT-4  AR. 
Classic CMT with intermediate NCVs 
 25-40 Peripheral myelin protein-22 
(PMP22) 17p12 
See CMT-IA 
Caused by autosomal recessive point 
mutations 
 
Myelin protein zero 
(MPZ or P0) 1q23 
 
See CMT-IB 
Abbreviations: AD=Autosomal dominant; AR=Autosomal recessive; aka=also known as; HMSN=hereditary motor and sensory neuropathy; PNS=peripheral nervous system; 
NCV=nerve conduction velocity  (49, 58, 73, 77, 78, 93, 97, 108, 200-237) 
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7.1.2 Table 32. Axonal CMT subtypes, their distinguishing features, and their associated genes and their functions 
CMT-II subtype Mode of inheritance & 
Distinguishing characteristics 
Gene name (symbol) 
chromosomal 
location 
Protein function 
CMT-IIA1 AD. Distinguishable from other forms of CMT-II by 
genetic evidence only. Caused by mitochondrial 
defect. Onset in first decade. 
Kinesin superfamily member 
1B (KIF1B) 1q36.22 
Motor for anterograde transport of 
mitochondria. Has microtubule plus end-
directed motility. Plays a role in the induction 
of neuronal apoptosis. 
CMT-IIA2 AD & AR. Distinguishable from other forms of 
CMT-II by genetic evidence only. Caused by 
mitochondrial defect. Highly variable phenotype 
and age of onset, and some mutation carriers may 
be asymptomatic. 
Mitofusin (MFN2) 1p.36.2 Located on out mitochondrial membrane and 
mediates mitochondrial fusion and thus, 
regulates mitochondrial architecture and 
morphology. 
CMT-IIB AD. Frequent ulcers and infections leading to 
amputation of the toes. Foot pain with swelling and 
deformity. Scoliosis, absent ankle reflexes, 
decreased distal sensation and lateral-gaze 
nystagmus may develop. 
Ras-associated protein 
RAB7 (RAB7A) 3q21.3 
Key regulator of endo-lysosomal trafficking. 
Roles in growth factor-mediated signalling, 
nutrient transporter mediated nutrient 
uptake, neurotrophin transport, and lipid 
metabolism. 
CMT-IIB1 AR. Onset in second decade. Proximal muscle 
involvement in some cases. 
Lamin A/C (LMNA) 1q22 Encodes two structural protein components 
of the nuclear lamina (lamina A and C). 
Roles in determining nuclear assembly, 
chromatin organisation, and nuclear 
membrane and telomere dynamics. 
CMT-IIB2 AR. Adult onset (28-42 years). Symmetrical 
weakness and wasting of the upper and lower 
limbs. Symmetrical ‘sock and glove’ pattern of 
sensory loss. 
Mediator complex subunit 
25 (MED25) 19q13.33 
Component of the mediator complex, 
involved in the regulated transcription of 
nearly all RNA polymerase II-dependent 
genes. Significant correlation between 
expression of MED25 and PMP22. 
CMT-IIC AD. Lateral or bilateral diaphragmatic, intercostal, 
and vocal cord weakness. Variable severity and 
age of onset. 
Transient receptor potential 
cation channel, subfamily V, 
member 4 (TRPV4) 
12q44.11 
Calcium channel found on the membrane of 
many cells types and plays a role in a 
number of different functions including the 
sensation of pain. Also implicated in SPSMA  
and congenital dSMA (table 35, appendix) 
CMT-IID AD. Onset between 16 and 30 years. Presents 
and predominates in the hands. 
Glycyl-tRNA (GARS) 7p14.3 Plays an important role in protein synthesis. 
Catalyses attachment of glycine to 
tRNA(Gly). 
CMT-IIE AD. Distinguishable from other forms of CMT-II by 
genetic evidence only. Onset between first and 
third decade of life. 
Neurofilament protein, light 
polypeptide (NEFL) 8p21.2 
Interacts with MTMR2 which is expressed in 
both myelinating and non-myelination 
Schwann cells, and both sensory and motor 
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neurones. 
 
CMT-IIF AD. Distinguishable from other forms of CMT-II by 
genetic evidence only. Variable age of onset from 
15 to 60 years. 
Heat-shock protein 27kDa 
(HSPB1) 7q11.23 
Co-expressed with NEFL. Expressed in 
response to environmental stress and 
involved in actin organisation. 
CMT-IIG AD. Onset between 9 and 76 years, although most 
present in second decade. 
Unknown 12q12-q13 Unknown  
CMT-IIH AR. CMT with pyramidal syndrome. Onset 
between 4 and 8 years. 
Unknown 8q13-q21.11 Maps to a locus containing GDAP1, in which 
mutations have been identified in other CMT 
cases. 
CMT-IIi AD. Onset between 47 and 70 years. Fast disease 
progression. 
Myelin protein zero 
(MPZ or P0) 1q23 
Comprises 50% of peripheral myelin. 
Expressed in Schwann cells and is the major 
myelin structural protein. 
CMT-IIJ AD. Pupillary abnormalities and deafness/partial 
hearing loss. Onset between late teens and sixth 
decades. 
Myelin protein zero 
(MPZ or P0) 1q23 
See CMT-IIi 
CMT-IIK AD & AR. Distinguishable from other forms of 
CMT-II by genetic evidence only. Onset in first 
decade for AR mutations and ranges from first to 
third decade for AD mutations. 
Ganglioside-induced 
differentiation-associated 
protein 1 (GDAP1) 8q21.11 
Regulator of mitochondrial dynamics that are 
vital for the function of myelinated peripheral 
nerves by promoting mitochondrial fission. 
Expressed in both Schwann cells and 
neurones. May be involved in neuronal 
development. Regulates glutathione 
metabolism, sensitivity to apoptosis, and 
reactive oxygen species levels. 
CMT-IIL AD. Distinguishable from other forms of CMT-II 
only by genetic evidence. Onset between 15 and 
33 years. 
Heat-shock protein 22kDa, 
protein 8 (HSPB8) 12q24 
Inhibits protein aggregation by acting as a 
chaperone. 
CMT-IIN AD. Onset between 6 and 54 years. Variable 
severity. Occasional sensorineural deafness of 
varying severity. 
Alanyl-tRNA synthetase 
(AARS) 16q22.1 
Attaches the amino acid alanine to its 
appropriate tRNA. Edits incorrectly charged 
tRNA(Ala) via its editing domain. 
CMT-IIO AD. Childhood onset. Slowly progressive. 
Occasional transient paraesthesia and neuropathic 
lower limb pain. 
Cytoplasmic dynein 1, 
heavy chain 1 (DYNC1H1) 
Motor for intracellular retrograde transport of 
vesicles and organelles along microtubules. 
CMT-IIP AD & AR. Onset in second and fourth decades. 
Slowly progressive. 
Leucine-rich repeat-and 
sterile alpha motif-
containing 1 (LRSAM1) 
9q33.3-q34.1 
Involved in protein ubiquitination and plays a 
role in sorting endocytic and exocytic cargos. 
CMT-IIQ AD. Distinguishable from other forms of CMT-II 
only by genetic evidence Onset between 13 and 
25 years.  
Dehydrogenase E1 and 
transketolase domains-
containing protein 1 
(DHTKD1) 10p14 
Forms part of the 2-oxoglutarate 
dehydrogenase complex, which catalyses 
the conversion of 2-oxoglutarate to succinyl-
CoA and CO2. 
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CMT-IIR AR. Onset in early infancy. Tracheomalacia, 
respiratory insufficiency associated with vocal cord 
paralysis. Decreased motor and sensory 
amplitudes. Decreased motor and sensory nerve 
conduction velocities consistent with sever axonal 
polyneuropathy. 
Tripartite motif-containing 
protein-2 (TRIM2) 4q31.3 
UBE2D1-dependent E3 ubiquitin-protein 
ligase. Mediates ubiquitination of NEFL and 
phosphorylated BCL2.  Plays a role in rapid 
ischemic tripartite-induced neuroprotection. 
Regulates neuronal polarisation. 
CMT-IIS AR. Onset in first decade. Presents as delayed 
motor development and gat difficulties, such as toe 
walking, foot drop, and steppage gait. Most 
patients require ankle foot orthoses for walking, 
some wheelchair bound. Hand involvement at 
onset or soon after. 
Immunoglobulin µ-binding 
protein 2 (IGHMBP2) 
11q13.3 
5’-3’ helicase. Binds a specific DNA 
sequence from the immunoglobulin mu chain 
switch region. Acts as a transcription 
regulator. Bot heterozygous and compound 
heterozygous mutations identified. 
Also mutant in dHMN-VI (table 35, appendix) 
CMT-IIT AR. Onset in third decade as unstable gait and 
dys/paresthesias in the distal lower limbs. 
DnaJ (Hsp40) homolog, 
subfamily member 2 
(DNAJB2)  2q35 
Encodes heat-shock protein 40 (HSP40), a 
molecular co-chaperone member of the heat 
shock protein family.  
CMT-IIU AD. Late onset (50 to 60 years). Muscle weakness 
and wasting presents in both the hands and feet 
with equal severity and progression. Neuropathic 
pain in some subjects. 
Methionyl-tRNA synthestase 
(MARS) 12Q13.3 
Enzyme responsible for charging tRNA 
molecules, which is essential for protein 
translation in cytoplasm and mitochondria. 
CMT-IIV AD. Late onset (30 to 61 years). Presenting and 
dominating feature is recurrent foot pain. Some 
subjects develop distal upper limb parathesias. 
Physical and electrophysiological examination 
suggestive of peripheral neuropathy.  
α-N-acetyl-glucosaminidase 
(NAGLU) 17Q21.2 
Enzyme involved in the hydrolysis of 
terminal non-reducing N-acetyl-D-
glucosamine residues in N-acetyl-α-D-
glucosaminides. Involved in degradation of 
heparin sulphate. Patient leukocytes show 
average of 45% decrease in enzymatic 
activity. 
CMT-IIW AD. Variable age of onset (childhood to 62 years). 
Presents in lower limbs as gait difficulties, 
steppage gait, or foot deformities. Pain and hand 
weakness in few subjects, but upper limb 
involvement is rare. 
Histidyl-tRNA synthetase 
(HARS) 5q31.3 
Enzyme responsible for charging tRNA 
molecules, which is essential for protein 
translation in cytoplasm and mitochondria. 
AR-CMT-II with 
neuromyotonia 
AR. Onset in first decade. ‘Motor greater than 
sensory neuropathy’- pure motor in some patients 
and mixed motor and sensory in others. 
Neuromyotonia. 
Histidine triad nucleotide 
binding (HINT1) 5q23.3 
Ubiquitously expressed. Binds and 
hydrolyses adenosine 5′-
monophosphoramidate substrates. 
Haploinsufficient tumour suppressor genes 
that promotes apoptosis, inhibits the 
transcriptional activity of beta-catenin/TCF4, 
USF2 and NFkappaB, and inhibits the 
expression of endogenous cyclin D1 and 
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TGFbeta2. 
 
HMSNP AD. Onset between third and fourth decade. 
Painful muscle cramps and fasciculations. 
TRK-fused gene (TFG) 
3q12.2 
Plays a role in normal dynamic function of 
the endoplasmic reticulum and its associated 
microtubules. 
CMT-II 
as yet 
unclassified 
AD. Onset between early childhood and fifth 
decade. Variable rate of progressing and severity.  
Valosin-containing protein 
Valosin-containing protein 
(VCP) 9p13.3 
Required for export of endoplasmic reticulum 
into the cytosol. Associated with several 
essential cell protein pathways including cell 
cycle, homotypic membrane fusion, nuclear 
envelope reconstruction, DNA damage 
response, apoptosis suppression, and 
ubiquitin-dependent protein degradation. 
CMT-II 
presenting as 
dHMN 
Mitochondrial. Onset from 3 years to second 
adolescence. Variable expression and variable, 
and sometimes incomplete penetrance. Often 
presents as a purely motor neuropathy with 
sensory symptoms developing subsequently.  
Mitochondrially encoded 
STP synthase 6 (MT-ATP6) 
base pairs 8,527 – 9,207 
Subunit of Complex V (ATP synthase), 
which produces ATP from ADP in the 
presence of a proton gradient across the 
mitochondrial membrane. 
HMSN-II with 
neurofilament 
accumulation 
AD. Classic CMT-II with axonal swelling (giant 
axons). Variable severity. More severe cases also 
have cardiomyopathy. 
DDB1- and CUL4-
associated factor 8 (DCAF8) 
1q23.2 
Contains 7 WD repeats that form a β-
propeller and interacts with DDB1 protein in 
the CUL4-DDB1 E3 ubiquitin ligase 
macromolecular complex, which regulates 
cell proliferation, DNA repair, and chromatin 
integrity through targeted ubiquitination of 
specific substrates. 
Giant axonal 
neuropathy 
AR. Onset by 3 years. Severe progressive 
peripheral motor and sensory neuropathy. Frizzly 
hair in ~60%, CNS involvement in ~90%, sensory 
involvement in ~50%. Giant axons caused by 
neurofilament accumulation. 
Gigaxonin (GAN) 16q23.2 Ubiquitously expressed. Plays an important 
role in the cytoskeleton by stabilisation of the 
microtubule network. 
Abbreviations: AD=Autosomal dominant; AR=Autosomal recessive; tRNA= transfer RNA (40, 52, 53, 69, 72, 74, 76, 79, 83-85, 87, 89, 115, 128, 130, 238-282) 
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7.1.3 Table 33. Intermediate CMT subtypes, their distinguishing features, and their associated genes and their 
functions 
Intermediate 
CMT subtype 
Mode of inheritance & 
Distinguishing characteristics 
Average 
mNCVs 
(m/s) 
Gene name (symbol) 
chromosomal location 
Protein function 
DI-CMTA AD. Onset ~6 years. Slow but steady 
disease progression till 30 years. Rapid 
disease progression from 40 – 50 
years until later stabilisation. 
25-45 Unknown. 10q24.1-q25.1 Unknown 
DI-CMTB AD. Onset from 2 – 50 years. Shares 
clinical features with CMT-I and CMT-
II. Cataracts and neutropenia 
24-54 Dynamin-2 (DNM2) 19q13.2 GTPase involved in intracellular vesicle 
trafficking and cytoskeleton remodelling 
with ubiquitous tissue expression. 
DI-CMTC AD. Onset from 5-59 years. Motor 
symptoms predominate over sensory. 
Slow progression and moderate 
severity. 
30-40 Tyrosyl-tRNA synthetase 
(YARS) 1p35.1 
Essential enzyme for protein 
biosynthesis. Expressed ubiquitously. 
catalyses the aminoacylation of tRNATyr 
with tyrosine. 
DI-CMTD AD. Onset between 14 and 17 years. 
Calf hypertrophy. Aidie’s pupil. 
35-43 Myelin protein zero 
(MPZ or P0) 1q23 
Approximately 30% of MPZ mutations 
are associated with intermediate DI-
CMTD. Comprises 50% of peripheral 
myelin. Expressed in Schwann cells and 
is the major myelin structural protein. 
DI-CMTE AD. Onset from 5 - 28 years. CMT 
associated with focal segmental 
glomerulosclerosis. Proteinuria. 
Sensory loss in 50%. Sensorineural 
hearing loss in 30%. Muscle cramps. 
23-45 Inverted formin-2 (INF2) 
14q32.33 
Member of the diaphanousrelated 
formin family, which is involved in 
remodelling the microtubule cytoskeleton 
and actin. Interacts with Rho-GTPase 
CDC42, lymphocyte protein, and myelin- 
important commencement and 
maintenance of myelination. 
DI-CMTF AD. Onset from 10 – 45 years. Clinical 
severity from asymptomatic t 
wheelchair bound. 
 
16-46 Guanine-nucleotide-binding 
protein subunit beta-4, Gβ4 
(GNB4) 3q26.33 
Forms part of a complex that form a 
receptor which transmits extracellular 
signals into cells following activation by 
various signalling factors. Abundant in 
Schwann cells and peripheral axons.  
RI-CMTA AR. Mixed features of demyelinating 
and axonal CMT. Severity 
(CMTNS>20) 
25-35 Ganglioside-induced 
differentiation-associated 
protein 1 (GDAP1) 8q21.11 
Regulator of mitochondrial dynamics that 
are vital for the function of myelinated 
peripheral nerves by promoting 
mitochondrial fission. Expressed in both 
Schwann cells and neurones. May be 
involved in neuronal development. 
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Regulates glutathione metabolism, 
sensitivity to apoptosis, and reactive 
oxygen species levels. 
RI-CMTB AR. Dysmorphic features, 
developmental delay, self-abusive 
behaviour. and vestibular Schwannoma 
(benign intracranial tumour of Schwann 
cells) 
30-40 Lysyl-tRNA synthetase 
(KARS) 16q23.1 
Enzyme responsible for charging tRNA 
molecules, which is essential for protein 
translation in cytoplasm and 
mitochondria. 
RI-CMTC AR. Onset between first and fifth 
decades. Mildly increase serum 
creatine kinase, fatty replacement of 
muscle tissue. 
24-39 Pleckstrin homology domain-
containing family G member 5 
(PLEKHG5) 1p36.31 
Predominantly expressed in the 
peripheral nervous system. Dbl-
homology – pleckstrin-homology motif is 
the minimal unit for the nucleotide 
exchange-promoting function of guanine 
nucleotide exchange factors (GEFs). 
Pleckstrin-homology domain plays 
important role in the allosteric regulation 
of the RhoGEF domain- initiating 
mechanisms that regulate neuronal 
shape and plasticity, dendrite growth, 
synapse formation, neuronal survival. 
Abbreviations: AD=Autosomal dominant; AR=Autosomal recessive; CMTNS=Charcot-Marie-Tooth neuropathy score; tRNA= transfer RNA (50, 65, 75, 86, 88, 96, 283-297) 
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7.1.4 Table 34. X-linked CMT subtypes, their distinguishing features, and their associated genes and their functions. 
CMT-X 
subtype 
Mode of inheritance & 
Distinguishing characteristics 
Average 
mNCVs 
(m/s) 
Gene name (symbol) 
chromosomal location 
Protein function 
CMT-IX X-linked dominant. CMT-I phenotype 
(table 31) Affects heterozygous females 
more mildly than hemizygous males. 
Stroke like presentation has been 
reported. 
Males: 30-
50 
Females: 
31-52 
Gap junction protein, beta 1 
(GJB1) Xq13.1 
Also known as connexin-32 (CX32). 
Transmembrane channels that cluster 
in gap junction to allow diffusion of 
low molecular weight materials 
between cells. 
CMT-X2 X-linked recessive. Variable age of onset. 
Mental retardation in some cases, normal 
intelligence in others. 
N/A Unknown Xp22.2 Unknown 
CMT-X4 
(Cowchock 
syndrome) 
X-linked recessive. Childhood onset. 
Slowly progressive with deafness and 
cognitive impairment.  
Mildly 
reduced or 
normal 
Apoptosis-inducing factor (AIF) 
mitochondrion-associated 1 
(AIFM1) Xq26.1 
Mitochondrial flavoprotein involved in 
caspase-independent cell death 
CMT-X5 
(Rosenberg-
Chutorian 
syndrome) 
X-linked recessive. Polyneuropathy with 
visual impairment due to optic atrophy, 
and hearing loss. 
43-51 Ribose-phosphate 
pyrophosphokinase 1 (PRPS1) 
Xq22.3 
Metabolic enzyme that catalyses the 
synthesis of 
phosphoribosylpyrophosphate, 
essential for purine metabolism and 
nucleotide biosynthesis. 
CMT-X6 X-linked dominant. Onset between 2 and 
13 years in males, Slowly progressive but 
patients remain ambulant and enganged 
in employment or stdy. CMTNS = 11.5 
±3.3 in males; 2.0 ±2.2 in females.  
38-63 Pyruvate dehydrogenase kinase, 
isoenzyme 3 (PDK3) Xp22.11 
Located in mitochondrial matrix. One 
of 4 dehydrogenase enzymes, which 
negatively regulates pyruvate 
dehydrogenase complex activity- key 
enzyme linking glycolysis to Krebs 
cycle and lipogenic pathways.  
dHMN-X 
(SMAX3) 
X-linked recessive. Onset between 1 and 
30 years. Purely motor. 
 Copper-transporting ATPase 1 
(ATP7A) Xq21.1 
P-type ATPase copper transporter. 
Also defective in Menkes disease, a 
sever infantile-onset 
neurodegenerative condition. 
Abbreviations: N/A: information not available; CMTNS=Charcot-Marie-Tooth neuropathy score; SMAX3=Distal spinal muscular atrophy,  X-linked 3 (97, 98, 100-102, 104, 105, 
108, 109) 
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7.1.5 Table 35. Distal hereditary motor neuropathy subtypes, their distinguishing features, and their associated 
genes and their functions 
dHMN subtype Mode of inheritance & 
Distinguishing characteristics 
Gene name (symbol) 
chromosomal location 
Protein function 
dHMN AD, AR, and sporadic. Onset between 1 and 
45 years. Hyporeflexia or areflexia. Normal 
mNCVs. Onset usually in the lower limbs. 
Histidine triad nucleotide 
binding (HINT1) 
Ubiquitously expressed. Binds and hydrolyses 
adenosine 5′-monophosphoramidate 
substrates. Haploinsufficient tumour suppressor 
genes that promotes apoptosis, inhibits the 
transcriptional activity of beta-catenin/TCF4, 
USF2 and NFkappaB, and inhibits the 
expression of endogenous cyclin D1 and 
TGFbeta2. 
dHMN-I AD. Onset by 20 years, usually first decade. 
Classic dHMN features 
Unknown 7q34-q36 Unknown 
dHMN-II AR. Onset from early childhood to late 
adulthood. Variable severity. Some 
heterozygous gene carriers remain 
asymptomatic but show electrophysiological 
abnormalities.  
Histidyl-tRNA synthetase 
(HARS) 5q31.3 
Enzyme responsible for charging tRNA 
molecules, which is essential for protein 
translation in cytoplasm and mitochondria. 
dHMN-IIA AD. Onset between 15 and 20 years. Rapid 
disease progression with complete lower 
limb paralysis within 5 years of onset. 
Heat shock 22-KD protein 8 
(HSPB8) 12q24.23 
Displays temperature dependent chaperone 
activity. Role in prevention of protein 
aggregation as well as roles in regulation of cell 
proliferation, apoptosis, and carcinogenesis. 
dHMN-IIB AD. Onset from 21 to 54 years. Slow disease 
progress. Presents in lower limbs and 
progresses to upper limbs 10 to 15 years 
later. 
Heat shock 27-KD protein 1 
(HSPB1) 7q11.23 
Induced by environmental stress and 
developmental changes. Involved in stress 
resistance and actin organisation. Translocated 
from cytoplasm to nucleus in response to 
stress.  
dHMN-IIC AD. Onset at the start of the third decade. 
Slow disease progress. 
Heat shock 27-KD protein 3 
(HSPB3) 5q11.2 
Muscle specific inhibitor of actin polymerisation 
dHMN-IID AD. Onset between second and fourth 
decades. Slowly progressive lower limb 
weakness and wasting. Variable severity. 
F-box only protein 38 
(FBXO38) 5q32 
Contains F-box domain. May play a role in 
protein ubiquitination. 
dHMN-VA AD. Onset between 12 and 36. Most before 
20 years. Muscle weakness and wasting 
presents and predominates in the upper 
limbs. 
Glycyl-tRNA (GARS) 7p14.3 Plays an important role in protein synthesis. 
Catalyses attachment of glycine to tRNA(Gly). 
Seipin (BSCL2) 11q12.3 Regulator of lipid catabolism essential for 
adipocyte differentiation. Necessary for correct 
lipid storage and lipid droplets maintenance 
Also mutated in Silver syndrome. 
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dHMN-VB 
 
AD. Onset in first or second decade. Muscle 
weakness and wasting presents and 
predominates in the upper limbs. 
Receptor expression-enhancing 
protein 1 (REEP1) 2p11.2 
Mitochondrial protein that serves to enhance 
cell surface expression of odorant receptors. 
Also mutant in SPG31. 
dHMN-VI 
(dSMA6/SMARD1) 
AR. Early onset- 1 or 2 months of age. 
Presents as respiratory distress and a weak 
cry due to diaphragmatic paresis. 
Immunoglobulin µ-binding 
protein 2 (IGHMBP2) 11q13.3 
5’-3’ helicase. Binds a specific DNA sequence 
from the immunoglobulin mu chain switch 
region. Acts as a transcription regulator.  
dHMN-VII AD. Variable age of onset.  Muscle 
weakness and wasting present in the small 
muscles of the hand. Vocal cord paresis 
presents as a husky voice due to 
involvement of the tenth cranial nerve. 
Solute carrier family 5 [choline 
transporter], member 7 
(SLC5A7) 2q12.3 
Encodes the Na(+)- and Cl(-)- dependant high 
affinity choline transporter, CHT. Responsible 
for mediating choline uptake for acetylcholine 
synthesis at NMJ. 
dHMN-VIIB AD. Onset in early adulthood. Muscle 
weakness and wasting present in the small 
muscles of the hand. Respiratory difficulties 
due to vocal cord paresis.  
Dynactin (DCTN1) 2p13.1 p150
Glued
 subunit of dynactin. A complex of 
microtubule-based biologic motor proteins 
required for cytoplasmic dynein driven 
movement of organelles along microtubules. 
Interacts with dynein via p150
Glued
. 
dHMN-X 
(SMAX3) 
X-linked recessive. Onset from 1 to 50 years. 
Very slow disease progression. Remain 
ambulant.  
Copper-transporting ATPase 1 
(ATP7A) Xq21.1 
P-type ATPase copper transporter. Also 
defective in Menkes disease, a sever infantile-
onset neurodegenerative condition. 
dHMN Jaresh 
type  
AR. Onset from 6 to 10 years. Weakness 
and atrophy progresses from lower to upper 
limb muscles within 2 years of onset. Mild 
pyramidal tract signs. Only seen in the 
Jaresh Jewish community. 
Unknown   
9p21.1-p12 
Locus contains SIGMAR1, implicated in dSMA2 
Early onset 
dHMN with 
pyramidal tract 
signs  
(ALS4) 
AD. Onset between 2 and 25 years. Classic 
dHMN with pyramidal tract signs. 
Senataxin (SETX) 9q34.13 DNA/RNA helicase. Has strong homology with 
IGHMBP2. Plays a role in DNA repair. May play 
a role in the regulation/modulation of 
transcription. Also mutated in AR 
spinocerebellar ataxia 1. 
SPSMA AD. Neurogenic amyotrophy with variable 
expression. Congenital absence of muscles, 
progressive scapuloperoneal atrophy, 
laryngeal palsy, progressive distal muscle 
weakness and wasting. 
Transient receptor potential 
cation channel, subfamily V, 
member 4 (TRPV4) 12q44.11 
Calcium channel found on the membrane of 
many cells types and plays a role in a number 
of different functions including the sensation of 
pain.  
Congenital 
dSMA 
 
AD. Onset at birth. Nonprogressive. Variable 
severity from weakness of the distal lower 
limb muscles only, to additional weakness of 
the pelvic girdle and truncal muscles, 
resulting in scoliosis. 
Transient receptor potential 
cation channel, subfamily V, 
member 4 (TRPV4) 12q44.11 
Calcium channel found on the membrane of 
many cells types and plays a role in a number 
of different functions including the sensation of 
pain.  
dSMA2 AR. Onset between 9 and 12 years. Distal Sigma non-opiod (SIGMAR1) Involved in lipid transport from the endoplasmic 
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muscle weakness and wasting presents in 
the lower limbs with pes varus, and foot 
drop. Hand involvement occurs later. 
Pyramidal tract signs and Babinski tract sign 
occasionally present. Progressive from onset 
till ~ 20 years, then stable. 
9p13.3 reticulum. Involved in many cellular functions, 
including, BDNF signalling, EGF signalling, ion 
channel regulation, calcium signalling, 
proliferation, and cell survival and apoptosis. 
Also mutant in ALS16. 
dSMA3 AR. Variable onset (2 months to 19 years. 
Variable disease progression. Those with 
earlier onset (1
st
 year) loose ability to walk 
before 12 years and ability to write by 30 
years, and have bilateral diaphragmatic 
paralysis. Hip subluxation and genu 
recurvatum (knee deformity) often observed. 
Later onset retain ability to walk but have 
waddling gait. 
Unknown 
11q13 
Unknown 
dSMA5 AR. Onset between 16 and 23 years. Slowly 
progressive weakness, hypotonia, and 
muscle wasting of the lower limbs, more 
pronounced distally. Pure motor axonal 
neuropathy. 
DnaJ (Hsp40) homolog, 
subfamily member 2 (DNAJB2)  
2q35 
Encodes heat-shock protein 40 (HSP40), a 
molecular co-chaperone member of the heat 
shock protein family.  
SMAX2 X-linked recessive. Infantile onset. Severe 
hypotonia, areflexia, and arthrogryposis 
(multiple congenital contractures). Infantile 
death. 
Ubiquitin activating enzyme 1 
(UBE1) X11.3 
Catalyzes the first step in ubiquitin conjugation 
to mark cellular proteins for degradation 
through the ubiquitin-proteasome system. 
Essential for the formation of radiation-induced 
foci, timely DNA repair and for response to 
replication stress. 
SMALED1 AD. Between birth and 7 years, most by 2 
years. Non-progressive or mildly 
progressive. Prominent weakness and 
atrophy of the quadriceps muscles, 
moderate to severe atrophy of the hip 
abductors, and milder weakness in other leg 
muscles. Upper limbs unaffected. 
 
Dyanin, cytoplasmic 1, heavy 
chain 1 (DYNC1H1) 14q32.31 
Crucial subunit of the cytoplasmic dynein 
complex. Cytoplasmic dynein involved in 
intracellular motility, including retrograde axonal 
transport, protein sorting between apical and 
basolateral surfaces, and redistribution of 
organelles such as endosomes and lysosomes. 
SMALED2 AD. Weakness and atrophy predominantly 
affecting the proximal and distal muscles of 
the lower limbs. Some patients show upper 
limb involvement, foot deformities, and mild 
upper motor signs. 
Bicaudal D, homolog of 
drosophila 2 (BICD2) 9q22.31 
Motor adaptor protein that is involved in dynein-
mediated transport by linking the dynein motor 
complex to various cargoes. Also involved in 
Golgi dynamics and vesicular and mRNA 
transport. 
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SBMA 
(Kennedy 
disease) 
X-linked recessive. Onset in third to fifth 
decades. Slowly progressive limb and bulbar 
muscle weakness with fasciculations, muscle 
atrophy, and gynecomastia.  
Androgen receptor (AR) Xq12 Member of a group of nuclear receptors, the 
class I steroid receptors. Recognises canonical 
androgen response elements (AREs), and 
regulates gene expression and affects cellular 
proliferation and differentiation in target tissues. 
Also implicated in androgen insensitivity, partial 
androgen insensitivity with or without breast 
cancer, and hypospadias. 
Abbreviations: mNCV= Motor nerve condeuctione velocities; SPG31= Spastic paraplegia 31; tRNA= transfer RNA; dSMA=Distal spinal muscular atrophy; SMARD1=Spinal 
muscular atrophy with respiratory distress type 1; SPG31=Spastic paraplegia 31; SMAX3=Distal spinal muscular atrophy,  X-linked 3 ; ALS4=Amyotropic lateral sclerosis 4; 
SPSMA= Scapuloperoneal spinal muscular atrophy; ALS16=Amyotrophic lateral sclerosis; BDNF=Brain-derived neurotrophic factor; EGF=Epidermal growth factor; 
SMALED=Spinal muscular atrophy, lower extremity-predominant; SBMA=Spinobulbar muscular atrphy    (43, 60, 80, 82-84, 89, 102, 115, 117, 127-129, 133, 227, 298-316) 
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7.2 APPENDIX CHAPTER 2 
7.2.1 Table 36. Amounts of human SLC5A7 cDNA construct 
transfected/500,000 cells 
Label cDNAs transfected Amount transfected 
(µg) 
2X PRK5 pRK5 (empty vector) 1 
2X WT HA-SLC5A7
WT 1 
2X K499N HA-SLC5A7
K499Nfs*13 1 
2X H521Q HA-SLC5A7
H521Q 1 
2X V112E HA-SLC5A7
V112E 1 
2X S94R HA-SLC5A7
S94R 1 
2X pEGFP-C pEGFP-SLC5A7
WT-C 1 
2X N-GFP SLC5A7-N-GFP 1 
1X WT 
pRK5 
HA-SLC5A7WT 
0.5 
0.5 
1X K499N 
pRK5 
HA-SLC5A7K499Nfs*13 
0.5 
0.5 
1X H521Q 
pRK5 
HA-SLC5A7H521Qfs*2 
0.5 
0.5 
1X V112E 
pRK5 
HA-SLC5A7V112E 
0.5 
0.5 
1X S94R 
pRK5 
HA-SLC5A7S94R 
0.5 
0.5 
1X WT / 
1X K499N 
HA-SLC5A7WT 
HA-SLC5A7K499Nfs*13 
0.5 
0.5 
1X WT / 
1X H521Q 
HA-SLC5A7WT 
HA-SLC5A7H521Qfs*2 
0.5 
0.5 
1X WT / 
1X V112E 
HA-SLC5A7WT 
HA-SLC5A7V112E 
0.5 
0.5 
1X WT / 
1X S94R 
HA-SLC5A7WT 
HA-SLC5A7S94R 
0.5 
0.5 
1X WT / 
1X pEGFP-C 
HA-SLC5A7WT 
pEGFP-SLC5A7WT-C 
0.5 
0.5 
1X WT / 
1X N-GFP 
HA-SLC5A7WT 
 
0.5 
0.5 
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7.2.2 Table 37. Amounts of human SLC5A7 cDNA construct 
transfected/100,000 cells 
Label cDNAs transfected Amount transfected 
(ng) 
2X PRK5 pRK5 (empty vector) 200 
2X pCHT-N-GFP pCHT-N-GFP 200 
1X WT 
pRK5 
HA-SLC5A7WT 
100 
100 
1X HA-SLC5A7K499Nfs13 
pRK5 
HA-SLC5A7K499Nfs*13 
100 
100 
1X HA-SLC5A7H521Qfs*2 
pRK5 
HA-SLC5A7H521Qfs*2 
100 
100 
1X HA-SC5A7V112E 
pRK5 
1X HA-SC5A7V112E 
100 
100 
1X HA-SC5A7S94R 
pRK5 
1X HA-SC5A7S94R 
100 
100 
1X WT / 
1X HA-SLC5A7K499Nfs*13 
HA-SLC5A7WT 
HA-SLC5A7K499Nfs*13 
100 
100 
1X WT / 
1X HA-SLC5A7H521Qfs*2 
HA-SLC5A7WT 
HA- SLC5A7H521Qfs*2 
100 
100 
1X WT / 
1X HA-SC5A7V112E 
HA-SLC5A7WT 
1X HA-SC5A7V112E 
100 
100 
1X WT 
1X HA-SC5A7S94R 
HA-SLC5A7WT 
1X HA-SC5A7S94R 
100 
100 
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7.3 APPENDIX CHAPTER 3 
7.3.1 Table 38. dHMN-VII family 1 identification numbers across studies 
ID in this 
thesis  
ID in 
Young and 
Harper 
1980 
ID in 
Pridmore et 
al. 1992 
ID in 
McEntagart 
et al. 2001 
ID in Dick 
et al. 2008 
ID in 
Barwick et 
al. 2012 
I:1    I:1  
I:2    I:2  
II:1   YH1 I:1 II:1  
II:2   YH1 I:2 II:2  
II:3    II:3  
II:4    II:4  
III:1 I 2  YH1 II:2 III:1  
III:2 I 3  YH1 II:1 III:2  
III:3 I 4  YH1 II:3 III:3  
III:4   YH1 II:4 III:4  
III:5   P2 I:1 III:5  
III:6  I.1 P2 I:2 III:6  
IV:1 II 5  YH1 III:2 IV:1  
IV:2   YH1 III:1 IV:2  
IV:3   YH1 III:4 IV:3  
IV:4 II 6  YH1 III:3 IV:4  
IV:5 II 11  YH1 III:5 IV:5  
IV:6   YH1 III:6 IV:6  
IV:7   P2 II:4 IV:7  
IV:8  II.2 P2 II:3 IV:8  
IV:9  II.1 P2 II:2 IV:9 IV:9 
IV:10   P2 II:1 IV:10 IV:10 
V:1 III 12  YH1 IV:1 V:1 V:1 
V:2 III 13  YH1 IV:2 V:2 V:2 
V:3 III 14  YH1 IV:3 V:3 V:3 
V:4 III 15  YH1 IV:4 V:4 V:4 
V:5   YH1 IV:5 V:5  
V:6   YH1 IV:6 V:6  
V:7 III17  YH1 IV:7 V:7  
V:8    V:8  
V:9 III 24  YH1 IV:8 V:9 V:10 
V:10   YH1 IV:9 V:10 V:9 
V:11   YH1 IV:10 V:11 V:11 
V:12 III 25  YH1 IV:11 V:12 V:12 
V:13   P2 III:4 V:13 V:17 
V:14   P2 III:5 V:14 V:16 
V:15   P2 III:6 V:15  
V:16  III.5 P2 III:7 V:16  
V:17   P2 III:8 V:17  
V:18  III.3 P2 III:3 V:18 V:20 
V:19  III.2 P2 III:2 V:21 V:19 
V:20   P2 III:1 V:22 V:18 
V:21  III.4  V:23 V:21 
V:22    V:24  
VI:1 IV 22   VI:1  
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VI:2 IV 23  YH1 V:2 VI:2  
VI:3   YH1 V:1 VI:3  
VI:4 IV 24  YH1 V:3 VI:4  
VI:5 IV 26  YH1 V:4 VI:5 VI:5 
VI:6 IV 25  YH1 V:5 VI:6 VI:4 
VI:7 IV 29  YH1 V:8 VI:7 VI:6 
VI:8   YH1 V:6 VI:8 VI:7 
VI:9   YH1 V:7 VI:9 VI:8 
VI:10    VI:10 VI:10 
VI:11   P2 IV:2 VI:11 VI:9 
VI:12  IV.3 P2 IV:1 VI:12 VI:11 
VI:13  IV.4   VI:12 
VI:14  IV.7  VI:13  
VII:1    VII:1  
VII:2    VII:2  
VII:3   VI:1 VII:3  
 
 
7.3.2 Table 39. Primer sequences for cosegregation analysis of four 
candidate variants within dHMN-VII locus 
Variant  
(gene symbol) 
Forward Reverse 
Chr2:108627070 G/- 
(SLC5A7) 
CCCTGGCTATTACCCTGATG CACAAGTGCAAGTTCATCTAATTT 
Chr2:120404629 T/- 
(PCDP1) 
ACAGCTGCGATTCCTTCAAT GTTCCTCACAGCACCTCACA 
Chr2:101924635 T/C 
(RNF149) 
AGGGCCAACCCTGAAGAC  GACACGCGCTTCTTCGTG 
Chr2:121107178 A/G 
(INHBB) 
CCCTTTGTGGTGGTGCAG GTGGAAGGAGGAGGCAGAG 
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7.3.3 Table 40. SLC5A7 primer sequences 
Primer 
name 
Forward Reverse 
SLC5A7_1 ACGCCCTAGCACCACTCTC GCGTCCCTCCCCTCTAAAAC 
SLC5A7_2 TGAGCCAGCTGGTTTATTCC TGTCACTCTGAAGCCACACG 
SLC5A7_3 CTTCTAGTAGCCACTGGTTTGG TCAGAGTGTTTGACTTGTTATTCCA 
SLC5A7_4 TTCCTTGATAAATGGCAGCA AAGCCAAGGCTGAGGAAAGT 
SLC5A7_5 TGTTTTCATCCACTGCATTTC CAGTCCAATGGAGAGCACAC 
SLC5A7_6 TGAGCTGTGCAGTGTGTGAG GAGCCCACAAGCACATTTT 
SLC5A7_7 TGTGGCTACATGCCACATTT GTGGAGGAAAGAGGGGAGTG 
SLC5A7_8 CCAGCACATGGACTTCACAC TCTCGTATGCTTAAAGTACAGTCAGA 
SLC5A7_9a GAGCCATTTGAACCAGGAGA TGATGTAACCATGGCAAGTG 
SLC5A7_9b TTCTGGCCTCTTCCTGAGAA TGCTGCATACCATCTCTCCA 
SLC5A7_9c CAGAAGGGTCTGGGACTGAA AATTCATTGCACCATTCAAGG 
 
7.3.4 SLC5A7 c.1497delG screening in regional control subjects 
 
 
Figure 45. Restriction digest showing the presence of the c.1497delG variant 
in one dHMN-VII affected individual (indicated by white arrow), and its 
absence in 151 subjects control individuals.  
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7.3.5 Species conservation of CHT C-terminus compared to p.K499Nfs*13 
mutant protein 
 
 
Figure 46. Protein homology of the C-terminus of the SLC5A7 genes protein 
product in various species compared with the c.1497delG mutant molecule. The 
C-terminus contains amino acid residues that are highly conserved across 
species (Clustal Omega) 
 
  
5’ 
3’ 
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7.3.6 TMHMM analysis of CHT p.K499Nfs*13 
 
Figure 47. TMHMM transmembrane predictions of the SLC5A7 protein product of 
wild type and p.K499Nfs*13 mutant molecules. A) The wild type protein is 
predicted to have 12 transmembrane domains with the 3’ terminus not reaching 
the threshold to be considered a transmembrane region. Both the 5’ prime and 
the 3’terminals are predicted to be located extracellularly. B) The mutant proteins 
that results from the c.1497delG variant is predicted to create a more 
hydrophobic 3’ terminus which is considered more likely a transmembrane 
location such that the molecule now comprises 13 transmembrane regions. The 
3’ terminus is now predicted to be situated intracellularly, on the cytoplasmic 
side of the membrane.  
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7.3.7 SLC5A7 c.1563_1564delCA/p.H521Qfs*2 site-directed mutagenesis 
(SDM) primers 
SDM oligonucleotides were designed according to the QuickChange Lightning 
Site-Directed Mutagenesis kit guidelines. The deleted bases are bracketed and 
highlighted in yellow (these were not present in the oligonucleotide), the 
incorporation of which results in the H521Qfs*2 amino acid change leading to 
protein truncation. 
 
Primer name  Sequence 
CHT_H521Qfs*2_forward GATGCTGTTGTTGCAAGACAGTGAAGAAAACA(CA)TGGATAAGAC 
CHT_H521Qfs*2_reverse GTCTTATCCA(TG)TGTTTTCTTCACTGTCTTGCAACAACAGCATC 
 
 
7.3.8 Co-immunoprecipitation of tagged SLC5A7 wild type protein 
products and SLC5A7 c.1497delG/p.K499Nfs*13 mutant protein 
from transiently transfected HEK-293T cells   
Immunoprecipitation studies were undertaken in order to determine whether 
CHT functions as a multimer and how the SLC5A7 c.1497delG/p.K499Nfs*13 
variant effects multimerisation. This was carried out by co-transfecting HEK-
293T cells with wild type and mutant DNA constructs with and without HA- and 
various other tags, followed by immunoprecipitation with anti-HA agarose beads 
and western blot analysis of the pulled-down proteins. 
 
7.3.8.1 Methodology 
HEK-293T cells were plated and transfected in 6-well plates as previously 
described. As RIPA buffer can disrupt protein interactions due to its Triton X-
100 content, parallel transfections were performed using different lysis buffers in 
order to identify which did not interfere with the CHT proteins self-interactions 
should it form a multimer.  
After 24 hours incubation at 37°C following transfection, cells were washed 
twice with warm (37°C) 1X PBS before lysis with either one of the following: 
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Sodium chloride-Tris-EDTA (STE) buffer, Tris/Chaps buffer, low concentration 
Triton X-100 lysis (LCTL) buffer, or RIPA buffer, each containing protease 
inhibitors. Cells lysed with STE buffer were washed twice with STE, then 2ml 
STE was added to prior to the cells being scraped from the bottom of the wells 
and transferred to 2ml microcentrifuge tubes and spun at 1,500rpm for 3 
minutes at 4°C. The supernatant was removed, the pellet resuspended in STE, 
the spin repeated and again, the supernatant removed. 1ml SWELL buffer was 
added and the cells were incubated on ice for 10 minutes. The cells were then 
dounced 25-30 times and the salt concentration of the lysates was adjusted to 
0.15M with salt solution. Cells lysed in Tris/Chaps, LCTL, and RIPA were done 
so in 400µl of the respective buffers on the shaker for 1 hour a 4°C. Should a 
white pellet of DNA be visible in the lysates, it was removed with a pipette 
before the lysates were transferred to microcentrifuge tubes. Samples lysed in 
all of the various buffers were spun at maximum speed for 30 minutes, the 
supernatant was transferred to fresh tubes, and the globby pellet of cell debris 
was discarded. A BCA protein assay was then carried out as described 
previously in order to determine the protein concentrations for normalisation.  
Anti-HA agarose beads were prepared by washing 4 times in the various lysis 
buffers used earlier. The final wash was removed and 50µl of the respective 
lysis buffers was added. 30µl of each of the cell lysates was mixed with 30µl of 
beads in the appropriate buffer in microcentrifuge tubes and incubated at 4°C 
on the rotator overnight.  
The samples were spun at full speed for 5 minutes. The supernatant was 
removed, and that of the samples in RIPA buffer was prepared for western blot 
analysis. The supernatant from the other samples was discarded. The beds 
were washed 4 times with the appropriate lysis buffers, and the last wash 
removed to leave the beads almost dry.  30µl 4X Laemmli buffer was added to 
each sample before heating at 50°C for 10 minutes and subsequent 
centrifugation at full speed for 5 minutes. The samples were analysed by 
Western blot as described in chapter 2.6.5. Blots were probed with mouse 
monoclonal (m.m.) anti-HA primary antibody and goat-anti-mouse (GAM) 
secondary antibody as described to ensure HA-tagged proteins had been 
successfully immunoprecipitated by the anti-HA agarose beads. Blots were 
stripped in stripping buffer for 20 minutes at 50°C and washed 4 times for 15 
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minutes in 1X TBST. The blot was then probed again, this time with a rabbit 
polyclonal (r.p.) anti-CHT primary antibody in TBST with 3% BSA (1:1000), at 
4°C overnight. The blot was washed 4 times with TBST, blocked for 1 hour in 
3% BSA in TBST, then probed with mouse anti rabbit (MAR) secondary 
antibody (1:10,000) for 1 hour at room temperature before development with the 
use of  the Western Lightning® Plus-ECL, Enhanced 
ChemiluminescenceSubstrate Kit and Konica Minolta SRX-101 A-Xray film 
developer as described.  
Tris/CHAPS buffer and LCTL buffer were found not to disrupt the protein 
interaction.  The above procedure was repeated with these buffers with various 
CHT constructs incorporating various tags. However, following normalisation of 
the protein concentrations and prior to immunoprecipitation with anti-HA 
agarose beads, 20µl of each sample was removed and mixed with 10µl 4X 
Laemmli buffer for Western blot analysis of the total protein content. Western 
blot analysis of the immunoprecipitated proteins was carried out in duplicate. 
One of the blots was probed with m.m. anti-HA (1:1,000) primary antibody at 
room temperature for 2 hours and then in GAM (1:10,000) secondary antibody 
for 45 minutes. The other was probed with rabbit polyclonal (r.p.) anti-CHT 
(ab89875) (1:1000) primary antibody over night at 4°C, and mouse-anti-rabbit-
IgG MAR (1:10,000) secondary antibody for 1 hour at room temperature. Both 
blots were developed as above, then stripped and probed with m.m. anti-CHT 
(1:1000) primary antibody at 4°C overnight and GAM (1:10,000) secondary 
antibody for 1 hour at room temperature, and redeveloped. 
 
7.3.8.2 Results 
Unfortunately, due to the time constraints of my visit to Vanderbilt University, 
and because during the undertaking of these experiments Okuda and 
team(116) publish evidence that CHT forms a homo-oligomer on the cell 
surface, these experiments were not successfully completed. 
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7.3.9 Pulse chase analysis of CHT-WT and CHT-K499Nfs*13 in transiently 
transfected HEK-293T cells 
7.3.9.1 Methodology 
Pulse chase analysis was undertaken in order to determine whether the CHT 
p.K499Nfs*13 molecule exhibits altered constitutive trafficking compared to the 
wild type molecule; whether its biosynthesis, surface delivery, and stability are 
perturbed; and whether it effects the rate of transport to the cell surface of both 
itself and the wild type molecule.  
The following was carried out in a designated radioactivity laboratory, and 
conducted in conjunction with health and safety regulations. HEK-293T cells 
were plated in 6-well plates, and were transfected with 2X HA-SLC5A7K499Nfs*13, 
2X HA-SLC5A7WT, or co-transfected with 1X of each in replicates of 5 as 
described previously, and incubated at 37°C for 24 hours. Cells were washed 3 
times with DMEM (without glutamine, methionine and cysteine) (GIBCO®) 
supplemented with 1% penicillin-streptomycin, 1% L-glutamine, and 10% 
dialysed foetal bovine serum (cys/met free DMEM). The cells were then 
incubated in 500µl cys/met free DMEM containing 50µCi/ml [35S]methionine and 
[35S]cysteine at 37°C for 10 minutes. The time of commencement of incubation 
was noted as zero hour. The labelled medium was removed and disposed of as 
radioactive waste, and replaced with 2ml unlabelled complete medium, and the 
cells were incubated in 5% CO2 at 37°C. One well transfected with each of the 
three cDNA transfections mentioned above was solubilised in RIPA buffer with 
protease inhibitor as previously described -with all media and washes removed 
from the cells being disposed of as radioactive waste- at the following time 
intervals from zero hour: 30 minutes, 2 hours, 4 hours, 8 hours, and 24 hours. 
All lysates were then processed according to the protocol below. 
Following solubilisation in RIPA buffer with protease inhibitor, lysates were 
scraped from the bottom of the wells, transferred to 2ml microcentrifuge tubes 
and spun at full speed (13,000rpm) for 30 minutes at 4°C. Supernatants were 
transferred to fresh tubes and the pelleted cell debris was disposed of as 
radioactive waste. 20µl of each sample was mixed with 10µl 4X Laemmli buffer 
for Western blot analysis of the total protein content. Anti-HA agarose beads 
were prepared with RIPA containing protease inhibitors as done previously. 
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30µl beads were mixed with the lysates and put on the rotator overnight at 4°C. 
The beads were washed 4 times with RIPA buffer and all the liquid was 
removed. Each sample was mixed with 30µl 4X Laemmli buffer and put on the 
shaker for 30 minutes then stored at 4°C until all samples had been processed 
for SDS-PAGE. SDS-PAGE was carried out as before. The gel was fixed for 20 
minutes in 50% methanol and 10% acetic acid in ddH2O, rinsed in water, and 
placed in the autoradiography enhancing solution, Enlightening (New England 
Nuclear) for 20 minutes at room temperature before a second rinse. The gel 
was dried in a vacuum dryer for 2 hours at 65°C then placed in an exposure 
cassette with an X-ray film and exposed for 1 week at -80°C. 
 
7.3.9.2 Results 
Initial pulse chase analysis attempts in HEK-293T cells were unsuccessful 
(figure 48). Although CHT protein is visible for all three transfections in cells 
lysed at 30 minutes post incubation with cys/met free DMEM containing 
50µCi/ml [35S]methionine and [35S]cysteine (figure 48A, white arrows), at 2 
hours post incubation in radiolabelled medium HT is no longer visible. 
Transiently transfected cells only express the transfected gene for a finite period 
of time because the gene is not integrated into their genome and is thus, lost 
and not replicated on cell division. The loss of CHT visible from cells lysed at 2 
or more hours after zero hour could be due to further division of cells and there 
for a fewer portion of cells expressing the transfected proteins, resulting in 
insufficient levels of protein in the lysates to detect. Plans to carry out further 
pulse chase analysis in HEK-293T cells, which are derived from HEK-293 cells 
but are neomycin resistant and stably express the expression enhancer-binding 
SVA40 large T antigen, and had been found in-house to express higher protein 
levels than HEK-293 cells when transfected with CHT cDNA. Unfortunately, due 
to the time constraints of my visit to Vanderbilt University, I was unable to 
progress past trouble-shooting for these experiments. 
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Figure 48. Preliminary pulse chase analysis HEK-293 cells transiently 
transfected with 2X HA-SLC5A7WT, 2X HA-SLC5A7K499Nfs*13, or 1X HA-
SLC5A7WT with 1X HA-SLC5A7K499Nfs*13. A) Radiolabelled HA-tagged CHT 
proteins were pulled-down from total cell lysates with anti-HA agarose 
beads and run on SDS-PAGE. B) Total proteins from cell lysates run on 
SDS-PAGE. 
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7.3.10 Species conservation of CHT C-terminus compared to p.H521Q*fs2 
mutant protein 
Figure 49. Protein homology of the C-terminus of the SLC5A7 genes protein 
product in various species compared with the c.1563_1564delCA mutant 
molecule. The C-terminus contains amino acid residues that are highly 
conserved across species (Clustal Omega) 
  
5’ 
3’ 
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7.3.11 TMHMM analysis of CHT p.H521Q*fs2 
 
Figure 50. TMHMM transmembrane predictions of the SLC5A7 protein product of 
wild type and p.H521Qfs*2 mutant molecules. A) The wild type protein is 
predicted to have 12 transmembrane domains with the 3’ terminus not reaching 
the threshold to be considered a transmembrane region. Both the 5’ prime and 
the 3’terminals are predicted to be located extracellularly. B) The mutant protein 
that results from the c.1563_1564delCA variant is predicted to create a more 
hydrophobic 3’ terminus which is considered more likely a transmembrane 
location such that the molecule now comprises 13 transmembrane regions. The 
3’ terminus is now predicted to be situated intracellularly, on the cytoplasmic 
side of the membrane. 
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7.4 APPENDIX CHAPTER 4 
7.4.1 Table 41. Disorders featuring congenital central, peripheral, and 
combined hypotonia 
Disorder(s) Features Genetics 
Congenital central hypotonia 
Prader-Willi 
syndrome 
Central hypotonia, global developmental delay, 
short stature, genital hypoplasia, and failure to 
thrive in infancy leading to hyperphasia at ~1 
year. 
Deletion, uniparental 
disomy of paternal 
Chr15q11-13 . 
Angelman 
syndrome 
Central hyopotonia, global developmental delay, 
acquired microcephaly, seizures, prognathism, 
and skin hypopigmentation. 
Deletion, imprinting 
defect, uniparental 
disomy of maternal 
Chr15q11-13, or 
mutation of UBE3A. 
Rett syndrome Central hypotonia, acquired microcephaly, 
seizures, repetitive hand movements, and 
regression. 
X-linked. MECP2  and 
CDKL5 mutations 
Peroxisomal 
disorders 
Spectrum of disorders of varying severity. Central 
hypotonia, liver abnormalities, seizures, 
cataracts/retinal dystrophy, hearing loss, 
chondrodysplasia punctata, and flattened facies 
with large anterior fontanelle. 
AR. Mutation in 1 of 12 
PEX genes. Most 
commonly PEX1. 
Smith–Lemli–
Opitz (SLO) 
syndrome 
Central hypotonia, growth delay, global 
developmental delay, Y-shaped two/three-toe 
syndactyly, cleft palate, cataracts, heart defects, 
genital abnormalities, down slanting palpebral 
fissures with epicanthal folds, and anteverted 
nares. 
AR. DHCR7 mutations. 
Creatine 
transporter 
deficiency  
Central hypotonia, global developmental delay 
(most prominently with speech), mild seizures, 
and brain atrophy on MRI. 
X-linked. SLC6A8 
mutations. 
Congenital peripheral hypotonia 
Spinal 
muscular 
atrophy type 1 
(SMA1) 
Severe peripheral hypotonia, gross motor delay, 
mild contractures, particularly at the knees, and 
absence of tendon reflexes, poor head control, 
weak cry, poor feeding. Normal cognition. 
Fasciculations of the tongue are common. 
AR. SMN1mutations 
(SMN1 mutations account 
for 95% of all SMA0, 1, 2, 
3 cases and 70% of 
SMA4 cases). 
Distal SMA6 
(SMARD1)  
Peripheral hypotonia with distal weakness, 
respiratory distress due to hemidiaphragmatic 
palsy, and absent deep tendon reflexes. Onset 
rages from birth to 6 months 
AR. IGHMBP2 mutations 
Congenital 
myotonic 
dystrophy 
Peripheral hypotonia, facial diplegia, weak 
cry/poor suck, possible developmental 
delay/cognitive impairment, maternal family 
history of facial weakness and contraction 
myotonia, diabetes type II, and/or cataracts. 
AD. Expansion of the 
CTG trinucleotide repeat 
in the 3′ untranslated 
region of the DMPK. 
Congenital 
muscular 
dystrophies 
Heterogeneous group of disorders with clinical 
features ranging from sever e often with early 
fatality, so mild. In addition to peripheral 
hypotonia may include kyphoscoliosis, torticollis, 
joint contractures, joint hypermobility , increased 
signal intensity of brain white matter on MRI, 
progressive spinal rigidity, and scoliosis. 
AR. LAMA2, COL6A1, 2, 
and 3, and SEPN1 
mutations. 
Congenital 
myopathies 
Group of disorders generally presenting with 
peripheral hypotonia, muscle weakness, 
delayed motor milestones, feeding difficulties, 
facial and oral muscle weakness. Serum 
creatine kinase may be normal or slightly raised. 
RYR1 mutations in central 
core/multi-minicore 
disease, ACTA1, CFL2, 
NEB, TPM2 and 3, 
TNNT1 mutations in 
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Deep tendon reflexes may be diminished or 
abolished. Variable severity. 
 
 
Nemaline myopathy, and 
MTM1 in myotubular 
myopathy. 
Congenital 
myasthenic 
syndromes 
A group of syndromes whose features include 
peripheral muscle weakness that worsens with 
physical exertion, delayed motor milestones, 
poor suck/weak cry, ptosis, craniofacial 
weakness, and possible arthrogryposis. 
NMJ protein encoding 
CHRNE, RAPSN, CHAT, 
COLQ, DOK7 mutations. 
CPT2 mutations in 
Carnitine 
palmitoyltransferase 
deficiency type 2, GAA in 
Pompe disease, X-linked 
TAZ mutations in Barth 
syndrome. 
CMT poly-
neuropathies 
Peripheral hypotonia with distal weakness, 
atrophy, sensory loss, and decreased deep 
tendon reflexes. 
AR; AD. PMP22, MPZ, 
and ERG2  mutations. 
Marfan 
syndrome 
Mild peripheral hypotonia, joint hypermobility, 
aortic root or dilatation, scoliosis, pectus 
excavatum or carinatum, arachnodactyly, and 
tall stature. 
AD. FBN1 mutations. 
Loeys-Dietz 
syndrome 
Mild peripheral hypotonia, hypertelorism bifid 
uvula or cleft palate, tortuous blood vessels on 
magnetic resonance angiography, and 
craniosynostosis. 
AD. TGFBR1, and 1 
mutations. 
Congenital combined central and peripheral hypotonia 
Canavan 
disease 
Combined hypotonia, global developmental 
delay, macrocephaly, optic atrophy, seizures, 
‘spongy’ degeneration of white matter on MRI of 
the brain, and Ashkenazi Jewish ethnicity. 
AR. 98% of Ashkenazi 
Jewish cases result from 
E285A or Y231X 
mutations in ASPA . 
Marinesco–
Sjogren 
syndrome 
Central hypotonia and myopathy, global 
developmental delay, cerebellar atrophy, and 
ataxia, cataracts. 
AR. SIL1 mutations. 
Mitochondrial 
encephalopath
ies 
Extremely variable presentations. Features 
include: central hypotonia or myopathy, exercise 
intolerance, seizures and/or migraines, ataxia, 
cardiomyopathy, external ophthalmoplegia, 
sensorineural hearing loss, optic atrophy, 
hypothyroidism, diabetes mellitus, and maternal 
family history of any of these features. 
Mitochondrial DNA or 
specific nuclear 
mitochondrial related 
gene mutations. 
Abbreviations: AD=Autosomal dominant; AR=Autosomal recessive; SLO=Smith–Lemli–Opitz syndrome; 
SMA=Spinal muscular atrophy; SMARD1=Spinal muscular atrophy with respiratory distress type 1; 
CMT=Charcot-Marie-Tooth   (155, 317) 
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7.4.2 Species conservation of CHT C-terminus compared to p.S94R and 
p.V112E mutant proteins 
 
Figure 51. Protein homology of CHT at the amino acid positions of CHT p.S94R 
and p.V112E in various species and human wild type. The effected residues are 
highly conserves across species. (ClustalW2) 
 
  
5’ 3’ 
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7.4.3 TMHMM analysis of CHT p.S94R and p.V112E  
 
 
Figure 52. TMHMM transmembrane predictions of the SLC5A7 protein product of 
wild type and p.S94R and p.V112E mutant molecules. A) The wild type protein is 
predicted to have 12 transmembrane domains with the 3’ terminus not reaching 
the threshold to be considered a transmembrane region. Both the 5’ prime and 
the 3’terminals are predicted to be located extracellularly. B and C) No alteration 
in transmembrane topology is predicted as a result of the SLC5A7 c.282T>A, and 
c.335T>A variants. 
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7.4.4 SLC5A7 c.282T>A/ p.S94R and c.335T>A/V112E site-directed 
mutagenesis (SDM) primers 
SDM oligonucleotides were designed according to the QuickChange Lightning 
Site-Directed Mutagenesis kit guidelines. Mutated bases are highlighted in 
yellow, the incorporation of which results in the Ser94Arge and Val112Glu 
amino acid substitutions. 
 
Primer name  Sequence 
CHT_S94R_forward GCACAATTGGATATTCTCTTAGACTGATTTTAGGTGGCTG 
CHT_S94R_reverse CAGCCACCTAAAATCAGTCTAAGAGAATATCCAATTGTGC 
CHT_V112E_forward CCTATGCGTTCAAAGGGGTATGAGACCATGTTAGACCCG 
CHT_V112E_reverse CGGGTCTAACATGGTCTCATACCCCTTTGAACGCATAGG 
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7.5 APPENDIX CHAPTER 5 
7.5.1 CHT-related disease treatment hypotheses figures 
 
   
Figure 53. Normal cholinergic transmission at the NMJ.  
(A) Schematic diagram of a normal cholinergic transmission at the NMJ. Choline, 
the precursor of ACh, is synthesised in the neuronal soma and then transported 
to the axon terminal via CHT, where it is acetylated with acetyl coenzyme A 
(AcCoA) by choline actyltransferase (ChAT) to produce ACh. ACh is stored in 
presynaptic vesicles (ACh transport is indicated by thin black arrows) until 
depolarisation of the cell stimulates its release into the synaptic cleft via an 
influx of Ca2+ at the motor terminal (not shown). ACh binds to membrane bound 
nicotinic ACh receptors (nAChRs) on the postsynaptic muscles cell, causing ion 
channels to open which allows Na+ to flow into the muscle cell (not shown). This 
stimulates a depolarisation response of the muscle cells membrane, the degree 
of which is dependent on the number of activated nAChRs. Following 
postsynaptic depolarisation, ACh is rapidly cleaved back into choline and AcCoA 
by actelycholinesterase (AChE), which terminates synaptic transmission and 
prevents prolongation of muscle contraction and multiple depolarisations. CHT 
is responsible for choline reuptake into the presynaptic terminal for recycling, as 
well as choline transport into presynaptic vesicles. Choline reuptake is the rate 
limiting step in ACh synthesis and is therefore crucial to cholinergic 
transmission at the NMJ.  
(B) Simplified schematic of the postsynaptic membrane potential during normal 
cholinergic signalling at the NMJ. nAChR binding on the motor end plate and the 
subsequent inward flow of Na+  results in a relatively slow increase in the 
postsynaptic cells membrane potential from its resting potential of ~-70mV. If the 
membrane potential reaches -50mV, an action potential is elicited in the muscle 
cell via an influx of Na+, during which the membrane depolarises to ~+40mV and 
causes the muscle to contract. The ion channels then slowly close and the 
membrane potential reverses dropping back to the resting potential.  
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Figure 54. Defective cholinergic transmission at the NMJ due to the SLC5A7 
c.1497delG. 
(A) Schematic diagram of defective cholinergic signalling at the NMJ due to the 
SLC5A7 c.1497delG (p.K499Nfs*13) mutation. c.1497delG results in significantly 
reduced Choline transport by, which in turn results in a reduction in ACh 
synthesis and diminished vesicular ACh pools. On depolarisation of the 
presynaptic nerve terminal and the subsequent release of the contents of the 
presynaptic vesicles into the synaptic cleft, there is an insufficient amount of 
ACh release to saturate the postsynaptic nAChRs. This causes an insufficient 
increase in the postsynaptic membrane potential to elicit an action potential and 
subsequent muscle contraction.  
(B) Simplified schematic of the postsynaptic membrane potential during 
defective cholinergic signalling at the NMJ due to the SLC5A7 c.1497delG 
mutation. Reduced release of ACh from the presynaptic nerve terminal and 
subsequent nAChR binding on the motor end plate causes ion channels to open 
and allows Na+ to flow into the muscle cell (not shown). Due to incomplete 
saturation of the nAChRs by Ach, the membrane potential fails to reach the ~-
50mV action potential threshold. The membrane potential returns to resting 
potential due to AcCoA action and muscle contraction does not occur.  
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Figure 55. dHMN-VII treatment hypothesis (i) nAChR agonist. 
(A) Schematic diagram of proposed mechanism of action at the NMJ of a nAChR 
agonist as a treatment for dHMN-VII. It is hypothesised that administration of a 
nAChR agonist, which binds to and stimulates postsynaptic nAChRs, will 
provide extra nAChR stimulation at the NMJ, raising the resting potential of the 
postsynaptic muscle cells membrane. This will allow saturation of the 
postsynaptic nAChRs by the diminished amount of ACh released from 
presynaptic vesicles on depolarisation of the motor neurone, causing the muscle 
cells membrane potential to reach the action potential threshold and broadcast 
the action potential to the entire muscle membrane leading to muscle 
contraction.  
(B) Simplified schematic of the predicted postsynaptic membrane potential 
during cholinergic signalling at the dHMN-VII NMJ in the presence of a nAChR 
agonist. The presence of a nAChR agonist is hypothesised to result in an 
increased resting potential (>-70mV) of the postsynaptic muscle cells resting 
membrane potential. On nAChR binding of ACh a lesser increase in membrane 
potential is required in order to reach the action potential threshold and rapid 
depolarisation of the muscle cell.  
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Figure 56 dHMN-VII treatment hypothesis (ii) AChE inhibitor. 
(G) Schematic diagram of proposed mechanism of action at the NMJ of AChE 
inhibitors as a treatment for dHMN-VII. It is hypothesised that administration of 
AChE inhibitor, which inhibits the rapid breakdown of ACh by AChE, will prolong 
the time ACh remains within the synaptic cleft and therefore increase the chance 
of nAChR saturation, allowing postsynaptic action potential propagation.  
(H) Simplified schematic of the predicted postsynaptic membrane potential 
during cholinergic signalling at the dHMN-VII NMJ in the presence of AChE 
inhibitors. The presence of an AChE inhibitor is hypothesised to result in 
sufficient amounts of ACh to remain in the synaptic cleft for nAChR saturation. 
This will allow substantial flow of Na+ into the muscle cell for the slow increase 
in membrane potential to reach the action potential threshold leading to rapid 
depolarisation and muscle contraction. 
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7.5.2 Approach to mouse model generation 
In order to generate a patient-specific knock-in mouse model carrying the 
SLC5A7 c.1497delG mutation identified in dHMN-VII family 1 (chapter 3), 
CRISPR/Cas9-mediated gene editing(318) was employed. The homologous 
region of human SLC5A7 c.1497delG in the mouse genome was targeted by a 
specifically designed guide RNA (protospacer adjacent motif (PAM) sequence: 
GCCAAGTATCTATTTGAAAG). A S. pyogenes SF370 plasmid containing the 
Cas9 open reading frame (319) was transcribed in vitro to produce Cas9 mRNA 
with the use of the Thermo Fisher Scientific mMESSAGE mMACHINE® T7 
Transcription kit. An oligonucleotide was then designed in order to introduce 
both silent and codon altering changes to mimic the human c.1497delG 
mutation with 50 bases of homologous flanking sequence on either side 
(targeting oligonucleotide sequence: 
TTGTCCATGTTCTCTTCACTGTGCCTTGCGACAACAGCATCAAATACATCTA
ATTTAGGTGGCAAGGTTCGACCTTCAGGTATATGTTGGCTAGATAAGAAAC
ACAAATGTTGGTAAAGAATGAGGTAACCATGGAGAGAG). By microinjection, 
the guide RNA (50 ng/µl), Cas9 mRNA (100 ng/µl), and targeting 
oligonucleotide (100 ng/µl) were introduced into C57 black 6 mouse zygotes, 
and the zygotes were transferred into pseudo-pregnant female mice (318). 
Founder mosaic mice born from these zygote transfers were genotyped by ear 
punch biopsy followed by PCR and dideoxy Sanger sequence analysis for the 
presence of the exogenous oligo sequence present at the correct genomic 
location. Animals found to be positive for the mutation were cross-bread with 
wildtype C57Bl/6 mice from which germline transmission of the desired allele, 
termed Slc5a7indelAC (figure 57A). 
Due to the apparent dominant-negative mode of action of the 
c.1497delG/p.K499Nfs*13 mutant protein on wild type transporter function, it 
was imperative to compare any apparent phenotypes observed in Slc5a7indelAC/+ 
mice with those of the heterozygous loss-of-function model, allowing 
identification of aspects of the phenotype that are due to haploinsufficiency. 
Thus, animals carrying an Slc5a7 loss-of-function allele (Slc5a7TM1A) generated 
by the Sanger Institute Mouse Genetics Programme(320), were examined in 
parallel.  
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Mice were maintained in a specific pathogen-free unit under a 12 hr light, 12 hr 
dark cycle with ad libitum access to water and food. The care and use of mice 
were in accordance with the UK Home Office regulations, UK Animals 
(Scientific Procedures) Act of 1986. Animals were monitored for signs of motor 
weakness, fatigue, and gait defects.  Any findings were recorded and animal 
weights taken prior to culling.   
 
7.5.3 Assay for knock-in allele expression 
In order to confirm expression of the patient-specific Slc5a7indelAC allele at the 
mRNA level, adult Slc5a7indelAC/+ animals were sacrificed under the schedule 1 
procedure of the Home Office Animals (Scientific Procedures) Act 1986. 
Following confirmation of death, a spinal cord tissues biopsy was taken and 
mRNA extracted with the use of Invitrogen TRIzol® reagent. cDNA was 
generated from samples taken from both wild type control and knock-in mutant 
mice, and subjected to PCR to amplify the desired region followed by dideoxy 
Sanger sequencing. Equivalent expression levels of both wild type and 
Slc5a7indelAC mRNA in the Slc5a7indelAC/+ mice was confirmed (figure 57B).
 
Figure 57. Confirmation of knock-in allele expression. Diedeoxy Sanger 
sequencing analysis of A) genomic DNA from Slc5a7indelAC/+ pups,  followed by 
the DNA and peptide sequences flanking the mutation in wild type and 
heterozygous mutant animals, as well as the mutant peptide sequence in dHMN-
VII family 1 subjects; and B) spinal mRNA from from adult Slc5a7indelAC/+ mice. 
The overlapping traces indicate the position of the frameshift variant and confirm 
the presence of both the wild type and mutant allele at both the DNA and mRNA 
levels. The DNA sequence of the Slc5a7indelAC/+ animals doe not match that of 
dHMN-VII affected humans because silent and codon altering changes were 
introduced to the mouse DNA to mimic the human c.1497delG mutation with 50 
bases of homologous flanking sequence on either side. 
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7.5.4 Open field testing - methodology and results 
Following 30 minutes acclimatisation in the test room, control and mutant mice 
aged 18-22 weeks were placed in a clean 73 x 73cm open field arena for 20 
minutes under bright light conditions. Time spent moving, time spent stationary, 
and average velocity and distance travelled was tracked with the use of 
overhead infrared video cameras, and recorded and analysed using Ethovision 
XT 8.5 automated video tracking software from Noldus Information Technology, 
Wageningen, The Netherlands. Movement was defined as a velocity of 2 cm/s 
over two frames and non-movement was defined when velocity was lower than 
1.75 cm/s over two frames. There are no differences in distance covered (figure 
58), average velocity (not shown), or time spent moving (not shown) between 
either Slc5a7indelAC/+ or Slc5a7+/TM1A and their littermates. 
 
Figure 58. Distance covered in open field testing of 18-22 week old A) 
Slc5a7indelAC/+ mice and B) their  Slc5a7+/+ wild type littermates, and C) Slc5a7+/TM1A 
mice and D) their wild type littermates. The 20 minute open field analysis was 
split into time bins of 2 minutes in order to determine whether mutant animals 
tire more quickly than wild type controls. 
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7.5.5 Grip strength testing - methodology and results raw data 
Grip strength measurements were taken from wild type control and mutant mice 
at 18-22, 23-26 and 27-31 weeks of age. Mouse muscle strength was measured 
with the use of a Grip Strength Test BIO-GS3 force transducer meter from 
BIOSEB, and recorded in grams. Forepaw measurements were taken by 
holding the animal to be tested by the tail and lowering it to the metal grid 
attached to the force transducer meter until its front paws grasp the grid. The 
animals was then lowered by its tail such that its body was position almost 
horizontally before gently pulling the tail in the direction of the axle of the sensor 
until the animal released its grasp. All-paw measurements were carried out as 
forepaw measurements; however the animal was lowered as to allow for all four 
paws to grasp the grid.  Forepaw and all-paw measurements were repeated 3 
times for each time point and the maximum measurement of each was used in 
analysis. Measurements were discarded if the mouse failed to have paws 
gripping over the bar or if they were asymmetrically arranged on the bars.  
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7.5.5.1 Grip strength testing in Slc5a7indelAC/+ mice 
 
Figure 59. Grip strength test results taken at time points 1 (18-22 weeks), 2 (23-26 
weeks)  and 3 (27-31 weeks) from wild type (blue) vs. Slc5a7indelAC/+ (red) A) 
female mice forepaws, B) male mice forepaws, C) female mice all-paws and D) 
male mice all-paws. Difference of statistical significance are indicated by * where 
p=<0.05, and **** where p=<0.0001  
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Table 42. Female Slc5a7indelCA/+ mice grip strength summary statistics 
Female max forepaw     WT HET   
    N 15 13   
Wildtype vs. Het           
Time point 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 154.7 135.1 19.64 ns 0.1159 
2 140.7 134.1 6.574 ns 0.865 
3 134.1 112.6 21.46 ns 0.0741 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 154.7 140.7 14.01 ns 0.2377 
1 vs. 3 154.7 134.1 20.63 * 0.0495 
2 vs. 3 140.7 134.1 6.619 ns 0.7196 
Heterozygous           
1 vs. 2 135.1 134.1 0.9446 ns 0.9942 
1 vs. 3 135.1 112.6 22.45 * 0.0459 
2 vs. 3 134.1 112.6 21.51 ns 0.0583 
Female max All Paw     WT HET   
    N 15 13   
Wildtype vs. Het           
Time point 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 248 203.3 44.75 * 0.0334 
2 248.4 228.3 20.19 ns 0.5696 
3 261.4 239.2 22.15 ns 0.4928 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 248 248.4 
-
0.4407 ns 0.9994 
1 vs. 3 248 261.4 -13.37 ns 0.584 
2 vs. 3 248.4 261.4 -12.93 ns 0.6045 
Heterozygous           
1 vs. 2 203.3 228.3 -25 ns 0.2039 
1 vs. 3 203.3 239.2 -35.97 * 0.0418 
2 vs. 3 228.3 239.2 -10.97 ns 0.7295 
Abbreviations: WT= wild type; HET= heterozygous SLC5A7indelCA/+; diff= difference 
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Table 43. Male Slc5a7indelCA/+ mice grip strength summary statistics 
Male max 
Forepaw     WT HET   
    N 14 20   
Wildtype vs. Het           
Time point 
Mean 
1 
Mean 
2 
Mean 
diff Significance Adjusted p value 
1 144.3 153.6 -9.353 ns 0.5416 
2 135.9 125.3 10.66 ns 0.4299 
3 124.3 121.6 2.674 ns 0.9803 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance Adjusted p value 
1 vs. 2 144.3 135.9 8.333 ns 0.5124 
1 vs. 3 144.3 124.3 20.03 * 0.0261 
2 vs. 3 135.9 124.3 11.69 ns 0.2723 
Heterozygous           
1 vs. 2 153.6 125.3 28.35 **** < 0.0001 
1 vs. 3 153.6 121.6 32.05 **** < 0.0001 
2 vs. 3 125.3 121.6 3.709 ns 0.8262 
Male max All Paw     WT HET   
    N 14 20   
Wildtype vs. Het           
Time point 
Mean 
1 
Mean 
2 
Mean 
diff Significance Adjusted p value 
1 244.5 240.9 3.643 ns 0.9946 
2 261.8 220.7 41.12 * 0.0411 
3 242 223.5 18.46 ns 0.6005 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance Adjusted p value 
1 vs. 2 244.5 261.8 -17.29 ns 0.5668 
1 vs. 3 244.5 242 2.549 ns 0.9876 
2 vs. 3 261.8 242 19.84 ns 0.4748 
Heterozygous           
1 vs. 2 240.9 220.7 20.19 ns 0.3349 
1 vs. 3 240.9 223.5 17.36 ns 0.4432 
2 vs. 3 220.7 223.5 -2.823 ns 0.9784 
Abbreviations: WT= wild type; HET= heterozygous SLC5A7indelCA/+; diff= difference 
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7.5.5.2 Grip strength testing in Slc5a7+/TM1A mice 
 
 
Figure 60. Grip strength test results taken at time points 1 (18-22 weeks), 2 (23-26 
weeks)  and 3 (27-31 weeks) from wild type (blue) vs. Slc5a7+/TM1A (red) A) Male 
mice forepaws, B) male mice all-paws, C) female mice forepaws and D) female 
mice all-paws. Difference of statistical significance are indicated by * where 
p=<0.05, and **** where p=<0.0001  
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Table 44. Female Slc5a7+/TM1A mice grip strength summary statistics 
Female max forepaw     WT HET   
    N 13  13    
Wildtype vs. Het           
Timepoint 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 139.9 137.7 2.194 ns ns 
2 132.8 141.6 -8.732 ns ns 
3 138.6 145 -6.321 ns ns 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 139.9 132.8 7.02 ns 0.9909 
1 vs. 3 139.9 138.6 1.229 ns > 0.9999 
2 vs. 3 132.8 138.6 -5.792 ns 0.9968 
Heterozygous           
1 vs. 2 137.7 141.6 -3.906 ns 0.9997 
1 vs. 3 137.7 145 -7.286 ns 0.989 
2 vs. 3 141.6 145 -3.38 ns 0.9999 
Female max All Paw     WT HET   
    N 13 13   
Wildtype vs. Het           
Timepoint 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 216.1 240.2 -24.14 ns 0.2788 
2 243.7 239.2 4.512 ns 0.9859 
3 270.9 269.3 1.623 ns 0.9993 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 216.1 243.7 -27.69 ns 0.2534 
1 vs. 3 216.1 270.9 -54.86 ** 0.0012 
2 vs. 3 243.7 270.9 -27.17 ns 0.2726 
Heterozygous           
1 vs. 2 240.2 239.2 0.9619 ns > 0.9999 
1 vs. 3 240.2 269.3 -29.1 ns 0.206 
2 vs. 3 239.2 269.3 -30.06 ns 0.1776 
Abbreviations: WT= wild type; HET= heterozygous SLC5A7+/TM2A; diff= difference 
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Table 45. Male Slc5a7+/TM1A mice grip strength summary statistics 
Male max 
Forepaw     WT HET   
    N 14   20   
Wildtype vs. Het           
Timepoint 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 147.6 150.6 -3.043 ns 0.9821 
2 127.9 148.5 -20.57 ns 0.0767 
3 127.2 117.1 10.04 ns 0.6144 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 147.6 127.9 19.64 ns 0.2236 
1 vs. 3 147.6 127.2 20.4 ns 0.189 
2 vs. 3 127.9 127.2 0.7605 ns > 0.9999 
Heterozygous           
1 vs. 2 150.6 148.5 2.104 ns > 0.9999 
1 vs. 3 150.6 117.1 33.48 *** 0.0008 
2 vs. 3 148.5 117.1 31.38 ** 0.0019 
Male max All Paw     WT HET   
    N 14 20   
Wildtype vs. Het           
Timepoint 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 246.9 244.6 2.282 ns 0.9989 
2 239.4 229.7 9.757 ns 0.9275 
3 250.8 227.9 22.87 ns 0.4885 
            
Wildtype 
Mean 
1 
Mean 
2 
Mean 
diff Significance 
Adjusted p 
value 
1 vs. 2 246.9 239.4 7.462 ns 0.9994 
1 vs. 3 246.9 250.8 -3.899 ns > 0.9999 
2 vs. 3 239.4 250.8 -11.36 ns 0.9934 
Heterozygous           
1 vs. 2 244.6 229.7 14.94 ns 0.9461 
1 vs. 3 244.6 227.9 16.69 ns 0.9117 
2 vs. 3 229.7 227.9 1.75 ns > 0.9999 
Abbreviations: WT= wild type; HET= heterozygous SLC5A7+/TM2A; diff= difference 
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